Transplantation of Schwann Cells	1
Transplantation	1
Schwann Cells	20
Olfactory Ensheathing Glia into the Contused Spinal Cord	41
Olfactory Ensheathing Glia	41
the Contused Spinal Cord	73
Survival	99
Migration	109
Axon Association	120
Functional Recovery DAMIEN D. PEARSE	142
,1	179
ANDRE R. SANCHEZ ,1 FRANCISCO C. PEREIRA	183
ANDRE R. SANCHEZ ,1 FRANCISCO	183
C. PEREIRA	212
,2	222
CHRISTIAN M. ANDRADE ,1 RAISA PUZIS ,1 YELENA PRESSMAN	225
CHRISTIAN M. ANDRADE ,1 RAISA	225
PUZIS ,1 YELENA PRESSMAN	254
,1 KEVIN GOLDEN ,1 BRANDON M. KITAY	277
,1 KEVIN GOLDEN ,1	277
BRANDON M. KITAY	295
,1 BAS BLITS ,1 PATRICK M. WOOD ,1 AND MARY BARTLETT	311
,1 BAS BLITS ,1	311
PATRICK M. WOOD ,1 AND MARY BARTLETT	326
PATRICK M. WOOD ,1	326
MARY BARTLETT	348
BUNGE1 ,3	362
The Miami Project	371
Paralysis	397
University of Miami Miller School of Medicine	408
University	408
Miami Miller School of Medicine	422
Miami Miller School	422
Medicine	445
Miami	455
Florida 1Department of Neurological Surgery	462
Florida 1Department	462
Neurological Surgery	485
University of Miami Miller School of Medicine 2Department of Anatomy	507
University	507
Miami Miller School of Medicine 2Department	521
Miami Miller School	521
Medicine 2Department	544
Anatomy	568
Biomedical Sciences Institute	577
University of Sao Paulo	608
University	608
Sao Paulo	622
Brazil 3Department of Cell Biology and Anatomy	633
Brazil 3Department	633
Cell Biology and Anatomy	655
University	681
Miami Miller School	695
Medicine ABSTRACT Schwann cells	718
SCs	752
olfactory ensheathing glia	761
OEG	789
promise for spinal cord injury repair	805
promise	805
spinal cord injury repair	817
We	844
their in vivo identification following transplantation	854
their in vivo identification	854
transplantation	893
the contused adult rat spinal cord	914
1 week postinjury	952
-LRB- i -RRB- DNA	974
hybridization -LRB- ISH -RRB- with a Y-chromosome specific probe	990
hybridization -LRB- ISH -RRB-	990
hybridization	990
ISH	1005
a Y-chromosome specific probe	1015
male transplants	1057
female rats and -LRB- ii -RRB- lentiviral vector-mediated expression of EGFP	1077
female rats	1077
ii	1094
lentiviral vector-mediated expression of EGFP	1098
lentiviral vector-mediated expression	1098
EGFP	1139
Survival , migration , and axon-glia association	1145
Survival	1145
migration	1155
axon-glia association	1170
3 days	1213
9 weeks	1223
3 weeks after transplantation into the lesion	1256
3 weeks	1256
transplantation into the lesion	1270
transplantation	1270
the lesion	1291
a 60 -- 90 % loss of grafted cells	1303
a 60	1303
90 % loss of grafted cells	1308
90 % loss	1308
grafted cells	1320
OEG-only grafts	1348
the lesion	1392
injection outside the lesion	1410
injection	1410
the lesion	1428
a 60 % survival rate	1446
the injury milieu	1481
transplanted cells	1514
their proliferation	1550
later times post-grafting	1574
later times	1574
p75þ / EGFP2 cells in the lesion	1601
p75þ	1601
EGFP2 cells in the lesion	1607
EGFP2 cells	1607
the lesion	1622
EGFPþ cells	1645
all paradigms	1660
evidence of significant host SC infiltration	1675
evidence	1675
significant host SC infiltration	1687
SCs and OEG	1721
the injury failed to migrate from the lesion	1747
the injury	1747
the lesion	1781
Injection of OEG outside of the injury	1793
Injection	1793
OEG outside of the injury	1806
OEG	1806
the injury	1821
their migration	1844
the SC-injected injury site	1865
host tissue	1920
the pia	1942
the central canal	1957
all paradigms	1979
host axons	1994
association	2018
transplanted glia	2052
Numerous myelinated axons	2071
regions of grafted SCs but not OEG	2115
regions	2115
SCs but not OEG	2134
SCs	2134
OEG	2146
current study details	2155
the temporal survival , migration , axon association of SCs and OEG	2177
the temporal survival	2177
migration	2200
axon association of SCs	2211
axon association	2211
SCs	2231
OEG	2239
the contused spinal cord , research previously complicated	2288
the	2288
spinal cord , research previously complicated	2301
spinal cord	2301
research previously complicated	2314
research	2314
a lack of quality	2353
a lack	2353
quality	2363
long-term markers	2372
cell tracking in vivo	2394
cell tracking	2394
vivo	2411
INTRODUCTION Trauma to the spinal cord	2418
INTRODUCTION Trauma	2418
the spinal cord	2441
progressive cell death	2466
axonal degeneration	2490
functional loss in multiple motor , sensory , and autonomic systems	2515
functional loss	2515
multiple motor , sensory , and autonomic systems	2534
multiple motor	2534
sensory	2550
autonomic systems	2563
a structure relatively incapable of self-repair	2586
a structure	2586
self-repair	2622
the only means to ensure operative restitution to the spinal cord	2635
the only means	2635
operative restitution	2660
the spinal cord	2685
-LRB- i -RRB- neuroprotective therapies	2705
i	2706
tissue loss	2745
Beattie	2793
2004 ; Bethea et al. , 1999 ; Oudega et al. , 1999 ; Takami et al.	2802
2004	2802
Bethea et al. , 1999 ; Oudega et al. , 1999 ; Takami et al.	2808
Bethea	2808
et al. , 1999 ; Oudega et al. , 1999 ; Takami et al.	2815
et al. , 1999	2815
et al.	2815
1999	2823
Oudega et al. , 1999	2829
Oudega	2829
et al. , 1999	2836
et al.	2836
1999	2844
Takami et al.	2850
Takami	2850
et al.	2857
2002a	2865
ii	2877
molecular , cellular	2881
molecular	2881
cellular	2892
pharmacological treatments	2908
lost tissue	2956
axon regeneration and reconnection	2985
lost function	3031
Barakat and Pearse	3046
2006	3066
Li	3072
et al. , 2003b	3075
et al.	3075
2003b	3083
McDonald et al. , 1999	3090
McDonald	3090
et al. , 1999	3099
et al.	3099
1999	3107
Pearse and Barakat , 2006	3113
Pearse and Barakat	3113
2006	3133
Pearse et al. , 2004b	3139
Pearse	3139
et al. , 2004b	3146
et al.	3146
2004b	3154
Ram on-Cueto et al.	3161
Ram on-Cueto	3161
et al.	3174
2000	3182
Transplantation	3189
a diversity	3208
peripheral and central nervous system and immune cells	3223
undifferentiated stem cells	3281
spinal cord injury -LRB- SCI -RRB-	3313
spinal cord injury	3313
SCI	3333
repair	3338
McDonald	3346
et al. , 1999	3355
et al.	3355
1999	3363
Pearse et al. , 2004b	3369
Pearse	3369
et al. , 2004b	3376
et al.	3376
2004b	3384
Ram on-Cueto et al. , 2000	3391
Ram on-Cueto	3391
et al. , 2000	3404
et al.	3404
2000	3412
Rapalino et al. , 1998	3418
Rapalino	3418
et al. , 1998	3427
et al.	3427
1998	3435
Takami et al. , 2002b	3441
Takami	3441
et al. , 2002b	3448
et al.	3448
2002b	3456
progressive tissue loss	3476
Pearse	3501
et al. , 2004a	3508
et al.	3508
2004a	3516
retarded axonal dieback	3524
sensory , proprio	3558
sensory	3558
proprio	3567
supraspinal axon regeneration	3583
Li	3614
et al. , 1997	3617
et al.	3617
1997	3625
Ram on	3631
Ram	3631
Cueto et al. , 2000	3639
Cueto	3639
et al. , 2000	3645
et al.	3645
2000	3653
Pearse et al. , 2004b	3659
Pearse	3659
et al. , 2004b	3666
et al.	3666
2004b	3674
Xu et al. , 1997	3681
Xu	3681
et al. , 1997	3684
et al.	3684
1997	3692
myelination -LRB- Lankford et al. , 2002 ; Pearse et al. , 2004b -RRB-	3711
myelination	3711
Lankford	3724
et al. , 2002 ; Pearse et al. , 2004b	3733
et al.	3733
2002 ; Pearse et al.	3741
2002	3741
Pearse et al.	3747
Pearse	3747
et al.	3754
2004b	3762
improved functional outcome	3773
Li	3802
et al. , 2003b	3805
et al.	3805
2003b	3813
Rapalino et al. , 1998	3820
Rapalino	3820
et al. , 1998	3829
et al.	3829
1998	3837
Ram on-Cueto et al. , 2000	3843
Ram on-Cueto	3843
et al. , 2000	3856
et al.	3856
2000	3864
Pearse et al. , 2004b	3870
Pearse	3870
et al. , 2004b	3877
et al.	3877
2004b	3885
The versatility	3893
cellular implants	3912
many obstacles encountered after SCI	3942
many obstacles	3942
SCI	3975
them	3985
ideal therapeutic candidates for repair	3990
ideal therapeutic candidates	3990
repair	4023
Schwann cells	4031
SCs	4046
the myelinating cells	4052
the peripheral nervous system	4077
axonal regeneration	4122
peripheral injury	4148
CNS axon growth either as peripheral nerve grafts or purified	4179
CNS axon growth	4179
peripheral nerve grafts	4205
fluid grafts	4242
David and Aguayo , 1981 ; Takami et al. , 2002b ; Xu et al. , 1995	4256
David and Aguayo	4256
1981 ; Takami et al. , 2002b ; Xu et al.	4274
1981	4274
Takami et al. , 2002b ; Xu et al.	4280
Takami	4280
et al. , 2002b ; Xu et al.	4287
et al. , 2002b	4287
et al.	4287
2002b	4295
Xu et al.	4302
Xu	4302
et al.	4305
1995	4313
SCs	4320
a physical support to growing axons in vivo	4337
a physical support	4337
growing axons in vivo	4359
growing axons	4359
vivo	4376
a variety	4394
growth-promoting neurotrophins	4407
Acheson	4439
et al. , 1991 ; Rende et al. , 1992	4447
et al.	4447
1991 ; Rende et al.	4455
1991	4455
Rende et al.	4461
Rende	4461
et al.	4467
1992	4475
cell adhesion molecules -LRB- reviewed by Grumet , 1997 -RRB-	4482
cell adhesion molecules	4482
Grumet , 1997	4519
Grumet	4519
1997	4527
extracellular matrix -LRB- Chiu et al. , 1991 -RRB-	4537
extracellular matrix	4537
Chiu	4559
et al. , 1991	4564
et al.	4564
1991	4572
SCs also ensheathe and myelinate these axons -LRB- Bahr et al. , 1991 -RRB- .	4579
SCs	4579
also ensheathe and myelinate these axons -LRB- Bahr et al. , 1991 -RRB-	4583
also ensheathe	4583
myelinate these axons -LRB- Bahr et al. , 1991 -RRB-	4602
myelinate these axons	4602
Bahr	4625
et al. , 1991	4630
et al.	4630
1991	4638
respect to clinical importance	4650
respect	4650
clinical importance	4661
large numbers of human SCs	4682
large numbers	4682
human SCs	4699
autologous implantation	4728
minimally invasive surgery for peripheral nerve harvesting	4758
minimally invasive surgery	4758
peripheral nerve harvesting	4789
expansion and purification in culture -LRB- Bunge and Pearse , 2003 -RRB-	4821
expansion and purification	4821
culture -LRB- Bunge and Pearse , 2003 -RRB-	4851
culture	4851
Bunge and Pearse	4860
2003	4878
Olfactory ensheathing glia -LRB- OEG -RRB-	4885
Olfactory ensheathing glia	4885
OEG	4913
fiber regeneration	4981
the injured mammalian spinal cord	5003
Li	5038
et al. , 1997 ; Ram on-Cueto et al. , 1998 ; 2000	5041
et al.	5041
1997 ; Ram on-Cueto et al.	5049
1997	5049
Ram on-Cueto et al.	5055
Ram on-Cueto	5055
et al.	5068
1998 ; 2000	5076
functional recovery -LRB- Li et al. , 2003b ; Ram on - Cueto et al. , 2000 -RRB-	5103
functional recovery	5103
Li	5124
et al. , 2003b ; Ram on - Cueto et al. , 2000	5127
et al.	5127
2003b ; Ram on - Cueto et al.	5135
2003b	5135
Ram on - Cueto et al.	5142
Ram	5142
Cueto et al.	5150
Cueto	5150
et al.	5156
2000	5164
OEG ensheathe axons of olfactory sensory neurons	5171
OEG ensheathe axons	5171
olfactory sensory neurons	5194
their growth	5229
the olfactory epithelium to the olfactory bulb	5247
the olfactory epithelium	5247
the olfactory bulb	5275
their exposure	5309
inhibitory molecules	5327
Graziadei and Graziadei , 1979 ; Ram on-Cueto and Santos-Benito , 2001	5349
Graziadei and Graziadei	5349
1979 ; Ram on-Cueto and Santos-Benito	5374
1979	5374
Ram on-Cueto and Santos-Benito	5380
Ram on-Cueto	5380
Santos-Benito	5397
2001	5412
OEG	5419
axon growth in the injured CNS	5434
axon growth	5434
the injured CNS	5449
growth factors	5479
NGF , NT4/5 , NT3 , and BDNF	5502
Lipson et al. , 2003 ; Ram on-Cueto et al. , 1998 ; Woodhall et al. , 2001	5529
Lipson	5529
et al. , 2003 ; Ram on-Cueto et al. , 1998 ; Woodhall et al. , 2001	5536
et al. , 2003	5536
et al.	5536
2003	5544
Ram on-Cueto et al. , 1998	5550
Ram on-Cueto	5550
et al. , 1998	5563
et al.	5563
1998	5571
Woodhall et al. , 2001	5577
Woodhall	5577
et al. , 2001	5586
et al.	5586
2001	5594
cell adhesion molecules	5601
L1 and laminin -LRB- Barnett et al. , 2000 ; Bartolomei et al. , 2000 -RRB-	5633
L1 and laminin	5633
Barnett	5649
et al. , 2000 ; Bartolomei et al. , 2000	5657
et al.	5657
2000 ; Bartolomei et al.	5665
2000	5665
Bartolomei et al.	5671
Bartolomei	5671
et al.	5682
2000	5690
the axon	5714
chemorepellants via ensheathment -LRB- Ram on-Cueto et al. , 2000 -RRB-	5728
chemorepellants	5728
ensheathment -LRB- Ram on-Cueto et al. , 2000 -RRB-	5748
ensheathment	5748
Ram	5762
on-Cueto et al. , 2000	5766
on-Cueto	5766
et al.	5775
2000	5783
OEG	5790
remyelinate demyelinated spinal cord axons -LRB- Imaizumi et al. , 1998 -RRB-	5811
remyelinate	5811
spinal cord axons -LRB- Imaizumi et al. , 1998 -RRB-	5836
spinal cord axons	5836
Imaizumi	5855
et al. , 1998	5864
et al.	5864
1998	5872
the transplantation of SCs and OEG into the injured spinal cord	5888
the transplantation	5888
SCs and OEG	5911
the injured spinal cord	5928
survival and integration	6001
the host spinal cord , migration , or association	6031
the host spinal cord	6031
migration	6053
association	6067
myelination of axons	6088
myelination	6088
axons	6103
the lack of specific cellular labels	6133
the lack	6133
specific cellular labels	6145
long-term tracking of the transplanted cells in vivo	6174
long-term tracking	6174
the transplanted cells in vivo	6196
the transplanted cells	6196
vivo	6222
labels	6248
leakage and transfer	6286
host cells	6310
Harvey , 1994 ; Honig and Hume , 1986 ; Horan and Slezak , 1989	6322
Harvey , 1994	6322
Harvey	6322
1994	6330
Honig and Hume , 1986	6336
Honig and Hume	6336
1986	6352
Horan and Slezak , 1989	6358
Horan and Slezak	6358
1989	6376
endogenous cells	6433
e.g. p75 ; Pearse et al. , 2004b	6451
e.g.	6451
p75 ; Pearse et al. , 2004b	6456
p75	6456
Pearse et al. , 2004b	6461
Pearse	6461
et al. , 2004b	6468
et al.	6468
2004b	6476
chemical instability	6487
loss of the label within days or weeks	6522
loss	6522
the label within days or weeks	6530
the label	6530
days or weeks	6547
post-transplantation -LRB- Li et al. , 2003a ; Mosahebi et al. , 2000 -RRB-	6561
post-transplantation	6561
Li	6583
et al. , 2003a ; Mosahebi et al. , 2000	6586
et al.	6586
2003a ; Mosahebi et al.	6594
2003a	6594
Mosahebi et al.	6601
Mosahebi	6601
et al.	6610
2000	6618
the present study	6628
we	6647
two labeling techniques	6659
these limitations	6698
DNA	6717
hybridization -LRB- ISH -RRB- with a rat Y-chromosome-specific DNA probe	6729
hybridization -LRB- ISH -RRB-	6729
hybridization	6729
ISH	6744
a rat Y-chromosome-specific DNA probe	6754
male cell grafting	6798
a female host or lentiviral vector transduction	6822
a gene	6873
a fluorescent protein	6889
the cells	6916
Chamberlin	6927
et al. , 1998	6938
et al.	6938
1998	6946
Harvey et al. , 1992	6952
Harvey	6952
et al. , 1992	6959
et al.	6959
1992	6967
Keirstead et al. , 1999	6973
Keirstead	6973
et al. , 1999	6983
et al.	6983
1999	6991
Okada et al. , 1999	6997
Okada	6997
et al. , 1999	7003
et al.	7003
1999	7011
O'Leary and Blakemore , 1997	7017
O'Leary and Blakemore	7017
1997	7040
Pearse and Bunge , 2006	7046
Pearse and Bunge	7046
2006	7064
Previous studies	7071
these labels	7102
various cell implants , including SCs and OEG	7139
various cell implants	7139
SCs and OEG	7172
SCs	7172
OEG	7180
demyelinating lesions	7188
the spinal cord	7213
Imaizumi	7230
et al. , 1998	7239
et al.	7239
1998	7247
dorsal root injuries	7254
Ramer	7276
et al. , 2004	7282
et al.	7282
2004	7290
clip compression -LRB- Boyd et al. , 2004 -RRB-	7297
clip compression	7297
Boyd	7315
et al. , 2004	7320
et al.	7320
2004	7328
chronic , contusive SCI -LRB- Barakat et al. , 2005 -RRB-	7338
chronic	7338
contusive SCI -LRB- Barakat et al. , 2005 -RRB-	7347
contusive SCI	7347
Barakat	7362
et al. , 2005	7370
et al.	7370
2005	7378
The current study	7385
improved in vivo	7424
improved	7424
vivo	7436
picture	7441
temporal	7452
glial cell survival	7469
their capacity for host cord integration	7490
their capacity	7490
host cord integration	7509
their migratory properties	7532
their ability to associate with	7564
myelinate re-growing axons within the sub-acutely contused spinal cord	7600
myelinate re-growing axons	7600
the sub-acutely contused spinal cord	7634
these properties of the two cell types in a single study	7699
these properties	7699
the two cell types in a single study	7719
the two cell types	7719
a single study	7741
MATERIALS AND METHODS	7758
Cultures SCs SCs	7780
sciatic nerves	7816
adult male -LRB- Y chromosome label -RRB-	7834
adult male	7834
Y chromosome label	7846
female -LRB- lentiviral vector GFP label -RRB-	7869
female	7869
lentiviral vector GFP label	7877
Fischer rats -LRB- Harlan Co , Indianapolis , IN -RRB- as described previously	7906
Fischer rats	7906
Harlan Co , Indianapolis	7920
Harlan Co	7920
Indianapolis	7931
Morrissey	7974
et al. , 1991	7984
et al.	7984
1991	7992
additional modifications as later detailed in Meijs et al.	8003
additional modifications	8003
Meijs	8049
et al.	8055
2004	8064
Cells	8071
confluency	8091
new dishes	8118
three times	8129
Their purity for grafting	8142
Their purity	8142
grafting	8159
a method described earlier -LRB- Takami et al. , 2002b -RRB-	8172
a method	8172
earlier -LRB- Takami et al. , 2002b -RRB-	8191
earlier	8191
Takami	8200
et al. , 2002b	8207
et al.	8207
2002b	8215
95 -- 98 %	8239
95	8239
98 %	8242
OEG Highly purified cultures of OEG	8247
OEG	8247
cultures of OEG	8267
cultures	8267
OEG	8279
the nerve fiber layer	8302
the olfactory bulb	8327
adult male -LRB- Y chromosome label -RRB-	8349
adult male	8349
Y chromosome label	8361
female -LRB- lentiviral vector GFP label -RRB-	8384
female	8384
lentiviral vector GFP label	8392
Fischer rats -LRB- Harlan Co -RRB-	8421
Fischer rats	8421
Harlan Co	8435
a procedure modified from one described previously	8452
a procedure	8452
one described previously	8478
one	8478
Ram	8504
on-Cueto et al. , 1998	8508
on-Cueto	8508
et al.	8517
1998	8525
Care	8532
the inclusion of nonnerve fiber layer bulb tissue	8559
the inclusion	8559
nonnerve fiber layer bulb tissue	8576
the pia	8614
OEG	8635
a modification to the Ram	8664
a modification	8664
the Ram	8682
on-Cueto	8690
et al. -LRB- 1998 -RRB- method ,	8699
et al.	8699
1998	8707
method	8713
5 days	8738
forskolin -LRB- 0.8 µg/mL -RRB- and pituitary extract -LRB- 2 mg/mL -RRB-	8748
forskolin	8748
0.8 µg/mL	8759
pituitary extract	8774
2 mg/mL	8793
DMEM/F12/10 % FBS before purification	8805
DMEM/F12/10 % FBS	8805
purification	8829
p75 immuno-panning	8845
Takami	8880
et al.	8887
2002b	8895
the purity	8912
SCs except that p75 rather than S100	8938
SCs	8938
that p75 rather than S100	8949
that p75	8949
S100	8970
Hoechst nuclear staining	8989
Purity	9015
94 -- 98 %	9038
94	9038
98 %	9041
Lentiviral Vectors Lentiviral vector preparation Vector preparation	9046
Lentiviral Vectors	9046
Lentiviral vector preparation Vector preparation	9065
Follenzi	9155
et al. -LRB- 2000 -RRB-	9164
et al.	9164
2000	9172
the gene encoding	9188
green fluorescent protein -LRB- EGFP -RRB-	9215
green fluorescent protein	9215
EGFP	9242
a lentiviral vector plasmid	9267
This plasmid	9296
the cytomegalovirus -LRB- CMV -RRB- promoter	9319
CMV	9340
transgene expression	9363
the Woodchuck posttranscriptional regulatory element -LRB- WPRE -RRB-	9388
the Woodchuck posttranscriptional regulatory element	9388
WPRE	9442
mRNA transport	9459
Transfection of plasmids and viral harvesting	9475
Transfection	9475
plasmids and viral harvesting	9491
plasmids	9491
viral harvesting	9504
293T cells	9547
Virus	9559
ultracentrifugation	9585
20,000 g	9608
phosphate buffered saline -LRB- PBS -RRB-	9635
phosphate	9635
saline -LRB- PBS -RRB-	9654
saline	9654
PBS	9662
this	9674
the viral vectors	9680
units	9727
293T cells	9743
an enzyme	9766
immunosorbent assay	9783
ELISA ; Perkin Elmer , Wellesley , MA	9804
ELISA	9804
Perkin Elmer , Wellesley , MA	9811
quantifying p24 core protein concentrations	9844
manufacturer 's instructions	9902
manufacturer 's	9902
viral vector stocks	9940
280 C	9975
SC or OEG infection	9987
Lentiviral vector transduction of glia to express GFP Virus concentrated in PBS	10008
Lentiviral vector transduction	10008
glia to express GFP Virus concentrated in PBS	10042
GFP Virus	10058
PBS	10084
SCs and OEG	10107
Cultures	10120
the addition of a predetermined volume of concentrated virus in DMEM	10146
the addition	10146
a predetermined volume of concentrated virus in DMEM	10162
a predetermined volume	10162
concentrated virus in DMEM	10188
concentrated virus	10188
DMEM	10210
10 % FBS and mitogens	10220
A multiplicity of infection -LRB- MOI -RRB- of 50	10242
A multiplicity	10242
infection -LRB- MOI -RRB- of 50	10260
infection -LRB- MOI -RRB-	10260
infection	10260
MOI	10271
50	10279
all cultures	10294
high transduction efficiency -LRB- 95 -- 98 % -RRB-	10317
high transduction efficiency	10317
95 -- 98 %	10347
95	10347
98 %	10350
an absence of toxicity	10360
an absence	10360
toxicity	10374
Animals Adult female Fischer rats -LRB- Harlan Co , n = 261 ; 180 -- 200 g -RRB-	10384
Animals Adult female Fischer rats	10384
Animals	10384
Adult female Fischer rats	10392
Harlan Co , n = 261 ; 180 -- 200 g	10419
Harlan Co	10419
n = 261 ; 180 -- 200 g	10430
n = 261	10430
n	10430
261	10434
180 -- 200 g	10439
180	10439
200 g	10444
NIH and The Guide for the Care and Use of Animals	10476
NIH	10476
The Guide for the Care and Use of Animals	10484
The Guide	10484
the Care and Use	10498
Animals	10518
The Institutional Animal Care and Use Committee of the University of Miami	10527
The Institutional Animal Care and Use Committee	10527
the University of Miami	10578
the University	10578
Miami	10596
all animal procedures	10611
surgery	10643
rats	10652
anesthetized -LRB- 45 mg/kg ketamine , 5 mg/kg xylazine -RRB-	10662
anesthetized	10662
45 mg/kg ketamine	10676
5 mg/kg xylazine	10695
intraperitoneal injection	10716
Moderate thoracic contusion injury	10743
Contusion injury	10778
the MASCIS weight drop device	10810
New York University -LRB- Gruner , 1992 -RRB-	10853
New York University	10853
Gruner	10874
1992	10882
A laminectomy performed at thoracic vertebra T8	10889
A laminectomy	10889
thoracic vertebra T8	10916
the dorsal surface of the spinal cord	10945
the dorsal surface	10945
the spinal cord	10967
-LRB- T9 -RRB- without disrupting the dura mater	10994
-LRB- T9 -RRB-	10994
the dura mater	11018
The exposed spinal cord	11034
a 10.0 g rod	11093
a height of 12.5 mm	11111
a height	11111
12.5 mm	11123
The contusion impact height , velocity and compression	11132
The contusion impact height	11132
velocity	11161
compression	11174
Animals -LRB- n = 16 -RRB-	11202
Animals	11202
n	11211
16	11215
height or velocity errors	11250
6 %	11285
the compression distance	11294
the range of 1.35 -- 1.75 mm	11334
the range of 1.35	11334
the range	11334
1.35	11347
1.75 mm	11352
injury	11367
the muscles	11375
layers	11403
the skin	11414
metal wound clips	11435
The rats	11454
a warmed cage with water and food easily accessible	11490
a warmed cage	11490
water and food	11509
Gentamicin	11543
5 mg/kg , intramuscular ; Abbott Laboratories , North Chicago , IL	11555
5 mg/kg	11555
intramuscular ; Abbott Laboratories , North Chicago	11564
intramuscular	11564
Abbott Laboratories , North Chicago	11579
Abbott Laboratories	11579
North Chicago	11600
IL	11615
seven days	11679
The analgesic	11691
Buprenex	11706
0.01 mg/kg of 0.3 mg/mL , subcutaneous ; Reckitt Benckiser , Richmond , VA	11716
0.01 mg/kg of 0.3 mg/mL	11716
0.01 mg/kg	11716
0.3 mg/mL	11730
subcutaneous ; Reckitt Benckiser	11741
subcutaneous	11741
Reckitt Benckiser	11755
Richmond , VA	11774
Richmond	11774
VA	11784
2 days	11828
1 week postinjury	11839
rats	11858
fluid grafts of SCs , OEG or both cell types	11872
fluid grafts	11872
SCs , OEG or both cell types	11888
SCs	11888
OEG	11893
both cell types	11900
Animals	11917
the following treatment groups	11953
no transplantation -LRB- n = 16 -RRB- ; -LRB- ii -RRB- injured	11998
no transplantation	11998
n	12018
16	12022
-LRB- ii -RRB- injured	12027
-LRB- ii -RRB-	12027
fibroblast	12051
-LRB- FB -RRB- transplantation	12062
FB	12063
the injury site -LRB- n = 12 -RRB-	12088
the injury site	12088
n	12105
12	12109
iii	12115
SC transplantation	12139
the injury site -LRB- n = 70 -RRB-	12163
the injury site	12163
n	12180
70	12184
iv	12190
OEG transplantation	12213
the injury site -LRB- n = 50 -RRB-	12238
the injury site	12238
n	12255
50	12259
v	12265
female SC and male/EGFP OEG -LRB- 1:1 -RRB- transplantation	12277
female SC	12277
male/EGFP OEG -LRB- 1:1 -RRB- transplantation	12291
male/EGFP OEG	12291
1:1	12306
transplantation	12311
the injury site -LRB- n = 56 -RRB-	12332
the injury site	12332
n	12349
56	12353
vi	12363
female SC transplantation into the injury site with male/EGFP OEG	12376
female SC transplantation	12376
the injury site with male/EGFP OEG	12407
the injury site	12407
male/EGFP OEG	12428
4 mm on either side	12458
4 mm	12458
either side	12466
the host cord -LRB- n = 51 -RRB-	12481
the host cord	12481
n	12496
51	12500
Six uninjured animals	12505
controls	12537
Animals	12547
further	12560
each group	12587
time	12611
0 days , 3 days , 3 weeks , 9 weeks , or 12 weeks post-transplantation	12617
0 days	12617
3 days	12625
3 weeks	12633
9 weeks	12642
12 weeks post-transplantation	12654
endpoint analysis	12689
Animals	12708
the different treatment groups and outcome measures	12743
injury and implantation	12804
surgeries and interventions	12832
a randomized block design due to the large number of animals used for the study	12881
a	12881
block design	12894
the large number of animals used for the study	12914
the large number	12914
animals used for the study	12934
animals	12934
the study	12951
Transplantation Prior to implantation	12962
Transplantation	12962
implantation	12987
EGFP transduced SCs and OEG were harvested from culture via trypsinization	13001
EGFP	13001
SCs and OEG	13017
culture via trypsinization	13049
culture	13049
trypsinization	13061
SCs and OEG	13137
aliquots in DMEMF12 medium	13169
aliquots	13169
DMEMF12 medium	13181
ice	13213
surgery	13226
One week	13235
injury	13250
rats	13258
2 % halothane	13288
the injury site	13305
groups -LRB- i -RRB- 2 x 10 ^ 6 SCs	13337
groups -LRB- i -RRB- 2	13337
groups	13337
i	13345
2	13348
10 ^ 6 SCs	13352
10	13352
6 SCs	13355
-LRB- ii -RRB- 2	13362
-LRB- ii -RRB-	13362
2	13367
10 ^ 6 OEG , -LRB- iii -RRB- 1 x 10 ^ 6 SCs and 1 3 106 OEG ,	13371
10 ^ 6 OEG	13371
10	13371
6 OEG	13374
-LRB- iii -RRB- 1 x 10 ^ 6 SCs and 1 3 106 OEG	13381
-LRB- iii -RRB- 1	13381
-LRB- iii -RRB-	13381
1	13387
10 ^ 6 SCs	13391
10	13391
6 SCs	13394
1 3 106 OEG	13404
1 3	13404
106 OEG	13408
iv	13421
1	13425
10 ^ 6 fibroblasts	13429
10	13429
6 fibroblasts	13432
all in 6 µL of DMEM-F12 medium	13447
all	13447
6 µL of DMEM-F12 medium	13454
6 µL	13454
DMEM-F12 medium	13462
cells	13479
the epicenter of the contused area	13504
the epicenter	13504
the contused area	13521
v	13544
2 3 106 SCs in 6 µL of DMEM-F12 medium	13547
2 3 106 SCs	13547
6 µL of DMEM-F12 medium	13562
6 µL	13562
DMEM-F12 medium	13570
the epicenter of the contused area and 2 3 105 OEG	13605
the epicenter of the contused area	13605
the epicenter	13605
the contused area	13622
2 3 105 OEG	13644
2 3	13644
105 OEG	13648
0.5 µL of DMEM-F12	13659
0.5 µL	13659
DMEM-F12	13669
0.25 µL per injection	13693
0.25 µL	13693
injection	13705
the midline at 4 mm rostral and caudal	13731
the midline	13731
4 mm rostral and caudal	13746
the epicenter of the contused area at a depth of 1 mm	13773
the epicenter	13773
the contused area at a depth of 1 mm	13790
the contused area	13790
a depth of 1 mm	13811
a depth	13811
1 mm	13822
Injections	13828
a 10 or 1 µL	13867
Hamilton syringe	13892
a pulled , beveled glass	13914
pipette tip	13938
200 µm diameter	13951
a micromanipulator with a micro-injector	13977
a micromanipulator	13977
a micro-injector	14001
a rate of 2 µL/min -LRB- World Precision Instruments , Sarasota , FL -RRB-	14021
a rate	14021
2 µL/min -LRB- World Precision Instruments , Sarasota , FL -RRB-	14031
2 µL/min	14031
World Precision Instruments , Sarasota , FL	14041
World Precision Instruments , Sarasota	14041
FL	14080
The injection pipette	14085
place for an additional 3 min	14119
place	14119
an additional 3 min	14129
leakage	14161
withdrawal	14174
the injections	14192
the muscle layers and the skin	14208
the muscle layers	14208
the skin	14230
animals	14266
postoperative care	14283
Injury-only controls	14322
no spinal cord injections	14352
Anterograde	14379
10 weeks	14455
postinjury -LRB- 9 weeks post-transplantation -RRB- rats	14464
postinjury	14464
9 weeks	14476
2 % halothane	14537
-LRB- i -RRB- 10 %	14562
-LRB- i -RRB-	14562
Molecular Probes	14575
Eugene	14593
OR	14601
n = 6 per group	14635
n = 6	14635
n	14635
6	14639
group	14645
the hind limb area	14669
the motor cortex -LRB- 2 3 0.5 µL -RRB- , or -LRB- ii -RRB- 1.5 % CTB	14691
the motor cortex -LRB- 2 3 0.5 µL -RRB- , or -LRB- ii -RRB- 1.5 %	14691
the motor cortex -LRB- 2 3 0.5 µL -RRB- ,	14691
the motor cortex	14691
2 3 0.5 µL	14709
2	14709
3 0.5 µL	14711
3 0.5	14711
µL	14717
ii	14726
1.5 %	14730
CTB	14735
List	14740
Biological Laboratories , Campbell , CA	14745
Biological Laboratories	14745
Campbell , CA	14770
n = 6 per group	14798
n = 6	14798
n	14798
6	14802
group	14808
the right sciatic nerve -LRB- 1 x 1.5 µL -RRB-	14820
the right sciatic nerve	14820
1 x 1.5 µL	14845
1	14845
1.5 µL	14849
Brains from anterogradely traced animals	14858
Brains	14858
anterogradely traced animals	14870
accurate tracer injection	14937
the hind limb area of the motor cortex	14968
the hind limb area	14968
the motor cortex	14990
each animal	15010
Histology	15023
13 weeks after injury -LRB- 12 weeks post-transplantation -RRB-	15036
13 weeks	15036
injury -LRB- 12 weeks post-transplantation -RRB-	15051
injury	15051
12 weeks	15059
rats	15091
70 mg/kg ketamine	15122
10 mg/kg xylazine	15141
4 % paraformaldehyde -LRB- PFA , 0.1 M , pH 7.4 -RRB-	15193
4 % paraformaldehyde	15193
PFA	15214
0.1 M	15219
pH 7.4	15226
The brain and spinal cord	15235
The brain	15235
spinal cord	15249
overnight in 4 % PFA	15288
overnight	15288
4 % PFA	15301
4 °C	15311
phosphate-buffered 30 % sucrose for 48 hours	15340
phosphate-buffered 30 % sucrose	15340
48 hours	15375
4 C for tissue cryoprotection -LRB- gelatin embedding -RRB-	15387
4 C	15387
tissue cryoprotection -LRB- gelatin embedding -RRB-	15395
tissue cryoprotection	15395
gelatin embedding	15418
5 days in 4 % PFA -LRB- refreshed daily -RRB-	15454
5 days	15454
4 % PFA -LRB- refreshed daily -RRB-	15464
4 % PFA	15464
The T7-11 thoracic spinal cords	15490
20 - mm-long piece	15523
20	15523
mm-long piece	15527
the complete lesion and graft site	15559
paraffin	15633
n = 6 per group , no cords embedded for injury only and FB transplant	15643
n	15643
6 per group , no cords embedded for injury only and FB transplant	15647
6 per group	15647
6	15647
group	15653
no cords embedded for injury only and FB transplant	15660
no cords	15660
injury only and FB transplant	15682
injury only	15682
FB transplant	15698
phosphate-buffered 10 % gelatin solution	15719
Difco Laboratories	15760
Detroit	15780
MI	15789
n = 12 per group	15794
n = 12	15794
n	15794
12	15798
group	15805
Barakat	15813
et al. , 2005	15821
et al.	15821
2005	15829
Paraffin-embedded spinal cords	15836
10 µm on a microtome	15896
10 µm	15896
a microtome	15905
stereological counting of numbers of surviving	15930
stereological counting	15930
numbers of surviving	15956
numbers	15956
surviving	15967
transplanted male cells following DNA in situ and 3D	15978
transplanted male cells	15978
DNA in situ and 3D	16012
DNA	16012
situ and 3D	16019
reconstruction	16031
computer-assisted microscopy	16049
Every third section	16079
sectioning	16120
six series	16146
Snowcoat X-tra slides -LRB- Surgipath , Winnipeg , Manitoba -RRB-	16162
Snowcoat X-tra slides	16162
Surgipath	16185
Winnipeg	16196
Manitoba	16206
27 °C	16230
hybridization	16254
Gelatin embedded spinal cords	16269
Gelatin	16269
embedded spinal cords	16277
30 µm on a freezing microtome	16328
30 µm	16328
a freezing microtome	16337
EGFP cell migration	16375
axon growth support in combination	16399
axon growth support	16399
combination	16422
specific immunochemical stains	16439
a separate group of animals , tract tracing	16477
a separate group	16477
animals , tract tracing	16497
animals	16497
tract tracing	16506
tract	16506
Sections	16521
six series in PBS -LRB- 0.1 M , pH 7.4 -RRB-	16550
six series	16550
PBS -LRB- 0.1 M , pH 7.4 -RRB-	16564
PBS	16564
0.1 M	16569
pH 7.4	16576
4 °C	16598
further processing	16608
Western blotting Animals	16628
3 days , 3 weeks or 9 weeks post-transplantation	16681
3 days	16681
3 weeks	16689
9 weeks post-transplantation	16700
a 10-mm piece	16733
spinal cord	16750
the injury/graft site	16775
280 C in liquid nitrogen	16833
280 C	16833
liquid nitrogen	16842
n 5 4 per time point	16859
n	16859
5 4 per time point	16861
5 4	16861
time point	16869
EGFPþ SC	16881
A pregrafted aliquot of 2 million EGFPþ SCs	16904
A pregrafted aliquot	16904
2 million EGFPþ SCs	16928
a 0 day baseline control	16958
Samples	16984
Pearse et al. , 2001	17047
Pearse	17047
et al.	17054
2001	17062
Protein concentrations	17069
the Bradford protein assay -LRB- Bio-Rad , Hercules , CA -RRB-	17114
the Bradford protein assay	17114
Bio-Rad	17142
Hercules	17151
CA	17161
samples	17176
concentrations of 10 mg/mL	17189
concentrations	17189
10 mg/mL	17207
Aliquots	17217
50 µg total protein	17237
loaded for one-dimensional 10 % SDSpolyacrylamide gel electrophoresis	17262
one-dimensional 10 % SDSpolyacrylamide	17273
Proteins	17332
PVDF membranes	17366
5 % nonfat dry milk	17395
then	17418
primary rabbit anti- GFP antibody	17436
1:2,000 ; Santa Cruz Biotechnology , CA	17471
1:2,000	17471
Santa Cruz Biotechnology , CA	17480
HRP-conjugated goat	17522
anti-rabbit IgG -LRB- 1:2,000 ; Santa Cruz Biotechnology -RRB-	17542
anti-rabbit IgG	17542
1:2,000 ; Santa Cruz Biotechnology	17559
1:2,000	17559
Santa Cruz Biotechnology	17568
Membranes	17595
Chemiluminescence Reagent Plus	17630
PerkinElmer Life Sciences , Wellesley , MA	17662
PerkinElmer Life Sciences	17662
Wellesley , MA	17689
1 min	17708
Kodak X-OMAT films -LRB- Eastman Kodak , Rochester , NY -RRB-	17729
Kodak X-OMAT films	17729
Eastman Kodak	17749
Rochester	17764
NY	17775
Quantification of GFP signal	17780
Quantification	17780
GFP signal	17798
a Fluor-S Multi Imager -LRB- Bio-Rad -RRB-	17826
a Fluor-S Multi Imager	17826
Bio-Rad	17850
Band densitometry measurements	17860
Quantity One software version 4.2.0 -LRB- Bio-Rad -RRB-	17907
Quantity One software version 4.2.0	17907
Quantity One software	17907
version 4.2.0	17929
Bio-Rad	17944
consistent loading of equal protein amounts	17964
consistent loading	17964
equal protein amounts	17986
blots	18009
b-actin mouse monoclonal antibody -LRB- 1:1,000 , AbCam -RRB-	18053
b-actin mouse monoclonal antibody	18053
1:1,000 , AbCam	18088
1:1,000	18088
AbCam	18097
b-actin signal	18105
Non-radioactive DNA-DNA ISH	18155
The rat Y-chromosome	18183
specific DNA probe in plasmid pUC18	18204
specific DNA probe	18204
plasmid pUC18	18226
a gift from Dr. Barbara Hoebee -LRB- Essers et al. , 1995 -RRB-	18244
a gift	18244
Dr. Barbara Hoebee -LRB- Essers et al. , 1995 -RRB-	18256
Dr. Barbara Hoebee	18256
Essers	18276
et al. , 1995	18283
et al.	18283
1995	18291
The plasmid	18298
nick translation with digoxigenin	18328
nick translation	18328
digoxigenin	18350
DIG ; Roche Applied Science , Indianapolis , IN	18363
DIG	18363
Roche Applied Science , Indianapolis , IN	18368
Roche Applied Science , Indianapolis ,	18368
Roche Applied Science	18368
Indianapolis	18391
a probe size of 0.1 -- 0.5 kbp	18419
a probe size of 0.1	18419
a probe size	18419
0.1	18435
0.5 kbp	18439
The probe	18448
0.2	18478
0.5 µg/mL	18482
hybridization buffer	18495
50 % Formamide -LRB- Sigma , St.Louis , MO -RRB-	18531
50 % Formamide	18531
Sigma	18546
St.Louis	18553
MO	18563
2X SSC -LRB- pH 8.0 -RRB- , 1X Denhardt 's	18568
2X SSC -LRB- pH 8.0 -RRB-	18568
2X SSC	18568
pH 8.0	18576
1X Denhardt 's	18585
1 mg / mL Herring sperm DNA -LRB- Sigma -RRB-	18600
1 mg / mL Herring sperm DNA	18600
mL Herring sperm DNA	18606
mL Herring	18606
sperm DNA	18617
Sigma	18628
10 % Dextran sulfate -LRB- Sigma -RRB-	18639
10 % Dextran sulfate	18639
Sigma	18660
probe	18676
95 C	18699
use	18719
Sagittal	18724
10 µm paraffin-embedded spinal cord sections	18734
180 µm intervals ; ≈ 10/cord	18780
180 µm intervals	18780
180 µm	18780
intervals	18787
10/cord	18799
xylene	18837
ethanol washes	18877
the tissue for hybridization	18904
the tissue	18904
hybridization	18919
sections	18934
10 µg/mL Proteinase K	18967
USB , Clevelend , OH	18990
USB	18990
Clevelend	18995
OH	19006
TE buffer	19013
The DNA in the tissue	19024
The DNA	19024
the tissue	19035
incubation	19067
0.01 M citrate buffer	19081
pH 6.0	19104
96 °C	19115
slide immersion	19132
50 % Formamide/2X SSC at 75 C and then 70 % ethanol at 270 C. Hybridization	19151
50 % Formamide/2X SSC at 75 C	19151
50 % Formamide/2X SSC	19151
75 C	19175
70 % ethanol at 270 C. Hybridization	19189
70 % ethanol at 270	19189
70 % ethanol	19189
270	19204
C. Hybridization	19208
48 C	19252
post-hybridization washes	19264
the immunodetection process	19291
incubation	19328
solution	19359
alkaline phosphatase-conjugated anti-DIG antibody -LRB- 1:1,000 -RRB-	19379
alkaline phosphatase-conjugated anti-DIG antibody	19379
1:1,000	19430
Roche Applied Science	19440
alkaline phosphatase detection buffer	19476
nitroblue tetrazolium chloride -LRB- NBT -RRB-	19525
nitroblue tetrazolium chloride	19525
NBT	19557
5-bromo-4-chloro-3-indolyl phosphate -LRB- BCIP -RRB-	19566
5-bromo-4-chloro-3-indolyl phosphate	19566
BCIP	19604
Roche Applied Science	19611
Methyl Green -LRB- Vector Laboratories ; Burlingame , CA -RRB-	19662
Methyl Green	19662
Vector Laboratories ; Burlingame , CA	19676
Vector Laboratories	19676
Burlingame , CA	19697
slides	19714
VectaMount medium -LRB- Vector Laboratories -RRB- for microscopic analysis	19744
VectaMount medium -LRB- Vector Laboratories -RRB-	19744
VectaMount medium	19744
Vector Laboratories	19763
microscopic analysis	19788
Male and female cord sections	19810
each ISH reaction as positive and negative controls	19857
each ISH reaction	19857
positive and negative controls	19878
Immunochemistry Every other sixth sagittal section	19924
Immunochemistry	19924
Every other sixth sagittal section	19940
fluorescent microscopy as previously described -LRB- Barakat et al. , 2005 -RRB-	20008
fluorescent microscopy	20008
Barakat	20056
et al. , 2005	20064
et al.	20064
2005	20072
The following primary antibodies	20079
a mix of the monoclonal antibody	20130
a mix	20130
the monoclonal antibody	20139
anti-glial fibrillary acidic protein	20163
GFAP , SMI - 22 , 1:1,000 ; Sternberger Monoclonals , Lutherville , MA	20201
GFAP , SMI - 22 , 1:1,000	20201
GFAP	20201
22	20212
1:1,000	20216
Sternberger Monoclonals , Lutherville , MA	20225
Sternberger Monoclonals	20225
Lutherville , MA	20250
one of the following polyclonal antibodies	20271
one	20271
the following polyclonal antibodies	20278
anti-serotonin	20315
5-HT , 1:5,000 ; Immunostar , Hudson , WI	20331
5-HT	20331
1:5,000 ; Immunostar	20337
1:5,000	20337
Immunostar	20346
Hudson , WI	20358
anticalcitonin gene	20371
related peptide	20391
CGRP , 1:1,000 ; Peninsula Laboratories , San Carlos , CA	20408
CGRP	20408
1:1,000 ; Peninsula Laboratories , San Carlos	20414
1:1,000	20414
Peninsula Laboratories , San Carlos	20423
Peninsula Laboratories	20423
San Carlos	20447
CA	20459
goat anti-CTB -LRB- 1:20,000 ; List Biological Laboratories -RRB-	20466
goat anti-CTB	20466
1:20,000 ; List Biological Laboratories	20481
1:20,000	20481
List Biological Laboratories	20491
List	20491
Biological Laboratories	20496
a mix	20524
the polyclonal anti-GFAP antibody	20533
1:1,000 ; DakoCytomation , Carpinteria , CA	20568
1:1,000	20568
DakoCytomation , Carpinteria , CA	20577
one of the following monoclonal antibodies	20614
one	20614
the following monoclonal antibodies	20621
anti low-affinity neurotrophin receptor	20658
p75 , IgG-192	20699
p75	20699
IgG-192	20704
hybridoma cell line , 1:2	20718
hybridoma cell line	20718
1:2	20739
anti-myelin basic protein -LRB- SMI-94 , 1:1,000 , Sternberger Monoclonals -RRB-	20745
anti-myelin basic protein	20745
SMI-94	20772
1:1,000	20780
Sternberger Monoclonals	20789
anti-neurofilaments	20817
CPCA-NF-M and CPCA-NF-H , 1:500 , Encor Biotechnology , Alachua , FL	20838
CPCA-NF-M and CPCA-NF-H	20838
1:500	20863
Encor Biotechnology	20870
Alachua	20891
FL	20900
the primary antibodies	20911
sections	20935
the fluorescent secondary antibodies	20964
a mix	21002
Alexa 660-conjugated donkey	21011
rabbit -LRB- 1:200 ; Molecular Probes -RRB- and Alexa	21054
rabbit -LRB- 1:200 ; Molecular Probes -RRB-	21054
rabbit	21054
1:200 ; Molecular Probes	21062
1:200	21062
Molecular Probes	21069
Alexa	21091
594-conjugated goat	21097
rabbit or rabbit	21133
rabbit	21133
rabbit	21143
anti-goat	21150
1:200 ; Molecular Probes	21161
1:200	21161
Molecular Probes	21168
Sections	21187
Snowcoat X-tra slides -LRB- Surgipath -RRB-	21214
Snowcoat X-tra slides	21214
Surgipath	21237
Vectashield mounting	21270
me	21291
dium -LRB- Vector Laboratories -RRB-	21295
dium	21295
Vector Laboratories	21301
the nuclear	21333
Hoechst	21349
4 C.	21369
fluorescent visualization	21378
BDA-traced corticospinal tract axons , every other sixth section	21407
BDA-traced corticospinal tract axons	21407
every other sixth section	21445
1 hour	21489
horseradish peroxidase steptavidin	21501
rhodamine -LRB- Vector Laboratories -RRB-	21550
rhodamine	21550
Vector Laboratories	21561
Sections	21583
Snowcoat X-tra slides -LRB- Surgipath -RRB-	21610
Snowcoat X-tra slides	21610
Surgipath	21633
Vectashield mounting medium -LRB- Vector Laboratories -RRB-	21666
Vectashield mounting medium	21666
Vector Laboratories	21695
the nuclear	21727
Hoechst	21743
4 °C	21763
Stereological quantification	21768
male , EGFPþ or p75þ cell number	21800
one series	21835
mounted sagittal sections	21849
male cells	21876
DNA ISH or EGFPþ and p75þ cells	21907
fluorescent signal	21954
an unbiased method	21993
computer-assisted microscopy and StereoInvestigator software	22022
MicroBrightField	22084
the 3D structure	22113
the spinal cord	22133
n	22150
= 6 per group at each time point	22152
= 6	22152
group at each time point	22160
group	22160
each time point	22169
3 days , 3 weeks , or 9 weeks post-transplantation	22186
3 days	22186
3 weeks	22194
9 weeks post-transplantation	22206
each section	22240
the boundary of the cell graft	22253
the boundary	22253
the cell graft	22269
a dense area -LRB- s -RRB-	22299
a dense area	22299
alkaline phosphatase-positive -LRB- male -RRB- cell nuclei	22318
EGFPþ or p75þ cells	22368
a 203 objective	22411
the StereoInvestigator software	22443
serial section manager	22481
the positions	22519
each section -LRB- 10 sections per spinal cord at 180 µm intervals -RRB-	22536
each section	22536
10 sections per spinal cord at 180 µm intervals	22551
10 sections	22551
spinal cord at 180 µm intervals	22567
spinal cord	22567
180 µm intervals	22582
the Z-axis of the 3D reconstruction of the spinal cord	22607
the Z-axis	22607
the 3D reconstruction of the spinal cord	22621
the 3D reconstruction	22621
the spinal cord	22646
optical fractionator , the traced contour of each section	22675
optical fractionator	22675
the traced contour of each section	22697
the traced contour	22697
each section	22719
50 3 50 µm2 counting frames	22749
these frames	22778
two	22813
four cells	22820
the grid size	22838
the software	22884
counting of 35 sampling sites	22907
counting	22907
35 sampling sites	22919
each traced contour of each section	22944
each traced contour	22944
each section	22967
each sampling site	22984
the number	23003
positive cells	23017
methyl green -LRB- in situ -RRB- or Hoechst -LRB- fluorescence -RRB-	23037
methyl green	23037
situ	23054
Hoechst	23063
fluorescence	23072
nuclei	23094
a dissector probe	23123
a 633 objective	23147
Algorithms	23164
the Zstack total counts of positive cells	23190
the Zstack total counts	23190
positive cells	23217
the 3D structure of each spinal cord	23239
the 3D structure	23239
each spinal cord	23259
StereoInvestigator 3.0 -LRB- MicroBrightField -RRB-	23304
StereoInvestigator 3.0	23304
MicroBrightField	23328
The coefficient	23347
error -LRB- CE -RRB-	23366
error	23366
CE	23373
Gundersen	23378
each estimated count	23393
less than 10 %	23418
Assessment	23433
glial cell migratory ability	23447
the migratory ability of transplanted glial cells	23486
the migratory ability	23486
transplanted glial cells	23511
the injured spinal cord , sections that contained Y-probe labeled cells	23543
the injured spinal cord	23543
sections that contained Y-probe labeled cells	23568
sections	23568
Y-probe labeled cells	23592
Y-probe	23592
cells	23608
GFAP	23637
the borders of the injury site	23652
the borders	23652
the injury site	23667
Spinal cords	23684
3D	23724
StereoInvestigator software and computer-assisted microscopy	23733
n = 5/group	23795
n	23795
= 5/group	23797
the 3D representation of the spinal cord from each animal	23816
the 3D representation	23816
the spinal cord from each animal	23841
the spinal cord	23841
each animal	23862
50	23891
x 50 x 30 µm3 3D sampling grids	23894
50	23896
30 µm3 3D sampling grids	23901
cell counts	23937
The number of cell counts obtained within each grid -LRB- 20 3 5 arrays -RRB-	23971
The number	23971
cell counts obtained within each grid -LRB- 20 3 5 arrays -RRB-	23985
cell counts	23985
each grid -LRB- 20 3 5 arrays -RRB-	24013
each grid	24013
20 3 5 arrays	24024
20 3	24024
5 arrays	24029
a percentage of the total counts for the whole spinal cord	24061
a percentage	24061
the total counts for the whole spinal cord	24077
the total counts	24077
the whole spinal cord	24098
We	24121
these percentages	24138
each of the 100 gids	24159
each	24159
the 100 gids	24167
all the animals	24186
a particular group	24209
specific transplant type and timepoint i.e. SCs into the lesion at 3 days	24229
specific transplant type and timepoint i.e. SCs	24229
specific transplant type and timepoint	24229
the lesion at 3 days	24282
the lesion	24282
3 days	24296
this method	24311
we	24324
the spatial density of the grafted cells	24347
the spatial density	24347
the grafted cells	24370
rostral-caudal , dorsal-ventral space relative to the injection site	24391
rostral-caudal , dorsal-ventral space	24391
the injection site	24440
visualization of how they changed over time within a specific	24495
visualization	24495
they	24516
time	24534
a specific	24546
group	24565
no deviations	24575
the method	24608
statistical comparisons	24629
Quantitative assessment of traced fibers BDA - or CTB-labeled axons	24672
Quantitative assessment	24672
fibers BDA - or CTB-labeled axons	24706
fibers BDA	24706
fibers	24706
BDA	24713
CTB-labeled axons	24721
every sixth section of the T8 -- 10 cord segments , i.e.	24756
every sixth section	24756
the T8 -- 10 cord segments , i.e.	24779
the T8	24779
10 cord segments	24786
every 180 µm interval	24809
the width of the spinal cord	24840
the width	24840
the spinal cord	24853
12 weeks	24872
axons	24911
fluorescence microscopy	24939
The number of BDA-labeled axons	24964
The number	24964
BDA-labeled axons	24978
all	25023
axons	25035
imaginary lines	25050
the rostral-caudal cord axis at 2,000 µm and 500 µm rostral	25090
the rostral-caudal cord axis	25090
2,000 µm and 500 µm rostral	25122
2,000 µm	25122
500 µm rostral	25135
the graft-host or injury-host interface	25153
the graft-host	25153
injury-host interface	25171
the GFAP-EGFP or GFAPþ-GFAP2 border	25208
the epicenter of the graft/injury site	25252
the epicenter	25252
the graft/injury site	25269
oil immersion	25297
a 633 objective	25316
The number of CTB-labeled axons	25333
The number	25333
CTB-labeled axons	25347
2,000 µm and 500 µm caudal to the graft-host or injury-host interface	25396
2,000 µm	25396
500 µm caudal to the graft-host or injury-host interface	25409
500 µm caudal	25409
the graft-host or injury-host interface	25426
the graft-host	25426
injury-host interface	25444
the epicenter of the graft/injury site	25473
the epicenter	25473
the graft/injury site	25490
The number of fibers from each section , 10 sections per spinal cord ,	25513
The number of fibers from each section	25513
The number	25513
fibers from each section	25527
fibers	25527
each section	25539
10 sections per spinal cord	25554
10 sections	25554
spinal cord	25570
each rat	25603
the number of fibers per section	25625
the number	25625
fibers per section	25639
fibers	25639
section	25650
the totals	25659
the number of sections examined	25691
the number	25691
sections examined	25705
sections	25705
Tracing efficiency	25724
animals	25768
intensity in the dorsal columns of five transverse sections	25793
intensity	25793
the dorsal columns of five transverse sections	25806
the dorsal columns	25806
five transverse sections	25828
either the C2 or L5 spinal cord	25858
the C2	25865
L5 spinal cord	25875
BDA and CTB	25894
each animal	25934
Images of the dorsal columns in each of the sections	25947
Images	25947
the dorsal columns in each of the sections	25957
the dorsal columns	25957
each of the sections	25979
each	25979
the sections	25987
intensity-measuring software	26020
van der Lest et al. , University of Njimegen ,	26050
van der	26050
et al. , University of Njimegen ,	26063
et al.	26063
University of Njimegen	26071
University	26071
Njimegen	26085
The Netherlands	26095
The software automatically measured , and gave in arbitrary units	26113
The software	26113
arbitrary units	26162
the total pixel intensity of the	26179
the total pixel intensity	26179
the	26208
staining	26216
each image	26228
These values	26240
the five sections	26277
a mean BDA or CTB intensity	26303
each animal	26335
a measure of tracing efficiency	26350
a measure	26350
efficiency	26371
Determination of 5HT and CGRP	26383
Determination	26383
5HT and CGRP	26400
fiber growth	26413
The numbers of 5HT	26426
The numbers	26426
5HT	26441
axons	26454
all	26488
axons	26500
imaginary lines	26515
the rostral-caudal axis of the spinal cord at 2,000 µm and 500 µm rostral	26555
the rostral-caudal axis	26555
the spinal cord at 2,000 µm and 500 µm rostral	26582
the spinal cord	26582
2,000 µm and 500 µm rostral	26601
2,000 µm	26601
500 µm rostral	26614
the grafthost or injury-host interface	26632
the grafthost	26632
injury-host interface	26649
the GFAPEGFP or GFAPþ-GFAP2 border	26686
the epicenter of the graft/injury site	26729
the epicenter	26729
the graft/injury site	26746
oil immersion	26774
a 633 objective	26793
The number of CGRP-labeled axons	26810
The number	26810
CGRP-labeled axons	26824
2,000 and 500 lm caudal to the graft-host or injury-host interface	26874
2,000 and 500 lm caudal	26874
the graft-host or injury-host interface	26901
the graft-host	26901
injury-host interface	26919
the epicenter of the graft/injury site	26948
the epicenter	26948
the graft/injury site	26965
The number of fibers from each section , ≈ 10 sections per spinal cord ,	26988
The number	26988
fibers from each section , ≈	27002
fibers	27002
each section	27014
10 sections per spinal cord	27029
10 sections	27029
spinal cord	27045
each rat	27078
n = 6 per group	27088
n = 6	27088
n	27088
6	27092
group	27098
12 weeks	27107
the number of fibers per section	27151
the number	27151
fibers per section	27165
fibers	27165
section	27176
the totals	27185
the number of sections examined	27217
the number	27217
sections examined	27231
sections	27231
Assessment	27250
We	27276
myelination of axons	27288
myelination	27288
axons	27303
SC and OEG transplants in vivo using high power	27316
SC and OEG transplants	27316
high power	27353
the number	27390
axons	27404
myelin basic protein -LRB- MBP -RRB- immunostaining	27415
MBP	27437
the number	27469
EGFP	27483
cells	27496
three regions of the transplants	27510
three regions	27510
the transplants	27527
three sections	27547
one	27563
the central canal and two	27578
the central canal	27578
two	27600
180 µm on either side , 200 µm2 areas	27607
180 µm	27607
either side , 200 µm2 areas	27617
either side	27617
200 µm2 areas	27630
the center of the graft and at distances 1,500 µm both rostral and caudal	27663
the center of the graft	27663
the center	27663
the graft	27677
distances	27694
1,500 µm both rostral and caudal	27704
1,500 µm	27704
rostral and caudal	27718
the center	27740
the transplants , from pictures obtained of the grafts	27769
the transplants	27769
pictures obtained of the grafts	27791
pictures	27791
the grafts	27812
oil immersion with the 633 objective	27829
oil immersion	27829
the 633 objective	27848
Neuroleucida	27872
software -LRB- Micro - BrightField -RRB-	27898
software	27898
Micro - BrightField	27908
Micro	27908
BrightField	27915
each of these three areas	27932
each	27932
these three areas	27940
the numbers of MBPþ axons and EGFPþ cells	27959
the numbers	27959
MBPþ axons and EGFPþ cells	27974
ratios of myelinated axons to grafted cells obtained	28015
ratios	28015
myelinated axons to grafted cells obtained	28025
myelinated axons	28025
grafted cells obtained	28045
grafted cells	28045
these ratios	28072
the three sections	28106
Myelination	28126
those animals	28154
EGFPþ SCs alone or SCs and EGFPþ OEG	28181
EGFPþ SCs	28181
SCs and EGFPþ OEG	28200
the injury site due to the formation of large , substantive transplants	28223
the injury site	28223
the formation of large , substantive transplants	28246
the formation	28246
large , substantive transplants	28263
these groups	28302
Behavioral testing Gross	28316
limb performance	28346
1 to 9 weeks post-transplantation	28389
1 to 9 weeks	28389
the open field locomotor test -LRB- BBB -RRB-	28429
the open field locomotor test	28429
BBB	28460
Basso	28478
et al. -LRB- 1995 -RRB- -LRB- n = 12 per group -RRB-	28484
et al. -LRB- 1995 -RRB-	28484
et al.	28484
1995	28492
n = 12 per group	28499
n = 12	28499
n	28499
12	28503
group	28510
A BBB sub-score	28518
the recovery of some animals	28546
the recovery	28546
some animals	28562
the progression of the BBB score	28590
the progression	28590
the BBB score	28609
BBB sub-scores	28624
paw position	28665
parallel paw rotation	28679
initial contact -LRB- 1 point/limb -RRB- and liftoff -LRB- 1 point/limb -RRB-	28704
initial contact	28704
1 point/limb	28721
liftoff	28739
1 point/limb	28748
toe clearance	28763
occasional clearance -LRB- < 50 % of the time , 1 point / limb -RRB-	28778
occasional clearance	28778
< 50 % of the time , 1 point / limb	28800
< 50 %	28800
<	28800
the time , 1 point / limb	28808
the time	28808
1 point / limb	28818
limb	28827
frequent clearance -LRB- 51 -- 95 % , 2 points/limb -RRB-	28834
frequent clearance	28834
51	28854
95 % , 2 points/limb	28857
95 %	28857
2 points/limb	28862
consistent clearance -LRB- > 95 % , 3 points/limb -RRB- ; tail position , up /	28878
consistent clearance -LRB- > 95 % , 3 points/limb -RRB-	28878
consistent clearance	28878
> 95 % , 3 points/limb	28900
>	28900
95 %	28901
3 points/limb	28906
tail position	28922
1 point	28947
2 points	28961
trunk stability -LRB- 1 point -RRB-	28976
trunk stability	28976
1 point	28993
The cumulative scores for each hind limb and tail position	29003
The cumulative scores	29003
each hind limb and tail position	29029
a single score -LRB- maximum of 13 per rat -RRB-	29083
a single score	29083
maximum of 13 per rat	29099
maximum	29099
13	29110
rat	29117
Footprint analysis	29123
endpoint	29159
a procedure	29174
de Medinaceli et al. -LRB- 1982 -RRB-	29200
de Medinaceli et al.	29200
n = 12 per group and n = 6 uninjured controls	29229
n = 12 per group and n	29229
n = 12	29229
n	29229
12	29233
group and n	29240
= 6 uninjured controls	29252
Pearse	29301
et al. , 2004a	29308
et al.	29308
2004a	29316
Deficits in descending motor control	29324
Deficits	29324
descending motor control	29336
the animals	29386
an irregularly-spaced grid walk apparatus	29401
endpoint as previously described -LRB- Pearse et al. , 2004a -RRB-	29446
endpoint	29446
Pearse	29480
et al. , 2004a	29487
et al.	29487
2004a	29495
Statistical analysis One-way ANOVA followed by the Bonferroni post-hoc test	29503
Statistical analysis One-way ANOVA	29503
the Bonferroni post-hoc test	29550
results	29602
anterograde tracing and axon counts	29613
immunohistochemical detection of specific fiber types	29655
immunohistochemical detection	29655
specific fiber types	29688
A mixed factorial	29710
measures	29738
ANOVA followed by the Tukey-Kramer test	29748
ANOVA	29748
the Tukey-Kramer test	29766
comparison of weekly functional recovery patterns	29801
comparison	29801
weekly functional recovery patterns	29815
injury	29857
Differences	29865
P	29926
0.05	29930
< 0.01 **	29937
< 0.01	29937
<	29937
0.01	29938
< 0.001 *** , compared with injury-only controls	29949
< 0.001 ***	29949
<	29949
0.001 ***	29950
injury-only controls	29974
All errors	29996
standard deviations	30020
RESULTS	30042
1	30056
Myelination of Axons	30059
Myelination	30059
Axons	30074
SC and OEG Transplants In Vivo	30087
SC and OEG Transplants	30087
Vivo	30113
High Power Microscopic Assessment	30124
the Number of Axons with Myelin Basic Protein	30161
the Number	30161
Axons with Myelin Basic Protein	30175
Axons	30175
Myelin Basic Protein	30186
MBP	30208
Immunostaining Compared with the Number of EGFP	30213
Immunostaining	30213
the Number of EGFP	30242
the Number	30242
EGFP	30256
Cells	30269
Three Regions	30283
the Transplants -LRB- Rostral 200 µm2 , Center 200 µm2 , Caudal 200 µm2 -RRB-	30300
the Transplants	30300
Rostral	30317
200 µm2 , Center 200 µm2 , Caudal 200 µm2	30325
200 µm2	30325
Center 200 µm2	30334
Caudal 200 µm2	30350
Fig. 1	30367
Survival of exogenous male glia in spinal cord	30375
Survival	30375
exogenous male glia in spinal cord	30387
exogenous male glia	30387
spinal cord	30410
female rats	30430
A : The NBT-BCIP reaction product	30443
The NBT-BCIP reaction	30446
a single dark point	30490
the nucleus -LRB- methyl green nuclear counterstain -RRB-	30517
the nucleus	30517
methyl green nuclear counterstain	30530
methyl	30530
green nuclear counterstain	30537
each transplanted male SC at 9 weeks post-implantation -LRB- black arrows -RRB-	30568
each transplanted male SC	30568
9 weeks post-implantation -LRB- black arrows -RRB-	30597
9 weeks post-implantation	30597
black arrows	30624
Host female cells	30639
signal allowing differential identification of grafted versus host cells	30671
signal	30671
differential identification of grafted versus host cells	30687
differential identification	30687
host cells	30733
Scale	30745
20 µm	30757
B	30764
The graph	30767
the number of male SCs or OEG counted per rat	30783
the number	30783
male SCs or OEG	30797
rat	30825
a percentage of the original number of cells transplanted	30842
a percentage	30842
the original number of cells transplanted	30858
the original number	30858
cells transplanted	30881
cells	30881
There	30901
a significant loss	30910
both cell types within all paradigms at 3 and 9 weeks post-transplantation	30932
both cell types	30932
all paradigms at 3 and 9 weeks post-transplantation	30955
all paradigms	30955
at 3 and 9 weeks	30969
SCs -LRB- SC-C -RRB-	31008
SCs	31008
SC-C	31013
better survival	31027
OEG -LRB- OEG-C -RRB-	31048
OEG	31048
OEG-C	31053
the injury epicenter	31083
OEG show	31105
survival	31123
SCs -LRB- -LSB- SC -RSB- - OEG-C -RRB-	31155
SCs	31155
-LSB- SC -RSB- - OEG-C	31160
-LSB- SC -RSB-	31160
OEG-C	31165
normal-appearing host	31180
spinal cord	31202
lower numbers -LRB- -LSB- SC -RSB- - OEG-S -RRB-	31217
lower numbers	31217
-LSB- SC -RSB- - OEG-S	31232
-LSB- SC -RSB-	31232
OEG-S	31237
P	31248
0.001	31252
comparisons between the 3 day and both 3 and 9 week time points	31262
comparisons	31262
the 3 day and both 3 and 9 week time points	31282
the 3 day	31282
both 3 and 9 week time points	31296
each horizontal line	31342
Fig. 2 .	31365
Fig.	31365
2	31370
Efficiency	31373
lentiviral vector transfer	31387
EGFP to Schwann cells and olfactory ensheathing glia in vitro	31417
EGFP to Schwann cells	31417
EGFP	31417
Schwann cells	31425
olfactory ensheathing glia in vitro	31443
olfactory ensheathing glia	31443
vitro	31473
Immunostaining	31480
A.	31498
SC or B. OEG cultures	31501
SC	31501
B. OEG cultures	31507
the low-affinity neurotrophin receptor -LRB- p75 -RRB-	31527
the low-affinity neurotrophin receptor	31527
p75	31567
lentiviral vector transduction and spinal cord implantation	31581
lentiviral vector transduction	31581
spinal cord implantation	31616
the majority of the cells -LRB- > 98 % -RRB-	31652
the majority	31652
the cells -LRB- > 98 % -RRB-	31668
the cells	31668
> 98 %	31679
>	31679
98 %	31680
this marker	31702
infection of C. SCs or D. OEG with lentiviral vectors carrying the EGFP gene	31725
infection	31725
C. SCs or D. OEG with lentiviral vectors carrying the EGFP gene	31738
C. SCs	31738
D. OEG with lentiviral vectors carrying the EGFP gene	31748
D. OEG	31748
lentiviral vectors carrying the EGFP gene	31760
lentiviral vectors	31760
the EGFP gene	31788
high transduction efficiency -LRB- 95 -- 98 % -RRB-	31813
high transduction efficiency	31813
95 -- 98 %	31843
95	31843
98 %	31846
robust transgene expression	31855
Scale bars	31884
20 µm	31897
Fig. 3 .	31905
Fig.	31905
3	31910
Comparison of EGFP and p75	31913
Comparison	31913
EGFP and p75	31927
Schwann cells and olfactory ensheathing glia in vivo	31948
Schwann cells	31948
olfactory ensheathing glia in vivo	31966
olfactory ensheathing glia	31966
vivo	31996
A -- C : EGFPþ SCs	32002
C : EGFPþ	32004
C	32004
EGFPþ	32007
the injured spinal cord	32036
9 weeks following transplantation into the injury epicenter	32063
9 weeks	32063
transplantation into the injury epicenter	32081
transplantation	32081
the injury epicenter	32102
A : Schematic of the injured spinal cord after EGFP-SC implantation .	32124
A : Schematic of the injured spinal cord	32124
Schematic of the injured spinal cord	32127
Schematic	32127
the injured spinal cord	32140
EGFP-SC implantation	32170
a central region of EGFPþ/p75þ	32202
a central region	32202
EGFPþ/p75þ	32222
SCs and EGFP2/p75þ	32243
endogenous SCs -LRB- green dotted line -RRB-	32262
endogenous SCs	32262
green dotted line	32278
green	32278
line	32291
areas	32315
EGFP2/p75þ endogenous SCs within the lesion area -LRB- red dotted line -RRB-	32324
EGFP2/p75þ endogenous SCs	32324
the lesion area	32357
red dotted line	32374
red	32374
line	32385
B	32392
Immunoreactivity for p75 -LRB- red -RRB-	32395
Immunoreactivity	32395
p75 -LRB- red -RRB-	32416
p75	32416
red	32421
regions	32449
transplanted EGFPþ SCs	32468
areas devoid of EGFPþ SCs	32498
areas	32498
EGFPþ SCs	32514
C	32525
The number of p75þ cells	32528
The number	32528
p75þ cells	32542
that of EGFPþ SCs	32588
that	32588
EGFPþ SCs	32596
the center of the graft	32613
the center	32613
the graft	32627
D	32638
F	32640
9 weeks	32643
transplantation of unlabeled SCs and EGFPþ OEG into the injury epicenter	32657
transplantation of unlabeled SCs	32657
transplantation	32657
unlabeled SCs	32676
EGFPþ OEG into the injury epicenter	32694
EGFPþ OEG	32694
the injury epicenter	32709
D	32731
Schematic	32734
the injured spinal cord	32747
combination grafting	32777
a smaller EGFPþ	32804
that	32828
EGFP2/p75þ unlabeled exogenous and in-migrating endogenous SCs	32869
EGFP2/p75þ unlabeled exogenous	32869
EGFP2/p75þ	32869
in-migrating endogenous SCs	32904
E	32933
Regions	32936
p75þ/EGFP2 and p75þ/EGFPþ cells	32955
the injured spinal cord	33003
F	33028
areas of EGFPþ OEG	33038
areas	33038
EGFPþ OEG	33047
p75 immunoreactivity	33058
both EGFPþ and EGFP2 cells	33102
G -- I	33130
G	33130
I	33132
unlabeled SCs	33143
the lesion and EGFPþ OEG	33162
normal-appearing host tissue	33192
9 weeks	33224
almost all of the p75 reactivity	33275
almost all	33275
the p75 reactivity	33289
present within the grafted region	33308
present	33308
the grafted region	33323
GFAP -LRB- blue -RRB-	33343
GFAP	33343
blue	33349
host astrocytes	33376
All in vivo images	33393
All	33393
vivo images	33400
10 µm-thick confocal projection images	33416
White boxes	33456
regions that are shown as accompanying higher magnification images	33475
regions	33475
higher magnification images	33514
White scale bars	33543
20 µm , yellow scale bars = 200 µm	33562
20 µm	33562
yellow scale bars = 200 µm	33569
yellow scale bars	33569
= 200 µm	33587
200	33589
Fig. 4 .	33598
Fig.	33598
4	33603
Comparison	33606
EGFPþ and p75þ cell counts	33620
the injured spinal cord over time	33654
the injured spinal cord	33654
time	33683
different transplant paradigms	33691
EGFPþ cells	33723
counts of cells immunoreactive for p75	33751
counts	33751
cells immunoreactive for p75	33761
cells	33761
p75	33786
3 days	33793
groups	33819
A : EGFPþ SCs into the injury epicenter or C : EGFPþ OEG	33843
EGFPþ SCs into the injury epicenter or C	33846
EGFPþ SCs	33846
the injury epicenter or C	33861
SCs -LSB- 1:1 -RSB-	33902
SCs	33902
1:1 -RSB-	33907
the injury epicenter	33917
the number of EGFPþ cells	33939
the number	33939
EGFPþ cells	33953
3 to 9 weeks post-transplantation	33991
3 to 9 weeks	33991
the number of p75þ cells	34031
the number	34031
p75þ cells	34045
B	34076
EGFPþ	34082
OEG only	34088
both EGFPþ and p75þ cell	34105
3 to 9 weeks	34152
a large central cavity	34168
the injury/transplant site	34204
The number of p75þ cells	34232
The number	34232
p75þ cells	34246
counts of EGFPþ cells	34297
counts	34297
EGFPþ cells	34307
these time points	34322
D	34341
Transplantation	34344
non-labeled SCs	34363
the injury epicenter with a low number of EGFPþ OEG grafted on either side	34384
the injury epicenter	34384
a low number of EGFPþ OEG grafted on either side	34410
a low number	34410
EGFPþ OEG grafted on either side	34426
EGFPþ OEG	34426
either side	34447
a significant disparity	34471
all time points between the numbers of cells with the two different labels	34498
all time points	34498
the numbers of cells with the two different labels	34522
the numbers	34522
cells with the two different labels	34537
cells	34537
the two different labels	34548
E	34587
Graph	34590
temporal changes	34606
the number	34626
EGFPþ cells	34640
p75 immunoreactivity	34680
stereological cell counts	34706
grafted EGFP-OEG	34741
largely p75	34765
all time points at a percentage	34799
all time points	34799
a percentage	34818
that observed in vitro	34842
that	34842
implanted EGFP-SCs	34866
reduced p75 labeling over time	34895
reduced p75 labeling	34895
time	34921
some of the cells	34941
some	34941
the cells	34949
a myelinating phenotype	34980
Lines -- solid , EGFPþ ; dashed , p75þ .	35005
Lines -- solid , EGFPþ	35005
Lines	35005
solid , EGFPþ	35011
solid	35011
EGFPþ	35018
p75þ	35033
P <	35040
P	35040
<	35042
0.05	35044
P <	35052
P	35052
<	35054
0.01 and *** P	35056
0.01	35056
*** P	35065
0.001	35072
comparisons at each time point	35082
comparisons	35082
each time point	35097
the number	35121
cells with the two different labels	35135
cells	35135
the two different labels	35146
Fig. 5 .	35173
Fig.	35173
5	35178
Survival of EGFP	35181
Survival	35181
EGFP	35193
Schwann cells	35206
transplantation	35226
A : Immunoblot detection of EGFP levels in an aliquot of	35243
A : Immunoblot detection of EGFP levels	35243
Immunoblot detection of EGFP	35246
Immunoblot detection	35246
EGFP	35270
an aliquot of	35285
an aliquot	35285
SCs	35307
transplantation -LRB- 0 days -RRB-	35332
transplantation	35332
0 days	35349
a 10 mm piece of spinal cord	35363
a 10 mm piece	35363
spinal cord	35380
the injury epicenter/graft site	35405
3	35440
21 or 63 days following transplantation	35443
21 or 63 days	35443
transplantation	35467
Detection of b-actin following blot stripping	35484
Detection	35484
b-actin following blot stripping	35497
b-actin following blot	35497
equal protein loading	35549
B : Densitometry measurements for EGFP band intensity .	35572
B	35572
Densitometry measurements for EGFP band intensity	35575
Densitometry measurements	35575
EGFP band intensity	35605
A significant reduction in EGFP signal	35626
A significant reduction	35626
EGFP signal	35653
21 and 63	35677
3 days	35696
pregrafted controls	35738
EGFP levels	35759
21 and 63 days	35822
Legend	35838
EGFPþ SCs immediately prior to grafting into the injury site	35846
EGFPþ SCs	35846
the injury site	35891
EGFPþ SCs at 3 days post-transplantation	35908
EGFPþ SCs	35908
3 days	35921
EGFPþ SCs at 21 days post-transplantation	35950
EGFPþ SCs	35950
21 days	35963
EGFPþ SCs at 63 days post-transplantation	35993
EGFPþ SCs	35993
63 days	36006
*** P < 0.001 for comparisons between time points post-transplantation	36036
*** P	36036
< 0.001 for comparisons between time points post-transplantation	36041
0.001	36043
comparisons between time points	36053
comparisons	36053
time points	36073
0 days	36110
Fig. 6 .	36119
Fig.	36119
6	36124
Three-dimensional position of	36127
Three-dimensional position	36127
glial cells	36165
the injured spinal cord over time	36184
the injured spinal cord	36184
time	36213
different transplant paradigms	36221
A -- C : Localization of male SCs transplanted into the injury site at A	36253
A -- C : Localization	36253
C	36255
male SCs	36274
the injury site at A	36301
the injury site	36301
3 days , B	36323
3 days	36323
B	36331
3 weeks and C	36334
3 weeks	36334
C	36346
9 weeks after grafting	36349
9 weeks	36349
grafting	36363
SCs	36381
the initial site of deposition -LRB- red arrow -RRB-	36410
the initial site	36410
deposition -LRB- red arrow -RRB-	36430
deposition	36430
red arrow	36442
D	36454
F	36456
male OEG	36472
greater spread	36491
the injured spinal cord after transplantation	36513
the injured spinal cord	36513
transplantation	36543
the epicenter than SCs over time	36564
the epicenter	36564
SCs over time	36583
SCs	36583
time	36592
D	36601
3 days , E	36604
3 days	36604
E	36612
3 weeks or F	36615
3 weeks	36615
F	36626
9 weeks after grafting	36629
9 weeks	36629
grafting	36643
G	36653
I	36655
Transplantation	36658
SCs and EGFPþ OEG	36677
1:1 -RSB- into the injury epicenter	36696
1:1 -RSB-	36696
the injury epicenter	36706
a spinal cord distribution of OEG	36734
a spinal cord distribution	36734
OEG	36764
G	36771
3 days to H	36774
3 days	36774
H	36784
3 weeks to I	36787
3 weeks	36787
I	36798
9 weeks that was similar to their grafting alone	36801
9 weeks	36801
their grafting	36829
J	36851
L	36853
The injection	36856
EGFPþ OEG	36873
normal	36888
host cord	36905
rostral and caudal to SCs that were grafted into the injury epicenter	36921
rostral and caudal	36921
SCs that were grafted into the injury epicenter	36943
SCs	36943
the injury epicenter	36970
a temporal change in EGFPþ OEG distribution	37004
a temporal change	37004
EGFPþ OEG distribution	37025
J	37053
3 days to K	37056
3 days	37056
K	37066
3 weeks to L	37069
3 weeks	37069
L	37080
9 weeks as EGFPþ OEG migrated towards the injury site	37083
9 weeks	37083
EGFPþ OEG	37094
the injury site	37121
Abbreviations for 3D space locations	37138
Abbreviations	37138
3D space locations	37156
R , rostral ; C , caudal ; D , dorsal ; and V , ventral	37176
R , rostral	37176
R	37176
rostral	37179
C , caudal	37188
C	37188
caudal	37191
D , dorsal	37199
D	37199
dorsal	37202
V , ventral	37214
V	37214
ventral	37217
Intervals on 3D pimple graphs	37226
Intervals	37226
3D pimple graphs	37239
distances of 500 µm	37266
distances	37266
500 µm	37279
Red arrows	37287
the approximate location of the original deposition of the fluid graft	37307
the approximate location	37307
the original deposition of the fluid graft	37335
the original deposition	37335
the fluid graft	37362
injection	37381
The color of each square on the graph	37392
The color	37392
each square	37405
the graph	37420
the number of cells within each 500 µm3 3D space	37438
the number	37438
cells within each 500 µm3 3D space	37452
cells	37452
each 500 µm3 3D space	37465
a percentage of total remaining cells	37500
a percentage	37500
total remaining cells	37516
the injured spinal cord	37553
n	37595
= 5 : 1 %	37597
= 5	37597
1 %	37602
9 %	37634
cell type	37649
cell	37677
Fig. 7 .	37684
Fig.	37684
7	37689
Migration of EGFP	37692
Migration	37692
EGFP	37705
olfactory ensheathing glia and Schwann cells	37718
9 weeks	37776
no EGFPþ OEG	37784
host cord	37824
gray or white matter towards the injury after injection on either side	37834
gray or white matter	37834
the injury after injection on either side	37863
the injury	37863
injection on either side	37880
injection	37880
either side	37893
numerous EGFPþ OEG	37906
graft-injury sites	37944
either A : sub-pial from the injection entry site or B :	37976
either A	37976
sub-pial from the injection entry site or B	37986
sub-pial	37986
the injection entry site or B	38000
the injection entry site	38000
B	38028
the central canal	38035
C	38054
EGFPþ SCs	38065
the original site of deposition	38098
the original site	38098
deposition	38119
the injury epicenter	38137
GFAP	38159
blue or yellow	38165
immunostaining	38181
host astrocytes	38207
A : and B : are 20 µm-thick confocal projection images .	38224
A : and B : are 20 µm-thick confocal projection images	38224
A : and B :	38224
20 µm-thick confocal projection images	38238
White scale	38278
0 20 µm , yellow scale bar 0 1 µm	38294
0 20 µm	38294
yellow scale bar 0 1 µm	38303
yellow scale bar	38303
0 1 µm	38320
Fig. 8 .	38329
Fig.	38329
8	38334
Axonal growth support by transplanted glia .	38337
Axonal growth support	38337
transplanted glia	38362
Schematics	38381
Fig. 3A	38397
C to show location of areas in panels D	38405
location of areas in panels D	38415
location	38415
areas in panels D	38427
areas	38427
panels D	38436
K : EGFP-SC implantation into the injury epicenter -LRB- A -RRB-	38445
K	38445
EGFP-SC implantation into the injury epicenter -LRB- A -RRB-	38448
EGFP-SC implantation	38448
the injury epicenter -LRB- A -RRB-	38474
the injury epicenter	38474
A	38496
unlabeled SC grafting into the lesion with EGFP-OEG	38502
unlabeled SC	38502
the lesion with EGFP-OEG	38529
the lesion	38529
EGFP-OEG	38545
-LRB- B -RRB- or within -LRB- C -RRB- the lesion	38585
-LRB- B -RRB-	38585
within -LRB- C -RRB- the lesion	38592
within	38592
C	38600
the lesion	38603
EGFPþ SCs -LRB- D , E -RRB-	38615
EGFPþ SCs	38615
D , E	38626
D	38626
E	38628
the epicenter and EGFPþ OEG -LRB- F , G -RRB- grafts were supportive	38646
the epicenter and EGFPþ OEG -LRB- F , G -RRB-	38646
the epicenter and EGFPþ OEG	38646
F , G	38675
F	38675
G	38677
grafts	38680
substrates for the growth of numerous neurofilament	38703
substrates	38703
the growth of numerous neurofilament	38718
the growth	38718
numerous neurofilament	38732
positive axons -LRB- red -RRB-	38756
positive axons	38756
red	38772
both nearby dorsal roots and central neurons	38794
both nearby dorsal roots	38794
central neurons	38823
the spinal cord	38846
These axons	38863
parallel	38883
the orientation	38895
the grafted cells , whether cells were oriented	38914
the grafted cells	38914
cells	38941
D , E	38962
D	38962
E	38964
parallel	38967
F , G	38980
F	38980
G	38982
perpendicular to the rostral-caudal axis of the host spinal cord	38985
the rostral-caudal axis of the host	39002
the rostral-caudal axis	39002
the host	39029
supraspinal axons	39063
serotonergic axons	39090
red	39110
able to enter grafts of EGFPþ SCs	39116
grafts of EGFPþ	39130
grafts	39130
EGFPþ	39140
OEG : H : EGFPþ OEG grafted rostral to the injury epicenter	39153
OEG	39153
H : EGFPþ OEG grafted rostral to the injury epicenter	39158
H	39158
EGFPþ OEG grafted rostral to the injury epicenter	39161
EGFPþ OEG	39161
rostral	39179
the injury epicenter	39190
I : EGFPþ SCs grafted into the injury epicenter	39212
I	39212
EGFPþ SCs grafted into the injury epicenter	39215
EGFPþ SCs	39215
the injury epicenter	39238
J : EGFPþ OEG grafted with unlabeled SCs into the injury epicenter	39260
J	39260
EGFPþ OEG grafted with unlabeled SCs into the injury epicenter	39263
EGFPþ OEG	39263
unlabeled SCs	39286
the injury epicenter	39305
K	39327
Ascending axonal populations , such as those positive for CGRP -LRB- red -RRB- ,	39330
Ascending axonal populations	39330
those positive for CGRP -LRB- red -RRB-	39368
those positive for CGRP	39368
red	39393
EGFPþ SC or EGFPþ OEG	39410
EGFPþ SC	39410
EGFPþ OEG	39422
growth	39469
The number of CGRPþ axons present immediately caudal to the grafts	39477
The number of CGRPþ axons present	39477
The number of CGRPþ axons	39477
The number	39477
CGRPþ axons	39491
the grafts	39533
injury-only controls	39584
GFAP -LRB- blue -RRB-	39606
GFAP	39606
blue	39612
host astrocytes	39639
All images	39656
20 µm-thick confocal projection images	39671
White boxes	39711
regions that are shown as accompanying higher magnification images	39730
regions	39730
higher magnification images	39769
White scale bars	39798
50 µm , yellow scale bars = 200 µm	39817
50 µm	39817
yellow scale bars = 200 µm	39824
yellow scale bars	39824
= 200 µm	39842
200	39844
Fig. 9 .	39853
Fig.	39853
9	39858
Quantification of ascending and descending axon growth into grafts .	39861
Quantification	39861
axon growth	39904
grafts	39921
A : Quantification of CTB-labeled ascending axons from the sciatic nerve	39929
: Quantification of CTB-labeled ascending axons from the sciatic nerve	39930
Quantification	39932
axons	39972
the sciatic nerve	39983
provision of a SC or OEG or a SC-OEG graft into the injured spinal cord	40012
provision	40012
a SC or OEG or a SC-OEG graft into the injured spinal cord	40025
a SC or OEG	40025
a SC-OEG graft into the injured spinal cord	40040
a SC-OEG graft	40040
the injured spinal cord	40060
the growth of these traced fibers caudal to , or into , the injury-graft site	40100
the growth	40100
these traced fibers caudal to , or into , the injury-graft site	40114
these	40114
fibers	40127
the injury-graft site	40154
injury only	40188
significance	40205
OEG only	40243
B : SC-OEG grafts	40253
B	40253
SC-OEG grafts	40256
the number of CGRPþ axons present at 2,000 µm and 500 µm caudal	40289
the number of CGRPþ axons	40289
the number	40289
CGRPþ axons	40303
2,000 µm and 500 µm	40326
2,000 µm	40326
500 µm	40339
the graft/injury site	40370
Characterization	40393
5HTþ serotonergic fibers from the brainstem -LRB- C -RRB-	40413
5HTþ serotonergic fibers	40413
the brainstem -LRB- C -RRB-	40443
the brainstem	40443
C	40458
BDA-traced corticospinal tract axons from the sensorimotor cortex	40464
BDA-traced corticospinal tract axons	40464
the sensorimotor cortex	40506
D	40531
none of the grafts	40552
none	40552
the grafts	40560
the amount of axon growth above that observed within , or rostral	40581
the amount of axon growth above that observed within	40581
the amount	40581
axon growth above that observed within	40595
axon growth	40595
that observed within	40613
that	40613
rostral	40638
trabeculae of injury-only controls	40650
trabeculae	40650
injury-only controls	40664
12 weeks	40686
Legend : SCI only , SC graft	40716
Legend	40716
SCI only , SC graft	40724
SCI only	40724
SC graft	40734
the injury epicenter , OEG graft	40748
the injury epicenter	40748
OEG graft	40770
the injury epicenter	40785
SC and OEG combination graft	40807
SC	40807
OEG combination graft	40814
1:1 -RSB-	40837
the injury epicenter , SC graft	40847
the injury epicenter	40847
SC graft	40869
the injury epicenter with OEG on either side	40883
the injury epicenter	40883
OEG on either side	40909
OEG	40909
either side	40916
P <	40930
P	40930
<	40932
0.05	40934
P < 0.01 , and *** P <	40942
P	40942
< 0.01 , and *** P <	40944
< 0.01	40944
<	40944
0.01	40946
*** P <	40956
*** P	40956
<	40961
0.001	40963
injury-only controls	40988
grafted groups	41020
the horizontal lines	41051
Fig. 10 .	41074
Fig.	41074
10	41079
Myelination by transplanted glia .	41083
Myelination	41083
transplanted glia	41098
Diagram	41120
the grafted spinal cord	41131
the three regions	41163
the transplant	41184
rostral	41200
central	41209
caudal	41218
200 µm2 regions -LRB- black boxes -RRB-	41235
200 µm2 regions	41235
black boxes	41252
the determination of ratios of myelinated axons	41283
the determination	41283
ratios of myelinated axons	41304
ratios	41304
myelinated axons	41314
EGFPþ cells	41334
B	41347
The rostral region	41350
a SC graft	41372
the injury epicenter	41401
similar numbers of myelinated axons -LRB- red -RRB- and EGFPþ cells	41433
similar numbers	41433
myelinated axons -LRB- red -RRB- and EGFPþ cells	41452
myelinated axons -LRB- red -RRB-	41452
myelinated axons	41452
red	41470
EGFPþ cells	41479
this region	41511
A myelinated axon	41524
the white arrow	41559
C	41576
contrast	41582
no myelinated axons , only myelin debris ,	41592
no myelinated axons	41592
only myelin debris	41613
a comparable area of an OEG graft	41647
a comparable area	41647
an OEG graft	41668
unlabeled SCs	41700
the injury epicenter	41722
GFAP immunostaining , blue .	41744
GFAP immunostaining	41744
blue	41765
Scale	41771
5 20 µm	41781
Fig. 11 .	41791
Fig.	41791
11	41796
Open-field locomotor ability after glial cell transplantation .	41800
Open-field locomotor ability	41800
glial cell transplantation	41835
Only those animals	41866
combination SC and OEG grafts into the injury epicenter	41895
combination SC and OEG grafts	41895
the injury epicenter	41930
a modest , but significant , improvement in open-field locomotion	41964
a modest , but significant , improvement	41964
open-field locomotion	42006
injury-only or fibroblast controls	42040
BBB sub-score analysis	42076
animals receiving combination SC and OEG grafts into the injury epicenter	42116
animals	42116
combination SC and OEG grafts	42134
the injury epicenter	42169
significantly higher scores	42194
Legend : SCI only , fibroblast graft	42223
Legend	42223
SCI only , fibroblast graft	42231
SCI only	42231
fibroblast graft	42241
the injury epicenter , SC graft	42263
the injury epicenter	42263
SC graft	42285
the injury epicenter	42299
OEG graft into the injury epicenter , SC and OEG combination graft	42321
OEG graft	42321
the injury epicenter , SC and OEG combination graft	42336
the injury epicenter	42336
SC	42358
OEG combination graft	42365
1:1 -RSB-	42388
the injury epicenter , SC graft	42398
the injury epicenter	42398
SC graft	42420
the injury epicenter with OEG on either side	42434
the injury epicenter	42434
OEG on either side	42460
OEG	42460
either side	42467
P < 0.05 as compared to injury-only controls , n = 12/group	42481
P <	42481
P	42481
0.05	42485
injury-only controls , n = 12/group	42505
injury-only controls	42505
n = 12/group	42527
Fig. 12 .	42542
Fig.	42542
12	42547
Footprint analysis of conditioned locomotion and grid	42551
Footprint analysis	42551
conditioned locomotion and grid	42573
performance	42610
glial cell transplantation	42628
A : The angle of foot exorotation of the hind paws .	42656
A : The angle of foot exorotation of the hind paws	42656
A : The angle of foot exorotation	42656
The angle of foot	42659
The angle	42659
foot	42672
the hind paws	42692
B : The distance of the base of support between the hind paws .	42707
B	42707
The distance of the base of support between the hind paws	42710
The distance	42710
the base of support between the hind paws	42726
the base	42726
support between the hind paws	42738
support	42738
the hind paws	42754
C : The stride length .	42769
C	42769
The stride length	42772
D : The number of footfall errors on a grid walk test .	42791
D	42791
The number of footfall errors on a grid walk test	42794
The number	42794
footfall errors on a grid walk test	42808
footfall errors	42808
a grid walk test	42827
Significant improvements in foot rotation	42845
Significant improvements	42845
foot rotation	42873
animals receiving either SC only grafts	42904
animals	42904
SC only grafts	42929
SC only	42929
combination SC and OEG grafts	42947
the injury epicenter	42982
Legend	43004
uninjured control	43012
SCI only	43031
fibroblast graft into the injury epicenter	43041
fibroblast graft	43041
the injury epicenter	43063
SC graft into the injury epicenter	43085
SC graft	43085
the injury epicenter	43099
OEG graft into the injury epicenter	43121
OEG graft	43121
the injury epicenter	43136
SC and OEG combination graft	43158
-LSB- 1:1	43187
the injury epicenter	43198
SC graft into the injury epicenter with OEG	43220
SC graft	43220
the injury epicenter with OEG	43234
the injury epicenter	43234
OEG	43260
either side ; * P < 0.05	43267
either side	43267
P <	43281
P	43281
<	43283
0.05	43285
injury-only controls , n = 12/group	43307
injury-only controls	43307
n = 12/group	43329
Determination	43344
Cell Survival	43361
the Male Chromosome Marker After Transplantation Into	43381
the Male Chromosome	43381
Marker After Transplantation Into	43401
the Injury Site	43443
SCs	43470
OEG within the injured spinal cord following implantation	43481
OEG	43481
the injured spinal cord following implantation	43492
the injured spinal cord	43492
implantation	43526
the male chromosome	43583
a definitive marker	43606
Survival	43627
male SCs or OEG	43639
the injury epicenter of female rats	43685
the injury epicenter	43685
female rats	43709
1 week	43724
3 days	43756
82.6 ± 12.4 % and 69.4 ± 6.0 %	43783
82.6 ± 12.4 %	43783
82.6 ±	43783
12.4 %	43790
69.4 ± 6.0 %	43800
69.4	43800
6.0 %	43807
the original number	43815
cells prepared for transplantation -LRB- 2 million -RRB- , respectively	43838
cells	43838
transplantation -LRB- 2 million -RRB-	43857
transplantation	43857
2 million	43874
Fig. 1A , B	43900
Fig. 1A	43900
B	43908
this time	43915
the survival of the two cell types	43926
the survival	43926
the two cell types	43942
one another	43998
3 days	44025
survival	44033
OEG	44045
1:1	44057
SCs	44066
the injury site	44075
4-mm rostral and caudal	44102
the injury/SC graft site	44129
71.1 ± 11.9 % and 68.9 ± 10.1 %	44170
71.1 ± 11.9 %	44170
71.1	44170
11.9 %	44177
68.9 ± 10.1 %	44187
68.9	44187
10.1 %	44194
Fig. 1B	44216
Survival of OEG	44226
Survival	44226
OEG	44238
disparate locations	44281
different numbers of cells	44309
different numbers	44309
cells	44330
The small amount	44353
leakage	44373
spinal cord injection or the loss of cells	44398
spinal cord injection	44398
the loss of cells	44423
the loss	44423
cells	44435
procedures	44459
original counting to syringe loading	44475
original counting	44475
syringe loading	44496
some degree of this observed reduction in cell number in all cell groups	44535
some degree	44535
this observed reduction in cell number in all cell groups	44550
this	44550
reduction in cell number	44564
reduction	44564
cell number	44577
all cell groups	44592
3 weeks	44612
significant loss of cells	44642
significant loss	44642
cells	44662
all grafting paradigms	44684
male SCs	44708
the injury site -LRB- 22.4 ± 4.3 % cells remaining , P < 0.001 -RRB-	44722
the injury site	44722
22.4 ± 4.3 %	44739
22.4	44739
4.3 %	44746
cells remaining , P < 0.001	44751
cells remaining	44751
P < 0.001	44768
P <	44768
P	44768
0.001	44772
male OEG	44780
the injury site -LRB- 3.1 ± 1.4 % cells remaining , P < 0.001 -RRB-	44794
the injury site	44794
3.1 ± 1.4 %	44811
3.1	44811
1.4 %	44817
cells remaining , P < 0.001	44822
cells remaining	44822
P < 0.001	44839
P <	44839
P	44839
0.001	44843
male OEG	44851
SCs 1:1 into the injury site -LRB- 9.4 ± 0.7 % cells remaining , P < 0.001 -RRB-	44865
SCs 1:1	44865
the injury site -LRB- 9.4 ± 0.7 % cells remaining , P < 0.001 -RRB-	44878
the injury site	44878
9.4 ± 0.7 %	44895
9.4	44895
0.7 %	44901
cells remaining , P < 0.001	44906
cells remaining	44906
P < 0.001	44923
P <	44923
P	44923
0.001	44927
male OEG	44937
either side of SCs into the injury site -LRB- 48.4 ± 6.3 -RRB-	44946
either side	44946
SCs into the injury site	44961
SCs	44961
the injury site	44970
48.4 ± 6.3	44987
48.4 ±	44987
6.3	44994
% cells remaining , P < 0.001 -RRB-	44998
% cells	44998
P < 0.001	45017
P	45017
< 0.001	45019
<	45019
0.001	45021
Fig. 1B	45029
SCs	45039
significantly greater survival -LRB- 7-fold , P < 0.001 -RRB-	45053
significantly greater survival	45053
7-fold , P < 0.001	45085
7-fold , P <	45085
7-fold	45085
P <	45093
P	45093
<	45095
0.001	45097
OEG	45109
the injury site	45136
Transplantation	45153
OEG	45172
the relatively healthy tissue near the injury site at lower density	45181
the relatively healthy tissue	45181
the injury site at lower density	45216
the injury site	45216
lower density	45235
SCs into the injury site	45257
SCs	45257
the injury site	45266
their survival	45306
transplantation	45333
OEG	45352
the injury site : 16-fold -LRB- P < 0.001 -RRB- and 3-fold -LRB- P < 0.01 -RRB-	45367
the injury site : 16-fold -LRB- P < 0.001 -RRB- and 3-fold	45367
the injury site	45367
P < 0.001	45393
P	45393
< 0.001	45395
<	45395
0.001	45397
P < 0.01	45416
P	45416
< 0.01	45418
<	45418
0.01	45420
Assessment of cell survival at 9 weeks following transplantation	45441
Assessment	45441
cell survival at 9 weeks following transplantation	45455
cell survival	45455
9 weeks following transplantation	45472
9 weeks	45472
transplantation	45490
there	45518
no significant further loss	45528
grafted cells	45559
all of the transplantation paradigms compared to 3 weeks -LRB- Fig. 1B -RRB-	45576
all	45576
the transplantation paradigms compared to 3 weeks -LRB- Fig. 1B -RRB-	45583
the transplantation paradigms	45583
3 weeks -LRB- Fig. 1B -RRB-	45625
3 weeks	45625
Fig. 1B	45634
Determination	45644
Cell Survival	45661
EGFP	45681
Transplantation	45701
Into or Near the Injury Site Numbers of SCs	45717
Into or Near the Injury Site Numbers	45717
Into	45717
the Injury Site	45730
SCs	45757
OEG within the injured spinal cord following implantation	45768
OEG	45768
the injured spinal cord following implantation	45779
the injured spinal cord	45779
implantation	45813
a second independent marker , transfer of EGFP	45869
a second independent marker	45869
transfer of EGFP	45898
transfer	45898
EGFP	45910
lentiviral vector infection	45918
Cultures	45947
purified SCs and OEG	45959
immunoreactivity	45998
the low-affinity neurotrophin receptor p75	46019
high levels on both cell types	46081
high levels	46081
both cell types	46096
Fig. 2A , B	46113
Fig. 2A	46113
B	46121
a single exposure	46134
EGFP-encoding lentiviral vectors	46155
Lentiviral vector infection of either SCs or OEG at a MOI of 50	46189
Lentiviral vector infection	46189
either SCs or OEG	46220
SCs	46227
OEG	46234
a MOI of 50	46241
a MOI	46241
50	46250
robust expression of the EGFP transgene in 98 -- 99 % of the cells	46265
robust expression	46265
the EGFP transgene in 98 -- 99 % of the cells	46286
the EGFP transgene in 98	46286
the EGFP transgene	46286
98	46308
99 % of the cells	46311
99 %	46311
the cells	46318
48 hours	46335
EGFP	46345
fluorescent microscopy	46368
a strong signal within the cell nucleus	46394
a strong signal	46394
the cell nucleus	46417
efficient labeling of the cytoplasm and processes -LRB- Fig. 2C , D -RRB-	46439
efficient labeling	46439
the cytoplasm and processes -LRB- Fig. 2C , D -RRB-	46461
the cytoplasm and processes	46461
Fig. 2C , D	46490
Fig. 2C	46490
D	46498
MOIs lower than 50	46505
MOIs	46505
50	46521
reduced transduction efficiency	46525
Andrade et al. , 2007	46571
Andrade	46571
et al.	46579
2007	46587
Cells receiving the EGFP transgene	46594
Cells	46594
the EGFP transgene	46610
nontransduced cell controls	46649
proliferation rate or morphology for up to 9 passages -LRB- data not shown -RRB-	46687
proliferation rate or morphology	46687
up to 9 passages	46724
data not shown	46742
data	46742
Cells for transplantation	46759
Cells	46759
transplantation	46769
passage 4 -LRB- OEG -RRB- or 5 -LRB- SCs -RRB-	46798
passage 4	46798
OEG	46809
5	46817
SCs	46820
The implantation of EGFP-SCs into the lesion site -LRB- Fig. 3A -- C -RRB-	46826
The implantation	46826
EGFP-SCs into the lesion site -LRB- Fig. 3A -- C -RRB-	46846
EGFP-SCs	46846
the lesion site -LRB- Fig. 3A -- C -RRB-	46860
the lesion site	46860
Fig. 3A -- C	46877
Fig. 3A	46877
C	46885
EGFP-OEG	46889
unlabeled SCs	46903
the lesion site -LRB- Fig. 3D -- F -RRB-	46922
the lesion site	46922
Fig. 3D -- F	46939
Fig. 3D	46939
F	46947
unlabeled SCs into the lesion site with EGFP-OEG on either side	46954
unlabeled SCs	46954
the lesion site with EGFP-OEG on either side	46973
the lesion site	46973
EGFP-OEG on either side	46994
EGFP-OEG	46994
either side	47006
Fig. 3G -- I	47019
Fig. 3G	47019
I	47027
all	47030
substantive grafts that were able to significantly retard cavitation	47043
substantive grafts	47043
cavitation	47101
Only the implantation of EGFP-OEG alone within the lesion site	47113
Only the implantation	47113
EGFP-OEG alone within the lesion site	47138
EGFP-OEG alone	47138
the lesion site	47160
significant cavity formation that was similar to injury-only controls	47188
significant cavity formation	47188
injury-only controls	47237
The dramatic loss of male cells from 3 days to 3 weeks	47259
The dramatic loss	47259
male cells from 3 days to 3 weeks	47280
male cells	47280
3 days to 3 weeks	47296
the same	47334
groups	47351
EGFP	47363
the marker	47401
itself	47412
cell loss	47435
the cells but rather the conditions to which the cells were exposed	47466
the cells	47466
the conditions to which the cells were exposed	47487
the conditions	47487
the cells	47511
their disappearance -LRB- Fig. 4A -- D , solid lines -RRB-	47546
their disappearance	47546
Fig. 4A	47567
D , solid lines	47575
D	47575
solid lines	47578
Statistical comparison	47592
the numbers of identified cells within each transplant cohort at each time point	47618
the numbers	47618
identified cells within each transplant cohort at each time point	47633
identified cells	47633
each transplant cohort at each time point	47657
each transplant cohort	47657
each time point	47683
there	47711
no significant differences	47722
the numbers	47752
cells stereologically quantified using either EGFP or the male chromosome marker	47767
cells	47767
either EGFP or the male chromosome marker	47806
EGFP	47813
the male chromosome marker	47821
transplanted male cells	47854
EGFP SCs	47879
significantly better survival	47898
EGFP OEG	47933
the injury epicenter -LRB- Fig. 4A , B -RRB-	47962
the injury epicenter	47962
Fig. 4A , B	47984
Fig. 4A	47984
B	47992
a greater percentage of EGFP OEG	47999
a greater percentage	47999
EGFP OEG	48023
they	48050
the injury epicenter -LRB- Fig. 4B , D -RRB-	48080
the injury epicenter	48080
Fig. 4B , D	48102
Fig. 4B	48102
D	48110
cell survival	48133
transplantation	48164
we	48181
western blot analysis of GFP signal using only the EGFPþ SC group	48193
western blot analysis	48193
GFP signal using only the EGFPþ SC group	48218
GFP signal	48218
the EGFPþ SC group	48240
the aliquots prior to transplantation at 0 days or from a 10	48272
the aliquots	48272
transplantation	48294
0 days	48313
a 10	48328
mm block	48334
spinal cord	48346
the injury/graft site	48371
3 , 21 , or 56 days	48396
3	48396
21	48399
56 days	48406
injection of EGFPþ SCs	48420
injection	48420
EGFPþ SCs	48433
the injury site -LRB- n = 4 per time point -RRB- -LRB- Fig. 5A , B -RRB-	48448
the injury site -LRB- n = 4 per time point -RRB-	48448
the injury site	48448
n = 4 per time point	48465
n = 4	48465
n	48465
4	48469
time point	48475
Fig. 5A , B	48488
Fig. 5A	48488
B	48496
densitometry measurements of the resulting bands	48506
densitometry measurements	48506
the resulting bands	48535
we	48556
no significant reduction	48568
GFP signal from 0	48596
GFP signal	48596
0	48612
3 days post-transplantation -LRB- Fig. 5B -RRB-	48617
3 days post-transplantation	48617
Fig. 5B	48646
21 and 56 days after grafting	48659
21 and 56 days	48659
grafting	48680
significant reductions in EGFP signal	48699
significant reductions	48699
EGFP signal	48725
: 21 days , 54.7 % decrease , P < 0.001	48746
21 days , 54.7 % decrease	48748
21 days	48748
54.7 % decrease	48757
P < 0.001	48773
P <	48773
P	48773
0.001	48777
56 days , 67.1 % decrease	48784
56 days	48784
67.1 % decrease	48793
P < 0.001 -LRB- Fig. 5B -RRB-	48809
P	48809
< 0.001 -LRB- Fig. 5B -RRB-	48811
<	48811
0.001 -LRB- Fig. 5B -RRB-	48813
0.001	48813
Fig. 5B	48820
The pattern of decreased GFP signal by western blot analysis	48830
The pattern	48830
decreased GFP signal by western blot analysis	48845
decreased GFP signal	48845
western blot analysis	48869
the loss of Y-probe positive and EGFP SCs	48910
the loss	48910
Y-probe positive and EGFP SCs	48922
Y-probe positive	48922
EGFP SCs	48943
stereological quantification	48974
Examination of EGFP-labeled cells at 3 days posttransplantation	49004
Examination	49004
EGFP-labeled cells at 3 days posttransplantation	49019
EGFP-labeled cells	49019
3 days posttransplantation	49041
both SCs and OEG	49080
SCs	49085
OEG	49093
the site of deposition -LRB- Fig. 6A , D , G -RRB-	49116
the site	49116
deposition -LRB- Fig. 6A , D , G -RRB-	49128
deposition	49128
Fig. 6A	49140
D	49148
G	49150
many cells	49191
a rounded shape and few processes	49213
a rounded shape	49213
few processes	49233
EGFPþ cells	49248
patches of immune cells	49287
patches	49287
immune cells	49298
GFAPþ astrocytes	49329
the host spinal cord	49351
Identification of surviving cells at 3 -- 9 weeks using EGFP	49373
Identification	49373
surviving cells at 3 -- 9 weeks using EGFP	49391
surviving cells at 3	49391
surviving cells	49391
3	49410
9 weeks using EGFP	49412
9 weeks	49412
EGFP	49426
the cells	49443
one	49481
relatively continuous mass	49485
the site of the injection in both SC or SC plus OEG groups	49515
the site	49515
the injection in both SC or SC plus OEG groups	49527
the injection	49527
both SC or SC plus OEG groups	49544
SC	49549
SC plus OEG groups	49555
Figs. 6B , E , H , and 7C	49575
Figs. 6B	49575
E , H , and 7C	49584
smaller patches of EGFPþ cells	49609
smaller patches	49609
EGFPþ cells	49628
the main body of the graft	49666
the main body	49666
the graft	49683
small cavities	49696
areas of immune cells and debris	49732
areas	49732
immune cells and debris	49741
these cells	49773
the confines of the lesion	49803
the confines	49803
the lesion	49819
the animals	49834
OEG	49856
the injury site	49871
the dramatic , greater than 95 % loss of grafted cells	49888
the dramatic , greater than 95 % loss	49888
grafted cells	49927
pronounced central cavitation , not dissimilar	49953
pronounced central cavitation	49953
injury-only controls	50002
surviving cells	50029
the rim of injured tissue	50062
the rim	50062
injured tissue	50073
the cavity	50100
Comparison	50112
Cell Numbers	50126
Ex Vivo Introduction of EGFP	50153
Ex Vivo Introduction	50153
EGFP	50177
Viral Vector Versus Immunochemical Detection	50185
p75 + SCs or OEG The low affinity neurotrophin receptor p75	50233
p75 + SCs	50233
OEG The low affinity neurotrophin receptor p75	50245
OEG	50245
The low affinity neurotrophin receptor p75	50249
SCs and OEG	50347
vivo	50375
transplantation	50390
due to the high level of p75 expression	50407
the high level of p75	50414
the high level	50414
p75	50432
the nonmyelinating phenotypes	50450
these cells -LRB- Plant et al. , 2002 ; Fig. 2A , B -RRB-	50483
these cells	50483
Plant et al. , 2002 ; Fig. 2A , B	50496
Plant	50496
et al. , 2002 ; Fig. 2A , B	50502
et al. , 2002	50502
et al.	50502
2002	50510
Fig. 2A , B	50516
Fig. 2A	50516
B	50524
nontransplanted animals , p75þ endogenous cells	50540
the injury site	50608
the dorsal columns as early as 3 days	50644
contusion	50688
The presence of p75	50699
The presence	50699
p75	50715
axons within these areas	50740
axons	50740
these areas	50753
3 and 9 weeks	50769
numbers of p75þ cells within the injured spinal cord	50784
numbers	50784
p75þ cells within the injured spinal cord	50795
p75þ cells	50795
the injured spinal cord	50813
these cells	50859
the injury site	50900
a total of 80,000 cells per animal	50929
a total	50929
80,000 cells per animal	50940
80,000 cells	50940
animal	50957
any timepoint examined -LRB- results not shown -RRB-	50967
any timepoint	50967
grafting of SCs	51021
grafting	51021
SCs	51033
a high level of dense p75 immunoreactivity , predominantly cellular in nature ,	51038
a high level of dense p75 immunoreactivity	51038
a high level	51038
dense p75 immunoreactivity	51054
cellular in nature	51096
cellular	51096
nature	51108
the injury site -LRB- Fig. 3A -- C -RRB-	51147
the injury site	51147
Fig. 3A -- C	51164
Fig. 3A	51164
C	51172
A smaller amount of p75 immunoreactivity	51176
A smaller amount	51176
p75 immunoreactivity	51196
rostral and caudal streams	51237
nearby dorsal root entry sites	51296
similar to those observed in injured only animals	51328
those observed in injured only	51339
those	51339
We	51379
the groups	51391
either EGFPþ SCs or EGFPþ OEG	51412
EGFPþ SCs	51419
EGFPþ OEG	51432
the injury site	51447
3 days	51472
the number of EGFPþ cells	51501
the number	51501
EGFPþ cells	51515
the number of p75þ cells -LRB- Fig. 4A -- B -RRB-	51564
the number	51564
p75þ cells -LRB- Fig. 4A -- B -RRB-	51578
p75þ cells	51578
Fig. 4A -- B	51590
Fig. 4A	51590
B	51598
later time intervals following transplantation	51607
later time intervals	51607
transplantation	51638
there	51664
a significant loss of EGFPþ cells	51674
a significant loss	51674
EGFPþ cells	51696
contrast	51712
the number of p75þ cells within the injured spinal cord	51722
the number	51722
p75þ cells within the injured spinal cord	51736
p75þ cells	51736
the injured spinal cord	51754
a decrease that was significantly less than observed with EGFP cell counts	51788
a decrease	51788
EGFP cell counts	51846
both 3 and 9 weeks	51867
post-transplantation , p75þ cell counts	51886
counts	51956
EGFP cells	51966
SC	51980
3 weeks	51984
301 % higher , P < 0.05 ; 9 weeks : 307 % , P < 0.05 , Figs. 3A -- C , 4A	51993
301 % higher , P < 0.05	51993
301 %	51993
P	52006
0.05	52010
9 weeks	52016
9	52016
weeks	52018
307 % , P < 0.05 , Figs. 3A	52025
307 %	52025
P < 0.05	52031
P <	52031
P	52031
0.05	52035
Figs. 3A	52041
C , 4A	52050
C	52050
4A	52053
OEG -LRB- 3 weeks : 892 %	52061
OEG	52061
3 weeks : 892 %	52066
3 weeks	52066
892 %	52075
P < 0.05	52081
P <	52081
P	52081
0.05	52085
9 weeks	52091
755 %	52100
P < 0.05 , Fig. 4B -RRB- only transplant groups	52106
P	52106
0.05 , Fig. 4B	52110
0.05	52110
Fig. 4B	52116
transplant groups	52130
animals	52152
mixed grafts of nonlabeled SCs and EGFPþ OEG	52170
mixed grafts	52170
nonlabeled SCs and EGFPþ OEG	52186
nonlabeled SCs	52186
EGFPþ OEG	52205
counts of p75þ cells within the injured spinal cord	52216
counts	52216
p75þ cells within the injured spinal cord	52226
p75þ cells	52226
the injured spinal cord	52244
EGFP cells	52290
3 days	52304
the presence of large numbers of unlabeled	52332
the presence	52332
large numbers of unlabeled	52348
large numbers	52348
transplanted SCs -LRB- Fig. 4C -- D -RRB-	52376
transplanted SCs	52376
Fig. 4C -- D	52394
Fig. 4C	52394
D	52402
The number of p75þ cells	52406
The number	52406
p75þ cells	52420
3 to 9 weeks	52450
the number of EGFPþ OEG	52469
the number	52469
EGFPþ OEG	52483
Figs.	52509
3D -- I and 4C -- D	52515
3D	52515
I and 4C	52518
I	52518
4C	52524
D	52527
EGFP2/p75þ cells	52531
a number of different environments	52562
a number	52562
different environments	52574
the injury site	52618
Densely packed EGFP2/p75þ cells	52635
EGFPþ grafted cells within the injury site	52696
EGFPþ	52696
cells	52710
the injury site	52723
a scattered distribution with immune cells within EGFP2 areas of the injury site	52743
a scattered distribution	52743
immune cells within EGFP2 areas of the injury site	52773
immune cells	52773
EGFP2 areas of the injury site	52793
EGFP2 areas	52793
the injury site	52808
EGFP2 streams	52831
cells	52848
the injury site and nearby dorsal root entry sites	52867
the injury site	52867
nearby dorsal root entry sites	52887
Fig. 3D -- I	52919
Fig. 3D	52919
I	52927
Examination of p75 immunoreactivity within EGFP	52931
Examination	52931
p75 immunoreactivity within EGFP	52946
p75 immunoreactivity	52946
EGFP	52974
groups	52987
EGFP-OEG	53014
time	53058
90 %	53080
all time points	53087
the percentage of p75 immunoreactive EGFP-SCs	53105
the percentage	53105
p75 immunoreactive EGFP-SCs	53123
both 3 days to 3 weeks	53180
97.8 ± 1.0 %	53204
97.8	53204
1.0 %	53211
75.6 ± 2.1 % EGFPp75 co-labeling , respectively , a 22.7 % decrease , P < 0.001	53219
2.1 % EGFPp75 co-labeling , respectively	53226
2.1 %	53226
EGFPp75 co-labeling	53231
a 22.7 % decrease	53266
a 22.7 %	53266
decrease	53274
P < 0.001	53284
P <	53284
P	53284
0.001	53288
3 to 9 weeks	53304
75.6 ± 2.1 %	53318
75.6	53318
2.1 %	53325
8.0 % EGFP-p75 co-labeling , respectively	53340
8.0 %	53340
EGFP-p75 co-labeling	53345
a further 23.1 % decrease	53381
a further 23.1 %	53381
decrease	53397
P < 0.05	53407
P <	53407
P	53407
0.05	53411
implantation	53423
A loss of p75 immunoreactivity on SCs	53437
A loss	53437
p75 immunoreactivity on SCs	53447
p75 immunoreactivity	53447
SCs	53471
their conversion	53494
a myelinating phenotype -LRB- Morgan et al. , 1994 -RRB-	53514
a myelinating phenotype	53514
Morgan	53539
et al. , 1994	53546
et al.	53546
1994	53554
the transplanted SCs	53589
the myelination	53627
axons that had grown into the grafts -LRB- see Myelination section below -RRB-	53646
axons	53646
the grafts -LRB- see Myelination section below -RRB-	53672
the grafts	53672
Myelination section	53688
Assessment	53716
Cell Migration from the Site of Transplantation	53730
Cell Migration	53730
the Site of Transplantation	53750
the Site	53750
Transplantation	53762
The combination	53778
EGFP	53797
cells	53810
Y-probe DNA in situ of transplanted male cells with immunoreactivity for GFAP	53819
Y-probe DNA	53819
situ	53834
transplanted male cells with immunoreactivity for GFAP	53842
transplanted male cells	53842
immunoreactivity for GFAP	53871
immunoreactivity	53871
GFAP	53892
assessment	53907
the degree	53921
transplanted cells	53941
their original site of deposition	53986
their original site	53986
deposition	54009
regions of normalappearing host white and gray	54025
regions	54025
normalappearing host white and gray	54036
normalappearing host	54036
We	54080
the migratory ability of the transplanted cells	54092
the migratory ability	54092
the transplanted cells	54117
3 days , 3 weeks , or 9 weeks post-transplantation	54143
3 days	54143
3 weeks	54151
9 weeks post-transplantation	54163
the relative distribution	54205
labeled cells within the rostral	54234
labeled cells	54234
the rostral	54255
caudal	54268
dorsal-ventral 3D space	54276
the injured spinal cord for each grafting paradigm -LRB- Fig. 6 -RRB-	54303
the injured spinal cord	54303
each grafting paradigm -LRB- Fig. 6 -RRB-	54331
each grafting paradigm	54331
Fig. 6	54355
no migration of labeled cells	54373
no migration	54373
labeled cells	54389
regions of dense GFAP immunoreactivity	54421
regions	54421
dense GFAP immunoreactivity	54432
normal-appearing white and gray matter in all groups	54464
normal-appearing white and gray matter	54464
all groups	54506
grafts of labeled SCs or OEG into the injury site	54527
grafts	54527
labeled SCs or OEG into the injury site	54537
labeled SCs or OEG	54537
the injury site	54561
the two different cell types	54578
different distributions	54619
the area of original deposition	54650
the area	54650
original deposition	54662
SCs	54689
the immediate site	54736
injection over time -LRB- Figs. 6A -- C and 7C -RRB- , OEG ,	54758
injection over time	54758
injection	54758
time	54773
Figs. 6A -- C and 7C	54779
Figs. 6A	54779
C and 7C	54788
OEG	54799
SCs	54827
the lesion -LRB- Fig. 6D -- I -RRB-	54865
the lesion	54865
Fig. 6D -- I	54877
Fig. 6D	54877
I	54885
contrast	54892
injection of EGFPþ OEG 4 mm on either side of the injury site	54902
injection	54902
EGFPþ OEG 4 mm on either side of the injury site	54915
EGFPþ OEG	54915
4 mm on either side of the injury site	54925
4 mm	54925
either side of the injury site	54933
either side	54933
the injury site	54948
the presence	54978
small numbers of labeled OEG within the injury site -LRB- Fig. 6J -- L -RRB-	54994
small numbers	54994
labeled OEG within the injury site -LRB- Fig. 6J -- L -RRB-	55011
labeled OEG	55011
the injury site -LRB- Fig. 6J -- L -RRB-	55030
the injury site	55030
Fig. 6J -- L	55047
Fig. 6J	55047
L	55055
No EGFPþ OEG	55059
normal-appearing white or gray matter	55109
the injection sites and the injury site	55155
the injection sites	55155
the injury site	55179
EGFPþ OEG	55196
access	55223
the injury site	55233
the pia from the injection entry site -LRB- Fig. 7A -RRB-	55275
the pia	55275
the injection entry site -LRB- Fig. 7A -RRB-	55288
the injection entry site	55288
Fig. 7A	55314
the central canal -LRB- Fig. 7B -RRB-	55330
the central canal	55330
Fig. 7B	55349
the OEG injections	55388
the dorsal columns	55412
The implantation	55432
both EGFPOEG and unlabeled SCs	55452
EGFPOEG	55457
unlabeled SCs	55469
a combination graft into the injury epicenter	55486
a combination graft	55486
the injury epicenter	55511
in an	55541
that	55555
a heterogeneous mix of EGFPþ OEG and p75þ/EGFP2	55572
a heterogeneous mix	55572
EGFPþ OEG and p75þ/EGFP2	55595
endogenous or unlabeled exogenous SCs	55620
regions where EGFP cells were located -LRB- Fig. 3E -RRB-	55661
regions	55661
EGFP cells	55675
Fig. 3E	55700
Axonal Interactions and Growth Support	55710
Axonal Interactions	55710
Growth Support	55734
Transplanted Glia	55752
Neurofilament-immunoreactive -LRB- NF-IR -RRB- axons	55770
NF-IR	55800
high densities	55827
all substantive EGFPþ cell grafts -LRB- Fig. 8A -- G -RRB-	55849
all substantive EGFPþ cell grafts	55849
Fig. 8A -- G	55884
Fig. 8A	55884
G	55892
NF-IR axons	55896
a parallel orientation	55935
EGFPþ cellular processes	55961
a few	55994
very random growth patterns	56015
perpendicular or U-shaped directional growth	56053
Grafts containing EGFPþ SCs	56099
Grafts	56099
EGFPþ SCs	56117
a greater density	56147
NF-IR axons	56168
Fig. 8D -- E	56197
Fig. 8D	56197
E	56205
EGFPþ OEG implants -LRB- Fig. 8F -- G -RRB-	56213
EGFPþ OEG implants	56213
Fig. 8F -- G	56233
Fig. 8F	56233
G	56241
these axons	56245
a significant portion of the extracellular space	56266
a significant portion	56266
the extracellular space	56291
NF-IR axons	56316
EGFPþ cell grafts	56348
all directions	56371
the identification	56394
their origin	56416
fiber type specific markers	56448
Phenotypic Identification	56489
Axon Populations	56518
Present	56535
the Grafts Identification of specific	56550
the Grafts Identification	56550
specific	56579
fiber systems	56612
anterograde tract tracing or immunochemistry	56640
anterograde tract tracing	56640
anterograde tract	56640
immunochemistry	56669
the majority of axons recognized	56700
the majority	56700
axons recognized	56716
axons	56716
an appreciable distance	56757
any of the graft types employed , i.e.	56786
any	56786
the graft types employed , i.e.	56793
the graft types	56793
i.e.	56819
the center of the grafts -LRB- Figs. 8H -- K and 9A -- D -RRB-	56827
the center	56827
the grafts -LRB- Figs. 8H -- K and 9A -- D -RRB-	56841
the grafts	56841
Figs. 8H	56853
K and 9A -- D	56862
K and 9A	56862
D	56871
sensory axons	56901
the hind limbs	56920
we	56935
CTB	56972
2,000 and 500 µm caudal to the graft	56980
2,000 and 500 µm caudal	56980
the graft	57007
the number of CTBþ fibers	57018
the number	57018
CTBþ fibers	57032
all groups	57062
SCI control : an average of 33 ±	57074
control	57078
an average of 33 ±	57087
an average	57087
33 ±	57101
7 fibers per section -LSB- f/s -RSB- at 2,000 µm and 13	57106
7 fibers	57106
section -LSB- f/s -RSB- at 2,000 µm and 13	57119
section -LSB- f/s	57119
2,000 µm and 13	57136
2,000 µm	57136
13	57149
3 f/s	57154
500 µm	57163
Growth of CTB	57172
Growth	57172
CTB	57182
fibers	57203
all graft types	57226
a small number	57247
axons present within the center of the grafts -LRB- Fig. 9A -RRB-	57265
axons present within the center of the grafts	57265
axons	57265
the center of the grafts	57286
the center	57286
the grafts	57300
Fig. 9A	57312
This growth	57322
the number of CTBþ axons	57381
the number	57381
CTBþ axons	57395
the tissue trabeculae of injured-only controls	57413
the tissue trabeculae	57413
injured-only controls	57438
The growth of CGRPþ -LRB- untraced -RRB- fibers	57461
The growth of CGRPþ -LRB- untraced -RRB-	57461
The growth	57461
CGRPþ	57475
the grafts	57540
both groups	57555
the combination of SCs and OEG	57577
the combination	57577
SCs and OEG	57596
combination within the injury site	57619
combination	57619
the injury site	57638
both sides of a SC graft	57660
both sides	57660
a SC graft	57674
significantly more CGRPþ axons	57687
2,000 µm	57735
SC-OEG center	57745
152 %	57760
88 ± 16 f/s , P < 0.05 ; SC-OEG side : 138 % increase to 80 ± 25 f/s	57777
88 ± 16 f/s	57777
P < 0.05 ; SC-OEG side : 138 % increase to 80 ± 25 f/s	57790
P < 0.05	57790
P <	57790
P	57790
0.05	57794
SC-OEG side	57800
SC-OEG	57800
side	57807
138 % increase to 80 ± 25 f/s	57813
138 % increase	57813
80 ± 25 f/s	57830
P	57843
0.05	57847
SCOEG center : 188 % increase to 45 ± 17 f/s	57868
SCOEG center	57868
188 % increase to 45 ± 17 f/s	57882
188 % increase	57882
45 ± 17 f/s	57899
P < 0.05 ; SCOEG side : 188 % to 45 ± 16 f/s	57912
P < 0.05	57912
P <	57912
P	57912
0.05	57916
SCOEG side	57922
SCOEG	57922
side	57928
188 % to 45 ± 16 f/s	57934
188 % to 45	57934
± 16 f/s	57945
P < 0.05	57955
P <	57955
P	57955
0.05	57959
the injury/graft site	57975
injury-only controls -LRB- 2,000 µm , 58 ± 15 f/s ; 500 µm , 24 ± 7 f/s -RRB-	58011
injury-only controls	58011
2,000 µm , 58 ± 15 f/s ; 500 µm , 24 ± 7 f/s	58033
2,000 µm	58033
58 ± 15 f/s ; 500 µm	58043
58 ± 15 f/s	58043
58	58043
15 f/s	58048
500 µm	58056
24 ± 7 f/s	58064
Figs. 8K and 9B	58077
Figs. 8K	58077
9B	58090
Growth of CGRPþ axons into the graft/injury site	58095
Growth	58095
CGRPþ axons into the graft/injury site	58105
CGRPþ axons	58105
the graft/injury site	58122
any of the grafted groups compared to injury-only controls	58189
any	58189
the grafted groups compared to injury-only controls	58196
the grafted groups	58196
injury-only controls	58227
descending fiber systems	58261
we	58286
anterograde	58298
BDA from the sensorimotor cortex	58323
BDA	58323
the sensorimotor cortex	58332
corticospinal tract axons	58365
immunochemical detection	58395
5-hydroxytryptophan	58423
a marker	58444
serotonergic axons	58457
constituents of the raphespinal system	58495
constituents	58495
the raphespinal system	58511
injury-only controls	58538
we	58559
170 ± 50 and 58	58568
170	58568
50 and 58	58574
18 serotonergic f/s	58586
2,000 and 500 µm rostral to the injury site , respectively ,	58609
2,000 and 500 µm rostral	58609
the injury site , respectively ,	58637
the injury site	58637
7 ± 6 serotonergic f/s	58672
7 ±	58672
6 serotonergic f/s	58676
the center of trabeculae at the injury site	58702
the center	58702
trabeculae at the injury site	58716
trabeculae	58716
the injury site	58730
Grafting of SCs or OEG or both	58747
Grafting	58747
SCs or OEG or both	58759
SCs or OEG	58759
both	58773
the number of serotonergic axons	58795
the number	58795
serotonergic axons	58809
rostral to or within the graft/injury site -LRB- Figs. 8H -- J and 9C -RRB-	58835
rostral	58835
the graft/injury site	58856
Figs. 8H -- J and 9C	58879
Figs. 8H	58879
J and 9C	58888
the number of BDA	58910
the number	58910
BDA	58924
fibers	58935
31 ± 12	58946
31	58946
12	58951
18 ± 7 f/s at 2,000 and 500 µm rostral to the injury site , respectively	58958
18 ±	58958
7 f/s at 2,000 and 500 µm rostral to the injury site	58963
7 f/s	58963
2,000 and 500 µm rostral	58972
the injury site	59000
3 ± 3 f/s within the center of tissue trabeculae	59035
3 ± 3 f/s	59035
the center of tissue trabeculae	59052
the center	59052
tissue trabeculae	59066
the injury site of injury-only controls	59087
the injury site	59087
injury-only controls	59106
the number of BDA	59135
the number	59135
BDA	59149
axons	59160
rostral to or within the graft	59205
rostral	59205
the graft	59226
injury site	59237
all transplantation paradigms -LRB- Fig. 9D -RRB-	59259
all transplantation paradigms	59259
Fig. 9D	59290
neither SC nor OEG grafts	59316
SC	59324
OEG grafts	59331
the contusion injury model	59352
substrates for significant cortico	59405
substrates	59405
significant cortico	59420
raphe-spinal axon growth	59444
Similar axon growth responses from ascending and descending systems	59470
Similar axon growth responses	59470
systems	59530
fibroblast implants	59557
data not shown	59592
data	59592
the growth of supraspinal axons	59618
the growth	59618
supraspinal axons	59632
EGFP glial cell grafts	59689
significant numbers	59715
appreciable distances	59742
many of these axons	59765
many	59765
these axons	59773
regions	59801
adjacent to the rostral edge of the EGFP implants	59821
the rostral edge of the EGFP	59833
the rostral edge	59833
the EGFP	59853
Fig. 8J	59872
an area which contained a mixture of largely p75þ endogenous SCs	59882
an area	59882
a mixture of largely p75þ endogenous SCs	59906
a mixture	59906
largely p75þ endogenous SCs	59919
immune cells , such as macrophages	59951
immune cells	59951
macrophages	59973
A similar phenomenon	59986
the caudal edge of the EGFP implants with respect	60023
the caudal edge	60023
the EGFP implants with respect	60042
the EGFP implants	60042
respect	60065
CTB-labeled ascending or CGRPþ axons -LRB- Fig. 8K -RRB-	60076
CTB-labeled ascending or CGRPþ axons	60076
Fig. 8K	60114
the EGFP SC group	60138
it	60157
the implant milieu and the surrounding host	60192
milieu and the surrounding host	60204
milieu	60204
the surrounding host	60215
lesion environment	60236
SCs	60279
factors produced by intermingling cell types , such as macrophages	60291
factors	60291
intermingling cell types	60311
macrophages	60345
the differential responses of these SC populations to the factors or ECM	60361
the differential responses	60361
these SC populations to the factors or ECM	60391
these SC populations	60391
the factors or ECM	60415
the factors	60415
ECM	60430
they	60434
a more permissive environment for axon growth	60466
a more permissive environment	60466
axon growth	60500
Myelination	60513
Axons by Transplanted Glia Myelination by transplanted SCs and OEG	60528
Axons	60528
Transplanted Glia Myelination by transplanted SCs and OEG	60537
Transplanted Glia Myelination	60537
transplanted SCs and OEG	60570
transplanted SCs	60570
OEG	60591
high power microscopic assessment	60622
the ratio	60659
MBP immunostaining and EGFP	60672
cells in the rostral , central , and caudal regions of EGFPþ SC	60708
cells	60708
the rostral , central , and caudal regions of EGFPþ SC	60717
the rostral	60717
central	60730
caudal regions of EGFPþ SC	60743
caudal regions	60743
EGFPþ SC	60761
SC and EGFPþ OEG transplants -LRB- Fig. 10A -RRB-	60778
SC and EGFPþ OEG transplants	60778
Fig. 10A	60808
axons	60830
both SC and OEG grafts	60853
SC	60858
OEG grafts	60865
SC grafts	60880
numerous myelinated axons	60891
both rostral and caudal regions	60938
the grafts with ratios of MBPþ axons to EGFPþ cells of 1:1.4 and 1:1.2	60973
the grafts	60973
ratios of MBPþ axons to EGFPþ cells of 1:1.4 and 1:1.2	60989
ratios	60989
MBPþ axons to EGFPþ cells of 1:1.4 and 1:1.2	60999
MBPþ axons	60999
EGFPþ cells of 1:1.4 and 1:1.2	61013
EGFPþ cells	61013
1:1.4 and 1:1.2	61028
the center of the grafts	61062
the center	61062
the grafts	61076
significantly fewer myelinated axons	61097
a ratio of MBPþ axons to EGFPþ cells of 1:5.8 -LRB- Table 1 , Fig. 10B -RRB-	61154
a ratio	61154
MBPþ axons to EGFPþ cells of 1:5.8 -LRB- Table 1 , Fig. 10B -RRB-	61165
MBPþ axons	61165
EGFPþ cells of 1:5.8 -LRB- Table 1 , Fig. 10B -RRB-	61179
EGFPþ cells	61179
1:5.8 -LRB- Table 1 , Fig. 10B -RRB-	61194
1:5.8	61194
Table 1	61201
Fig. 10B	61210
SC and EGFPþ OEG grafts	61224
there	61249
a reasonable distinction	61270
the two	61303
transplanted cell types	61311
the injury/graft site	61342
The mass of EGFPþ OEG	61365
The mass	61365
EGFPþ OEG	61377
closely comparable p75þ-EGFPþ cell profiles	61397
these areas	61458
many EGFP2	61497
exogenous or endogenous SCs	61508
Care	61537
regions used to analyze myelination	61567
regions	61567
myelination	61591
EGFP2-p75þ areas of the injury	61621
EGFP2-p75þ areas	61621
the injury	61641
graft site	61653
SCs	61670
abundance	61686
Assessment of myelination within EGFPþ OEG grafts	61697
Assessment	61697
myelination within EGFPþ OEG grafts	61711
myelination	61711
EGFPþ OEG grafts	61730
very few MBPþ profiles	61756
all three regions	61786
ratios for MBPþ axons	61809
ratios	61809
MBPþ axons	61820
EGFPþ cells	61834
1:46.2 , 1:58.8 , and 1:41.9	61849
rostral , central and caudal regions of the transplants , respectively	61879
rostral	61879
central and caudal regions of the transplants	61888
central and caudal regions	61888
the transplants	61918
Table	61949
I , Fig. 10C	61955
I	61955
Fig. 10C	61958
The very low numbers of MBPþ axons in the EGFPþ OEG graft regions	61969
The very low numbers	61969
MBPþ axons in the EGFPþ OEG graft regions	61993
MBPþ axons	61993
the EGFPþ OEG graft regions	62007
the possibility	62066
these axons	62087
the small numbers	62122
exogenous or endogenous SCs	62143
EGFPþ OEG	62199
Recovery of Hind Limb Function	62210
Recovery	62210
Hind Limb Function	62222
Glia Transplantation	62247
the	62273
Spinal Cord Animals	62285
both the injury only and most transplant groups	62310
the injury only	62315
most transplant groups	62335
a characteristic improvement	62368
open-field locomotion that reached a plateau by ≈ 6 weeks -LRB- Fig. 11A -RRB-	62400
open-field locomotion	62400
a plateau	62435
≈	62448
6 weeks	62449
Fig. 11A	62458
endpoint -LRB- 9 weeks -RRB-	62472
endpoint	62472
9 weeks	62482
injury-only controls	62492
a BBB score of 10.7 ± 0.7	62526
a BBB score	62526
10.7 ± 0.7	62541
the animals	62569
occasional	62591
frequent weight-supported	62605
no fore limb-hind limb coordination	62645
The other control group , which received fibroblast grafts ,	62682
The other control group	62682
fibroblast grafts	62722
any significant improvement over the injury	62754
any significant improvement	62754
the injury	62787
group	62803
an endpoint BBB score of 9.8 ± 1.4	62820
an endpoint BBB score	62820
9.8 ± 1.4	62845
the SC and OEG transplant groups	62861
only those animals receiving both SCs and OEG into the injury site	62895
both SCs and OEG	62924
SCs	62929
OEG	62937
the injury site	62946
a significant improvement	62975
BBB score	63004
fibroblast transplant and injury-only controls	63026
fibroblast transplant	63026
injury-only controls	63052
The SC and OEG combination group	63074
statistically significant increases in locomotor ability	63117
statistically significant increases	63117
locomotor ability	63156
5 to 9 weeks post-transplantation with the animals	63179
5 to 9 weeks	63179
the animals	63218
an average BBB score of 12.3 ± 0.7	63239
an average BBB score	63239
12.3 ± 0.7	63263
endpoint	63277
fibroblast transplants , P < 0.001 ; versus injury controls , P < 0.05	63294
fibroblast transplants , P < 0.001 ; versus injury controls	63294
fibroblast transplants	63294
P < 0.001	63318
P <	63318
P	63318
0.001	63322
injury controls	63336
P < 0.05	63353
P <	63353
P	63353
0.05	63357
These animals	63364
frequent to consistent plantar	63388
occasional fore limb-hind limb coordination	63433
the open field	63480
A subscore analysis	63496
the BBB score	63538
the presence of features above a score of 14	63563
the presence	63563
features above a score of 14	63579
features	63579
a score of 14	63594
a score	63594
14	63605
the BBB scale -LRB- Fig. 11B -RRB-	63611
the BBB scale	63611
Fig. 11B	63626
a BBB subscore of 6.1 ±	63669
a BBB subscore	63669
6.1 ±	63687
3.1 at endpoint	63693
3.1	63693
endpoint	63700
The transplantation of fibroblasts	63710
The transplantation	63710
fibroblasts	63733
BBB subscores	63768
4 to 9 weeks post-transplantation with animals	63787
4 to 9 weeks	63787
animals	63826
2.6 ±	63843
3.2 at endpoint -LRB- P < 0.05 -RRB-	63849
3.2	63849
endpoint -LRB- P < 0.05 -RRB-	63856
endpoint	63856
P < 0.05	63866
P	63866
< 0.05	63868
<	63868
0.05	63870
Animals	63877
the combination of SCs and OEG	63898
the combination	63898
SCs and OEG	63917
the injury site	63934
significantly higher BBB subscores	63957
8 and 9 weeks compared with injury	63995
8 and 9 weeks	63995
injury	64023
The average endpoint BBB subscore	64045
9.2 ± 1.2 -LRB- P < 0.05 -RRB-	64083
9.2 ± 1.2	64083
9.2	64083
1.2	64089
P < 0.05	64094
P	64094
< 0.05	64096
<	64096
0.05	64098
No significant improvements in the BBB subscore	64105
No significant improvements	64105
the BBB subscore	64136
the other three transplant groups	64172
9 weeks	64210
footprint analysis of the hind paws	64240
footprint analysis	64240
the hind paws	64262
the animals performed conditioned locomotion -LRB- Fig. 12A -- C -RRB-	64292
the animals	64292
conditioned locomotion -LRB- Fig. 12A -- C -RRB-	64314
conditioned locomotion	64314
Fig. 12A -- C	64338
Fig. 12A	64338
C	64347
Analysis of uninjured animals	64351
Analysis	64351
uninjured animals	64363
a mean angle of rotation of the hind limbs of 13.0 ± 1.0 °	64390
a mean angle	64390
rotation of the hind limbs of 13.0 ± 1.0 °	64406
rotation	64406
the hind limbs of 13.0 ± 1.0 °	64418
the hind limbs	64418
13.0 ± 1.0 °	64436
13.0 ±	64436
1.0 °	64443
injury	64455
this parameter	64462
a mean of 32.2 ± 2.0 °	64490
a mean	64490
32.2 ± 2.0 °	64500
32.2 ±	64500
2.0 °	64507
Fibroblast transplantation	64513
the rotation of the hind limbs , 32.1 ± 3.1 °	64568
the rotation	64568
the hind limbs , 32.1 ± 3.1 °	64584
the hind limbs	64584
32.1 ± 3.1 °	64600
32.1 ±	64600
3.1 °	64607
Transplantation of either SCs alone or both SCs and OEG into the injury site	64613
Transplantation of either SCs alone or both SCs	64613
Transplantation	64613
either SCs alone or both SCs	64632
SCs alone	64639
SCs	64639
both SCs	64652
OEG into the injury site	64665
OEG	64665
the injury site	64674
foot rotation	64702
the degree of deficit	64726
the degree	64726
deficit	64740
26.0 ± 1.8 ° -LRB- P < 0.05 -RRB- and 25.3 ± 4.6 ° -LRB- P < 0.05 -RRB-	64751
26.0 ± 1.8 ° -LRB- P < 0.05 -RRB-	64751
26.0	64751
± 1.8 ° -LRB- P < 0.05 -RRB-	64756
± 1.8 °	64756
P < 0.05	64764
P	64764
< 0.05	64766
<	64766
0.05	64768
25.3 ± 4.6 ° -LRB- P < 0.05 -RRB-	64778
25.3 ±	64778
4.6 ° -LRB- P < 0.05 -RRB-	64785
P < 0.05	64791
P	64791
< 0.05	64793
<	64793
0.05	64795
No differences	64816
the other transplant groups -LRB- Fig. 12A -RRB-	64848
the other transplant groups	64848
Fig. 12A	64877
The other parameters measured , stride length and base of support ,	64888
The other parameters measured	64888
The other parameters	64888
stride length	64919
base of support	64937
base	64937
support	64945
significant deficits	64961
injury	64988
any of the transplants -LRB- Fig. 12B , C -RRB-	65019
any	65019
the transplants -LRB- Fig. 12B , C -RRB-	65026
the transplants	65026
Fig. 12B , C	65043
Fig. 12B	65043
C	65052
the final test , for coordinated motor performance	65059
the final test	65059
coordinated motor performance	65079
animals	65110
a grid	65159
bars	65187
the number of footfall errors -LRB- missed bars -RRB- made by each hind limb	65196
the number of footfall errors -LRB- missed bars -RRB-	65196
the number of footfall errors	65196
the number	65196
footfall errors	65210
bars	65234
each hind limb	65248
a pronounced impairment	65286
injury compared with uninjured controls	65333
injury	65333
uninjured controls	65354
none of the transplant groups	65374
none	65374
the transplant groups	65382
a significant improvement in performance over the injury	65413
a significant improvement	65413
performance over the injury	65442
performance	65442
the injury	65459
Fig. 12D	65485
DISCUSSION The use of a cellular transplant to bridge the injured spinal cord	65497
DISCUSSION	65497
The use of a cellular transplant	65508
The use	65508
a cellular transplant	65519
the injured spinal cord	65551
a cornerstone	65584
many successful repair strategies	65601
e.g.	65636
Li	65642
et al. , 2003b	65645
et al.	65645
2003b	65653
McDonald et al. , 1999	65660
McDonald	65660
et al. , 1999	65669
et al.	65669
1999	65677
Pearse et al. , 2004b	65683
Pearse	65683
et al. , 2004b	65690
et al.	65690
2004b	65698
Ram on-Cueto et al.	65705
Ram on-Cueto	65705
et al.	65718
2000	65726
The current study	65733
the survival	65759
migration	65773
axon association	65784
myelination	65806
two types	65821
glial cells	65834
promise for SCI repair	65862
promise	65862
SCI repair	65874
various transplantation paradigms , SCs or OEG	65888
Bamber	65943
et al. , 2001	65950
et al.	65950
2001	65958
Bunge and Pearse , 2003	65964
Bunge and Pearse	65964
2003	65982
Fouad et al. , 2005	65988
Fouad	65988
et al. , 2005	65994
et al.	65994
2005	66002
Li et al. , 1997 , 1998 , 2003b	66008
Li	66008
et al. , 1997 , 1998 , 2003b	66011
et al.	66011
1997	66019
1998	66025
2003b	66031
Pearse et al. , 2004a , 2004b	66038
Pearse	66038
et al. , 2004a , 2004b	66045
et al.	66045
2004a	66053
2004b	66060
Ramon-Cueto et al.	66067
Ramon-Cueto	66067
et al.	66079
1998 , 2000 ; Takami et al. , 2002b	66087
1998	66087
2000 ; Takami et al.	66093
2000	66093
Takami et al.	66099
Takami	66099
et al.	66106
2002b	66114
Bunge and Wood , 2006	66133
Bunge and Wood	66133
2006	66149
We	66156
cells	66170
vivo over time post-transplantation	66179
vivo	66179
time post-transplantation	66189
the use	66223
genetic markers	66234
the Y chromosome or lentiviral vector transfer	66251
EGFP	66301
markers	66307
leakage or cellular transfer	66347
leakage	66347
cellular transfer	66358
the host to permit long-term tracking	66400
long-term tracking	66419
Barakat	66439
et al. , 2005	66447
et al.	66447
2005	66455
Consiglio et al. , 2004	66461
Consiglio	66461
et al. , 2004	66471
et al.	66471
2004	66479
Ericson et al. , 2002	66485
Ericson	66485
et al. , 2002	66493
et al.	66493
2002	66501
Harvey et al. , 1992	66507
Harvey	66507
et al. , 1992	66514
et al.	66514
1992	66522
Tamaki et al. , 2002	66528
Tamaki	66528
et al. , 2002	66535
et al.	66535
2002	66543
Our study	66550
the relatively low survival of both types of glial cells after transplantation	66571
the relatively low survival	66571
both types of glial cells after transplantation	66602
both types	66602
glial cells after transplantation	66616
glial cells	66616
transplantation	66634
the epicenter of the injured spinal cord	66655
the epicenter	66655
the injured spinal cord	66672
survival of OEG	66704
survival	66704
OEG	66716
they	66741
combination	66762
lower densities	66778
host spinal cord distant	66803
host spinal cord	66803
the injury epicenter	66833
all grafting paradigms	66858
significant infiltration of endogenous SCs	66882
significant infiltration	66882
endogenous SCs	66910
accompanying transplantation	66938
endogenous cell numbers	66973
numbers of labeled cells within the injured spinal cord over time	67032
numbers	67032
labeled cells within the injured spinal cord over time	67043
labeled cells	67043
the injured spinal cord over time	67064
the injured spinal cord	67064
time	67093
contrast	67102
other studies -LRB- Ram on-Cueto et al. , 1998 , 2000 -RRB- , grafted	67114
other studies -LRB- Ram on-Cueto et al. , 1998 , 2000 -RRB-	67114
other studies	67114
Ram on-Cueto et al. , 1998 , 2000	67129
Ram on-Cueto et al. , 1998	67129
Ram	67129
et al. , 1998	67142
et al.	67142
1998	67150
2000	67156
glial cells	67171
their original site of deposition	67207
their original site	67207
deposition	67230
they	67253
access	67278
the central canal	67288
the pia from the injection entry site	67328
the pia	67328
the injection entry site	67341
both SCs and OEG	67376
highly supportive substrates	67398
NFþ axons	67431
the growth of long tract	67494
the growth	67494
long tract	67508
axons and only SC grafts	67543
axons	67543
SC grafts	67558
large numbers of myelinated axons	67578
large numbers	67578
myelinated axons	67595
The combination of SC and OEG implantation into the injury site	67613
The combination	67613
SC and OEG implantation into the injury site	67632
SC and OEG implantation	67632
the injury site	67661
modest , though significant , improvements	67699
open-field locomotion and hind paw positioning	67743
local axon growth	67807
DRG	67838
sensory or spinal cord proprioceptive neurons	67842
sensory or spinal cord	67842
proprioceptive neurons	67865
partial recovery of function	67903
partial recovery	67903
function	67923
previous studies	67936
a number of nuclear -LRB- Hoechst -RRB- and cytoplasmic dyes -LRB- PKH26 -RRB-	67953
a number	67953
nuclear -LRB- Hoechst -RRB- and cytoplasmic dyes -LRB- PKH26 -RRB-	67965
nuclear	67965
Hoechst	67974
cytoplasmic dyes	67987
PKH26	68005
SCs and OEG	68059
Evercooren et al. , 1991 ; Ram on-Cueto et al. , 1998 , 2000	68072
Evercooren et al.	68072
Evercooren	68072
et al.	68083
1991 ; Ram on-Cueto et al.	68091
1991	68091
Ram on-Cueto et al.	68097
Ram on-Cueto	68097
et al.	68110
1998 , 2000	68118
1998	68118
2000	68124
These labels	68131
the cells in culture prior to their transplantation	68163
the cells	68163
culture	68176
their transplantation	68193
the dyes label cells well in vitro ,	68225
the dyes label cells	68225
vitro	68254
a few passages	68277
leak	68310
the short-term -LRB- Mosahebi et al. , 2000 -RRB- , once transplanted	68318
the short-term -LRB- Mosahebi et al. , 2000 -RRB-	68318
the short-term	68318
Mosahebi	68334
et al. , 2000	68343
et al.	68343
2000	68351
transplanted	68363
the death of the labeled cells	68377
the death	68377
the labeled cells	68390
the	68418
it	68434
endogenous cells	68456
label host structures	68476
Ansselin et al. , 1997 ; Hermanns et al. , 1997 ; Horan and Slezak , 1989	68499
Ansselin	68499
et al. , 1997 ; Hermanns et al. , 1997 ; Horan and Slezak , 1989	68508
et al. , 1997	68508
et al.	68508
1997	68516
Hermanns et al. , 1997	68522
Hermanns	68522
et al. , 1997	68531
et al.	68531
1997	68539
Horan and Slezak , 1989	68545
Horan and Slezak	68545
1989	68563
specific identification of the grafted cells very difficult	68577
specific identification	68577
the grafted cells very difficult	68604
the grafted cells	68604
Other studies	68638
immunochemistry	68666
an antibody	68688
a protein	68703
the grafted glia	68741
the low-affinity neurotrophin receptor p75	68767
Takami	68811
et al. , 2002 ; Pearse et al. , 2004b	68818
et al.	68818
2002 ; Pearse et al.	68826
2002	68826
Pearse et al.	68832
Pearse	68832
et al.	68839
2004b	68847
The infiltration	68855
peripheral nerve elements	68875
the CNS	68906
SCs	68923
afferent fibers	68931
Beattie	68948
et al. , 1997 ; Brook et al. , 1998	68956
et al.	68956
1997 ; Brook et al.	68964
1997	68964
Brook et al.	68970
Brook	68970
et al.	68976
1998	68984
SCI	68997
this labeling	69012
both exogenous and endogenous glia and thus estimation of grafted cell survival	69037
both exogenous and endogenous glia	69037
estimation of grafted cell survival	69081
estimation	69081
grafted cell survival	69095
Pearse	69133
et al. , 2002 , 2004c	69140
et al.	69140
2002	69148
2004c	69154
there	69176
concomitant expression	69185
p75 by microglia and astrocytes -LRB- Harvey , 1994 -RRB-	69211
p75	69211
microglia and astrocytes -LRB- Harvey , 1994 -RRB-	69218
microglia and astrocytes	69218
Harvey	69244
1994	69252
there	69262
a loss	69271
expression	69281
p75 on SCs following myelination -LRB- Jessen and Mirsky , 1991 -RRB-	69295
p75	69295
SCs following myelination -LRB- Jessen and Mirsky , 1991 -RRB-	69302
SCs	69302
myelination -LRB- Jessen and Mirsky , 1991 -RRB-	69316
myelination	69316
Jessen and Mirsky , 1991	69329
Jessen	69329
Mirsky , 1991	69340
Mirsky	69340
1991	69348
early	69363
generation viral vectors , retro - and adeno-viral vectors	69369
generation viral vectors , retro	69369
generation	69369
viral vectors , retro	69380
viral vectors	69380
adeno-viral vectors	69406
nonmammalian genes such as lacZ or GFP	69457
nonmammalian genes	69457
lacZ or GFP	69484
glial cells ex vivo prior to implantation -LRB- Langford and Owens , 1990 -RRB-	69499
glial cells ex vivo prior to implantation	69499
glial cells	69499
ex vivo	69511
implantation	69528
Langford and Owens	69542
1990	69562
These delivery systems	69569
apparent short-term expression	69621
rapid down-regulation of the gene	69659
rapid down-regulation	69659
the gene	69684
interest	69696
Blits et al. , 1999 ; Ruitenberg et al. , 2002 ; Hendriks et al. , 2004	69706
Blits	69706
et al. , 1999 ; Ruitenberg et al. , 2002 ; Hendriks et al. , 2004	69712
et al. , 1999	69712
et al.	69712
1999	69720
Ruitenberg et al. , 2002	69726
Ruitenberg	69726
et al. , 2002	69737
et al.	69737
2002	69745
Hendriks et al. , 2004	69751
Hendriks	69751
et al. , 2004	69760
et al.	69760
2004	69768
the long-term tracking	69786
the cell 's fate	69812
the cell 's	69812
the two labels used in the current study	69838
the two labels	69838
the current study	69861
numerous advantages over those employed previously	69884
numerous advantages	69884
those employed previously	69909
those	69909
we	69936
both labels	69953
some short-comings	69975
particular analyses	70000
the presence of the GFP label throughout the cells	70021
the presence	70021
the GFP label throughout the cells	70037
the GFP label	70037
the cells	70062
it	70083
individual cells	70107
stereological counting	70131
axonal association	70163
tissue sections used for DNA ISH	70210
tissue sections	70210
DNA ISH	70235
the distinct labeling of the cell nucleus	70246
the distinct labeling	70246
the cell nucleus	70271
it	70293
cell morphology	70314
many antibodies employed for immunochemistry	70334
many antibodies	70334
immunochemistry	70363
DNA ISH -LRB- Andrade et al. , 2007 -RRB-	70400
DNA ISH	70400
Andrade	70409
et al. , 2007	70417
et al.	70417
2007	70425
the present study	70446
we	70465
labels	70482
their particular strengths	70502
the overall characterization of the glia transplants in the contused spinal cord	70533
the overall characterization	70533
the glia transplants in the contused spinal cord	70565
the glia transplants	70565
the contused spinal cord	70589
the	70589
spinal cord	70602
Stereological assessment of male SCs and/or OEG	70615
Stereological assessment	70615
male SCs and/or OEG	70643
male SCs	70643
OEG	70659
the survival of these cells	70681
the survival	70681
these cells	70697
the hostile milieu of the injury epicenter	70742
the hostile milieu	70742
the injury epicenter	70764
the presence of	70794
the presence	70794
gross examination	70817
a large graft	70856
most animals	70874
the formation of a central cavity	70902
the formation	70902
a central cavity	70919
The absence	70937
statistical significance	70952
cell survival	70980
all transplant groups between 3 and 9 weeks post-transplantation	70997
all transplant groups	70997
between 3 and 9 weeks	71019
dramatic cell loss	71077
3 days and 3 weeks post-transplantation	71113
3 days	71113
3 weeks post-transplantation	71124
The temporal profile of cell loss quantified by the number of male cells	71154
The temporal profile	71154
cell loss quantified by the number of male cells	71178
cell loss	71178
the number of male cells	71202
the number	71202
male cells	71216
a sequential reduction	71243
GFP signal	71269
immunoblot analysis	71297
stereological quantification	71323
numbers of GFP cells -LRB- Andrade et al. , 2007 -RRB-	71355
numbers	71355
GFP cells -LRB- Andrade et al. , 2007 -RRB-	71366
GFP cells	71366
Andrade	71377
et al. , 2007	71385
et al.	71385
2007	71393
The loss	71400
cells appeared to result primarily from cell death	71420
cells	71420
cell death	71460
the down-regulation	71484
lentiviral vector	71507
EGFP -LRB- Johansen et al. , 2002 -RRB-	71537
EGFP	71537
Johansen	71543
et al. , 2002	71552
et al.	71552
2002	71560
no statistically significant difference	71570
the cell counts obtained with both markers within	71631
the cell counts	71631
both markers	71661
cohorts across time	71689
cohorts	71689
time	71704
it	71732
the introduction	71759
a foreign protein	71779
EGFP	71798
the surface of producing cells	71839
the surface	71839
producing cells	71854
prime	71885
them for rejection	71891
them	71891
rejection	71900
the immune system	71913
a role	71948
the observed loss of cells	71958
the observed loss	71958
cells	71979
the lack of significant difference in cell counts between markers	71992
the lack	71992
significant difference in cell counts between markers	72004
significant difference	72004
cell counts between markers	72030
cell counts	72030
markers	72050
EGFP expression	72077
the major factor responsible for triggering cell death	72101
the major factor	72101
cell death	72145
The implantation of male cells into a female host	72157
The implantation	72157
male cells into a female host	72177
male cells	72177
a female host	72193
a targeted immune response	72226
the complement cascade through which this mechanism occurs	72261
the complement cascade	72261
this mechanism	72298
implantation -LRB- hours -RRB-	72357
implantation	72357
hours	72371
most of the cell death	72431
most	72431
the cell death	72439
we	72459
time points	72474
3 days	72493
implantation -LRB- Hodgetts and Grounds , 2001	72506
implantation -LRB- Hodgetts and Grounds	72506
implantation	72506
Hodgetts and Grounds	72520
Hodgetts	72520
Grounds	72533
2001	72542
this mechanism of sex-mismatched rejection	72562
this mechanism	72562
sex-mismatched rejection	72580
an important event	72615
humans	72637
a much smaller role in rodents -LRB- Hodgetts and Grounds , 2001 -RRB-	72661
a much smaller role	72661
rodents -LRB- Hodgetts and Grounds , 2001 -RRB-	72684
rodents	72684
Hodgetts and Grounds , 2001	72693
Hodgetts	72693
Grounds	72706
2001	72715
another study of SC survival	72725
another study	72725
SC survival	72742
SCs expressing human placental alkaline phosphatase	72755
SCs	72755
human placental alkaline phosphatase	72770
cyclosporin treatment	72829
we	72859
disappearance of the labeled cells	72875
disappearance	72875
the labeled cells	72892
cell death , not loss of the label -LRB- Hill et al. , 2006 -RRB-	72921
cell death	72921
not loss of the label -LRB- Hill et al. , 2006 -RRB-	72933
not loss	72933
the label -LRB- Hill et al. , 2006 -RRB-	72945
the label	72945
Hill	72956
et al. , 2006	72961
et al.	72961
2006	72969
The cell death observed in the current study	72976
The cell death	72976
the current study	73003
-LRB- i -RRB- the presence of a robust immune cell response	73050
the presence	73054
a robust immune cell response	73070
subsequent rejection	73104
allografted cells -LRB- Laylor et al. , 2005 ; Theele et al. , 1996 -RRB-	73132
allografted cells	73132
Laylor	73151
et al. , 2005 ; Theele et al. , 1996	73158
et al.	73158
2005 ; Theele et al.	73166
2005	73166
Theele et al.	73172
Theele	73172
et al.	73179
1996	73187
-LRB- ii -RRB- inadequate vascularization	73194
ii	73195
decreased oxygen supply	73239
carbon dioxide and altered acidity	73274
Ducker and Perot	73310
Ducker	73310
Perot	73321
1971 ; Griffiths , 1976	73328
1971	73328
Griffiths , 1976	73334
Griffiths	73334
1976	73345
the presence	73358
cytotoxic free radicals	73374
oxidative metabolites	73402
cellular disruption	73443
phagocytosis	73482
tissue debris	73498
Bao and Liu , 2002 ; Hall and Braughler , 1986 ; Pearse et al. , 2003	73513
Bao and Liu	73513
Bao	73513
Liu	73521
2002 ; Hall and Braughler	73526
2002	73526
Hall and Braughler	73532
1986 ; Pearse et al. , 2003	73552
1986	73552
Pearse et al. , 2003	73558
Pearse	73558
et al. , 2003	73565
et al.	73565
2003	73573
-LRB- iv -RRB- environmental shock	73580
iv	73581
cultured cells	73608
serum and mitogen deprivation	73633
transplantation -LRB- Brundin et al. , 2000 -RRB-	73680
transplantation	73680
Brundin	73697
et al. , 2000	73705
et al.	73705
2000	73713
a combination of all of the above	73723
a combination	73723
all of the above	73740
all	73740
the above	73747
Survival of transplanted OEG	73758
Survival	73758
transplanted OEG	73770
the cells	73804
lower densities	73837
normalappearing tissue rostral and caudal	73859
normalappearing tissue rostral	73859
caudal	73894
the injury site	73904
Grafting of the cells in lower densities	73921
Grafting	73921
the cells in lower densities	73933
the cells	73933
lower densities	73946
survival	73977
individual cells	74000
greater access	74017
the limited resources	74035
the injury milieu	74072
survival	74103
oxygen -LRB- Ducker and Perot , 1971 ; Griffiths , 1976 -RRB-	74121
oxygen	74121
Ducker and Perot	74129
Ducker	74129
Perot	74140
1971 ; Griffiths , 1976	74147
1971	74147
Griffiths , 1976	74153
Griffiths	74153
1976	74164
Survival of SCs or OEG	74171
Survival	74171
SCs or OEG	74183
other studies	74223
lower numbers	74242
the grafting	74274
a milder injury -LRB- Keyvan-Fouladi et al. , 2003 ; Li et al. , 2002 -RRB-	74315
a milder injury	74315
Keyvan-Fouladi	74332
et al. , 2003 ; Li et al. , 2002	74347
et al.	74347
2003 ; Li et al.	74355
2003	74355
Li et al.	74361
Li	74361
et al.	74364
2002	74372
the transplantation	74393
glia outside the hostile environment of the injury site	74416
glia	74416
the hostile environment of the injury site	74429
the hostile environment	74429
the injury site	74456
relatively normal-appearing tissue	74476
cell death	74525
their exposure	74548
excitotoxic , oxidative and proinflammatory molecules	74566
Bao and Liu , 2002 ; Hall and Braughler , 1986 ; Pearse et al. , 2003	74620
Bao and Liu	74620
2002 ; Hall and Braughler , 1986 ; Pearse et al.	74633
2002	74633
Hall and Braughler , 1986 ; Pearse et al.	74639
Hall and Braughler , 1986	74639
Hall and Braughler	74639
1986	74659
Pearse et al.	74665
Pearse	74665
et al.	74672
2003	74680
Previous studies employing OEG for SCI repair	74687
Previous studies	74687
OEG for SCI repair	74714
OEG	74714
SCI repair	74722
efficacy when the cells were deposited both rostral and caudal	74751
efficacy when the cells were deposited	74751
efficacy	74751
the cells	74765
Fouad et al. , 2005 ; Ram on-Cueto et al. , 1998 , 2000	74815
Fouad et al.	74815
Fouad	74815
et al.	74821
2005 ; Ram on-Cueto et al.	74829
2005	74829
Ram on-Cueto et al.	74835
Ram on-Cueto	74835
et al.	74848
1998 , 2000	74856
1998	74856
2000	74862
within -LRB- Barakat et al. , 2005 -RRB- , the injury site	74881
within	74881
Barakat	74889
et al. , 2005	74897
et al.	74897
2005	74905
the injury site	74912
addition	74932
methods for preparing the cells in culture prior to their implantation	74942
methods	74942
the cells in culture	74964
the cells	74964
culture	74977
their implantation	74994
the hostile environment of the injured spinal cord	75070
the hostile environment	75070
the injured spinal cord	75097
the study by Li et al. -LRB- 2003b -RRB-	75125
the study	75125
Li et al. -LRB- 2003b -RRB-	75138
Li et al.	75138
Li	75138
et al.	75141
2003b	75149
OEG	75157
the matrix they had produced during culture	75183
the matrix	75183
they	75194
culture	75219
The OEG-matrix	75228
the culture dishes	75259
pieces	75295
the hemisected spinal cord	75307
a fluid	75354
the current study	75376
The use of this procedure	75395
The use	75395
this procedure	75406
good survival of the GFP	75433
good survival	75433
the GFP	75450
OEG	75469
improvements	75484
functional outcome	75500
The spinal cord implantation of glia within their own or a purified matrix	75520
The spinal cord implantation	75520
glia within their own or a purified matrix	75552
glia within their own	75552
glia	75552
their own	75564
a purified matrix	75577
their death	75607
a result	75622
anoikis	75634
apoptosis that is induced by removal of cells from their matrix	75643
apoptosis	75643
removal of cells	75672
removal	75672
cells	75683
their matrix	75694
neighboring cells -LRB- Frisch and Screaton , 2001 -RRB-	75710
neighboring cells	75710
Frisch and Screaton	75729
2001	75750
Additional parameters that may affect the ability of	75757
Additional parameters	75757
the ability of	75795
the ability	75795
glia	75820
injection	75846
the injured cord	75861
their source	75886
derivation such as adult versus embryonic	75902
derivation	75902
adult versus embryonic	75921
adult	75921
embryonic	75934
Boyd	75945
et al. , 1995 ; Goodman et al. , 1993	75950
et al.	75950
1995 ; Goodman et al.	75958
1995	75958
Goodman et al.	75964
Goodman	75964
et al.	75972
1993	75980
the case of OEG	75994
the case	75994
OEG	76006
they	76019
the olfactory bulb or lamina propria	76043
Jani and Raisman , 2004 ; Richter et al. , 2005	76081
Jani and Raisman	76081
2004 ; Richter et al.	76099
2004	76099
Richter et al.	76105
Richter	76105
et al.	76113
2005	76121
they	76143
culture	76158
they	76171
they	76204
different mitogenic signals	76224
Li et al. , 2003b ; Pearse et al. , 2004a , b ; Ramon - Cueto et al.	76253
Li et al.	76253
Li	76253
et al.	76256
2003b ; Pearse et al.	76264
2003b	76264
Pearse et al.	76271
Pearse	76271
et al.	76278
2004a	76286
b ; Ramon - Cueto et al.	76292
b ; Ramon	76292
b	76292
Ramon	76295
Cueto et al.	76302
Cueto	76302
et al.	76308
1998 , 2000	76316
1998	76316
2000	76322
The survival	76329
glia derived from different sources or cultured for different periods	76345
glia	76345
different sources	76363
different periods	76397
the presence	76434
additional cell types	76450
stem or precursor cells	76483
Doucette	76508
1993	76518
SCs	76528
Rizek and Kawaja	76533
2006	76551
the implants	76564
embryonic , early passage or lamina	76578
propria-derived cultures	76613
lower purities	76654
Richter et al. , 2005 ; Rizek and Kawaja ; 2006	76671
Richter	76671
et al. , 2005 ; Rizek and Kawaja ; 2006	76679
et al. , 2005	76679
et al.	76679
2005	76687
Rizek and Kawaja ; 2006	76693
Rizek and Kawaja	76693
2006	76711
the dependence	76723
the cells	76741
signals	76754
culture	76774
Li et al. , 2003b ; Pearse et al. , 2004a , b ; Ram on-Cueto et al.	76783
Li et al.	76783
Li	76783
et al.	76786
2003b ; Pearse et al.	76794
2003b	76794
Pearse et al.	76801
Pearse	76801
et al.	76808
2004a	76816
b ; Ram on-Cueto et al.	76822
b	76822
Ram on-Cueto et al.	76825
Ram on-Cueto	76825
et al.	76838
1998 , 2000	76846
1998	76846
2000	76852
we	76867
the current study	76878
OEG	76901
SCs	76940
a cell type	76945
significant numbers	76980
OEG cultures derived from embryonic tissue or the lamina propria	77003
OEG cultures	77003
embryonic tissue or the lamina propria	77029
embryonic tissue	77029
the lamina propria	77049
early passage	77079
Rizek and Kawaja	77094
2006	77112
preimplantation conditions	77132
glia survival	77165
also the postimplantation , hypoxic conditions of the poorly vascularized ,	77199
also the postimplantation	77199
hypoxic conditions of the poorly vascularized	77226
hypoxic conditions	77226
the poorly vascularized	77248
the	77248
spinal cord can -LRB- Balentine , 1978 -RRB-	77281
spinal cord can	77281
spinal cord	77281
Balentine	77298
1978	77309
prime implanted cells to survive better within hypoxic tissues	77319
prime	77319
cells	77335
better	77352
hypoxic tissues	77366
recent studies	77383
culture methods	77412
cells	77440
a sublethal hypoxic or hyperthermic environment	77459
Schramm	77508
et al. , 2002 ; Yao et al. , 2005	77516
et al.	77516
2002 ; Yao et al.	77524
2002	77524
Yao et al.	77530
Yao	77530
et al.	77534
2005	77542
genes	77571
heme oxygenase	77586
them	77614
hypoxic stress -LRB- Tang et al. , 2005 -RRB-	77639
hypoxic stress	77639
Tang	77655
et al. , 2005	77660
et al.	77660
2005	77668
This conditioning	77675
survival	77726
transplanted cells within injured organs -LRB- Tang et al. , 2005 -RRB-	77738
transplanted cells	77738
injured organs -LRB- Tang et al. , 2005 -RRB-	77764
injured organs	77764
Tang	77780
et al. , 2005	77785
et al.	77785
2005	77793
the limited survival	77808
glia	77832
the	77840
spinal cord	77853
the use of an allograft	77871
the use	77871
an allograft	77882
the highly genetically inbred Fischer strain of rat	77902
the highly genetically inbred Fischer strain	77902
rat	77950
contrast	77960
the good survival	77972
cell allografts	77993
the same strains of mice -LRB- Colson et al. , 1995 -RRB-	78025
the same strains	78025
mice -LRB- Colson et al. , 1995 -RRB-	78045
mice	78045
Colson	78051
et al. , 1995	78058
et al.	78058
1995	78066
the importance	78087
Beattie et al. , 2002 ; Beattie , 2004	78140
Beattie	78140
et al. , 2002 ; Beattie , 2004	78148
et al. , 2002	78148
et al.	78148
2002	78156
Beattie , 2004	78162
Beattie	78162
2004	78171
Theele	78211
et al. , 1996	78218
et al.	78218
1996	78226
graft efficacy	78243
future studies	78261
male or GFPþ cells	78301
increasing numbers of host SCs	78331
increasing numbers	78331
host SCs	78353
the damaged dorsal root entry zones to gain access to the injured CNS	78400
the damaged dorsal root	78400
entry zones	78424
access	78444
the injured CNS	78454
This phenomenon	78471
the relatively static gross structure of the graft	78501
the relatively static gross structure	78501
the graft	78542
the different time points	78559
Previous reports	78586
both experimental models -LRB- Beattie et al. , 1997 ; Brook et al. , 1998 -RRB-	78606
both experimental models	78606
Beattie	78632
et al. , 1997 ; Brook et al. , 1998	78640
et al.	78640
1997 ; Brook et al.	78648
1997	78648
Brook et al.	78654
Brook	78654
et al.	78660
1998	78668
human cases of SCI	78678
human cases	78678
SCI	78693
Guest	78698
et al. , 2005	78704
et al.	78704
2005	78712
significant spinal cord infiltration	78734
peripheral nervous system restricted SCs	78774
Bunge and Wood	78816
2006	78832
the present study	78842
numbers of these endogenous cells	78861
numbers	78861
these endogenous cells	78872
GFPþ glia -LRB- 2 - to 10-fold -RRB-	78934
GFPþ glia	78934
2	78945
9 weeks	78966
a false picture	79003
the exogenous cell grafts	79024
numbers over time	79079
numbers	79079
time	79092
p75 immunostaining	79138
These results	79164
the inadequacies	79200
immunohistochemistry for p75	79226
immunohistochemistry	79226
p75	79251
implanted SCs or OEG	79275
the injured spinal cord	79303
our group and others	79362
Bunge and Pearse , 2003 ; Pearse et al. , 2004a , b	79384
Bunge and Pearse	79384
Bunge	79384
Pearse	79394
2003 ; Pearse et al.	79402
2003	79402
Pearse et al.	79408
Pearse	79408
et al.	79415
2004a , b	79423
2004a	79423
b	79429
The combination of EGFP labeling and p75 immunochemistry in the current study	79433
The combination	79433
EGFP labeling and p75 immunochemistry in the current study	79452
EGFP labeling and p75 immunochemistry	79452
the current study	79493
definite counting	79529
transplanted	79560
SCs or OEG versus infiltrating endogenous SCs	79573
SCs or OEG	79573
endogenous SCs	79604
Fig. 3	79620
endogenous SC migration	79647
a major component and possibly a confounder in cell implantation paradigms	79674
a major component	79674
a confounder in cell implantation paradigms	79705
a confounder	79705
cell implantation paradigms	79721
note	79753
SC infiltration	79768
SCI-only spinal cords -LRB- data not shown -RRB-	79800
SCI-only spinal cords	79800
data not shown	79823
data	79823
a significantly greater amount	79840
a cell transplant	79885
The higher numbers of p75þ	79917
The higher numbers	79917
p75þ	79939
EGFP2 cells in SC and OEG	79945
EGFP2 cells	79945
SC and OEG	79960
groups	79979
controls -LRB- more than 10-fold in cases -RRB- ,	80011
controls	80011
more than 10-fold in cases	80021
more than 10-fold	80021
cases	80042
the implantation and/or death of these SCs or OEG	80063
implantation	80067
death of these SCs or OEG	80087
death	80087
these SCs or OEG	80096
these SCs	80096
OEG	80109
the ingress of endogenous SCs	80132
the ingress	80132
endogenous SCs	80147
the injured spinal cord	80167
The signals	80192
the ingress of SCs	80230
the ingress	80230
SCs	80245
the injured spinal cord	80254
a number	80312
sources	80324
angiogenic -LRB- Gilmore et al. , 1993 ; Raine et al. , 1978 -RRB-	80342
angiogenic	80342
Gilmore	80354
et al. , 1993 ; Raine et al. , 1978	80362
et al.	80362
1993 ; Raine et al.	80370
1993	80370
Raine et al.	80376
Raine	80376
et al.	80382
1978	80390
immune -LRB- Fukaya et al. , 2003 -RRB-	80397
immune	80397
Fukaya	80405
et al. , 2003	80412
et al.	80412
2003	80420
axonal -LRB- Raine et al. , 1978 -RRB-	80427
axonal	80427
Raine	80435
et al. , 1978	80441
et al.	80441
1978	80449
ECM -LRB- King et al. , 2006 -RRB-	80458
ECM	80458
King	80463
et al. , 2006	80468
et al.	80468
2006	80476
SCI	80493
SCs migrating into the CNS	80498
SCs	80498
the CNS	80517
close association	80550
newly formed blood vessels	80578
Gilmore	80606
et al. , 1993 ; Raine et al. , 1978	80614
et al.	80614
1993 ; Raine et al.	80622
1993	80622
Raine et al.	80628
Raine	80628
et al.	80634
1978	80642
sensory axons -LRB- Bunge et al. , 1994 ; Raine et al. , 1978 -RRB-	80662
sensory axons	80662
Bunge	80677
et al. , 1994 ; Raine et al. , 1978	80683
et al.	80683
1994 ; Raine et al.	80691
1994	80691
Raine et al.	80697
Raine	80697
et al.	80703
1978	80711
either angiogenic or axonal signals	80731
the proliferation and ingress of SCs from the dorsal roots	80777
the proliferation and ingress	80777
SCs from the dorsal roots	80810
SCs	80810
the dorsal roots	80819
The observation	80837
cell grafting into the injured spinal cord	80858
cell grafting	80858
the injured spinal cord	80877
endogenous SC ingress	80910
the current study and others	80941
the current study	80941
others	80963
possibly chemotaxic factors	80984
galectin-1 -LRB- Fukaya et al. , 2003 ; Rabinovich et al. , 1999 -RRB-	81021
galectin-1	81021
Fukaya	81033
et al. , 2003 ; Rabinovich et al. , 1999	81040
et al.	81040
2003 ; Rabinovich et al.	81048
2003	81048
Rabinovich et al.	81054
Rabinovich	81054
et al.	81065
1999	81073
an enhanced immune response	81092
the death	81133
clearance of the implanted cells	81150
clearance	81150
the implanted cells	81163
SC migration	81200
PNS injury	81225
there	81236
close coordination between the immune system	81245
close coordination	81245
the immune system	81272
macrophages , and SCs	81299
macrophages	81299
SCs	81316
repair	81336
Chumasov and Svetikova , 1992	81344
Chumasov and Svetikova	81344
1992	81368
the implantation	81389
various ECM constructs	81409
fibronectin mats -LRB- King et al. , 2006 -RRB-	81441
fibronectin mats	81441
King	81459
et al. , 2006	81464
et al.	81464
2006	81472
SC recruitment	81528
the injured spinal cord	81546
The observation	81571
these ECM structures	81592
large numbers	81640
immune cells	81657
macrophages , newly formed blood vessels and axons	81679
macrophages	81679
newly formed blood vessels and axons	81692
newly formed blood vessels	81692
axons	81723
King	81730
et al. , 2006	81735
et al.	81735
2006	81743
the signal for promoting SC ingress	81765
the signal	81765
SC ingress	81790
the ECM	81821
the various immune	81841
vasculature	81861
axonal elements it supports	81876
axonal elements	81876
it	81892
It	81905
future experiments	81931
factor -LRB- s -RRB-	81968
factor	81968
the injured spinal cord	81981
cells and/or the immune system in response	82014
cells	82014
the immune system in response	82027
the immune system	82027
response	82048
the grafted cells	82060
the invasion of peripheral nerve elements	82087
the invasion	82087
peripheral nerve elements	82103
the injured CNS	82134
these factors	82162
the need	82194
glia	82216
Limited migration of GFPþ SCs and OEG	82222
Limited migration	82222
GFPþ SCs and OEG	82243
GFPþ SCs	82243
OEG	82256
all time points post-injury	82276
all time points	82276
GFPþ SCs or OEG	82305
regions of normalappearing white or gray matter	82346
regions	82346
normalappearing white or gray matter	82357
OEG	82405
rostral and caudal	82422
the injury , where they exhibited higher cell survival	82444
the injury	82444
they	82462
higher cell survival	82477
they	82499
the site of deposition	82527
the site	82527
deposition	82539
host tissue	82567
other studies	82603
complete transection -LRB- Ramon-Cueto et al. , 1998 , 2000 -RRB-	82627
complete transection	82627
Ramon-Cueto	82649
et al. , 1998 , 2000	82661
et al.	82661
1998	82669
2000	82675
These discrepancies in the migratory ability of transplanted OEG	82682
These discrepancies	82682
the migratory ability of transplanted OEG	82705
the migratory ability	82705
transplanted OEG	82730
the leakage of dyes used for cell labeling	82773
the leakage	82773
dyes used for cell labeling	82788
dyes	82788
cell labeling	82802
transfer	82824
migrating host cells in these former studies	82836
migrating host cells	82836
these former studies	82860
they	82884
the different injury environments of specific types of SCI	82907
the different injury environments	82907
specific types of SCI	82944
specific types	82944
SCI	82962
the absence of GFPþ SCs or OEG in normal host tissue	82975
the absence of GFPþ SCs	82975
the absence	82975
GFPþ SCs	82990
OEG in normal host tissue	83002
OEG	83002
normal host tissue	83009
OEG	83034
4 mm rostral and caudal	83059
4 mm rostral	83059
caudal	83076
the injury site	83086
GFPþ cells	83103
the injury epicenter	83135
The OEG	83157
access	83182
the injury epicenter	83192
the central canal , when the midline injection disrupted its structure	83228
the central canal	83228
the midline injection	83252
its structure	83284
the pia	83308
the injection entry site	83322
It	83348
labeled glia , following transplantation into the spinal cord ,	83385
labeled glia	83385
transplantation into the spinal cord	83409
transplantation	83409
the spinal cord	83430
significant distances -LRB- 12 mm -RRB-	83463
significant distances	83463
12 mm	83486
the central canal -LRB- Li et al. , 2003a -RRB-	83500
the central canal	83500
Li	83519
et al. , 2003a	83522
et al.	83522
2003a	83530
the pia -LRB- Langford and Owens , 1990 -RRB-	83546
the pia	83546
Langford and Owens	83555
1990	83575
our study	83585
the GFPþ cells within the central canal	83596
the GFPþ cells	83596
the central canal	83618
the surrounding ependymal layer	83659
they	83697
the site of the injury epicenter	83714
the site	83714
the injury epicenter	83726
OEG	83748
the pia	83793
SCs in a complete injury	83824
SCs	83824
a complete injury	83831
paradigm -LRB- Ramon-Cueto et al. , 1998 , 2000 -RRB-	83862
paradigm	83862
Ramon-Cueto	83872
et al. , 1998 , 2000	83884
et al.	83884
1998	83892
2000	83898
note	83908
regenerating 5-HT fibers	83914
the OEG/fibroblast milieu	83958
the OEG	83997
SC bridge	84006
this model	84019
the current study	84034
none of the specific supraspinal axon populations examined	84062
none	84062
the specific supraspinal axon populations examined	84070
the specific supraspinal axon populations	84070
these migrating OEG	84148
The timing of implantation	84169
The timing	84169
implantation	84183
a significant role in the ability of grafted EGFP glia	84210
a significant role	84210
the ability of grafted EGFP glia	84232
the ability	84232
grafted EGFP glia	84247
their original site of deposition	84281
their original site	84281
deposition	84304
The implantation of cells	84316
The implantation	84316
cells	84336
injury	84360
the formation	84375
a glial scar around the lesion site -LRB- Silver and Miller ,	84392
a glial scar around the lesion site	84392
a glial scar	84392
the lesion site	84412
Silver	84429
Miller	84440
2004	84448
the cells	84466
the injection site	84496
Li et al. , 2003a ; Ram on-Cueto et al. , 1998 , 2000 ; Richter et al. , 2005	84516
Li et al.	84516
Li	84516
et al.	84519
2003a ; Ram on-Cueto et al.	84527
2003a	84527
Ram on-Cueto et al.	84534
Ram on-Cueto	84534
et al.	84547
1998	84555
2000 ; Richter et al. , 2005	84561
2000	84561
Richter et al. , 2005	84567
Richter	84567
et al. , 2005	84575
et al.	84575
2005	84583
later times	84593
a delay of one week as in the current study	84620
a delay	84620
one week as in the current study	84631
one week	84631
the current study	84646
the formation of the glial boundary within the injured spinal cord	84665
the formation	84665
the glial boundary within the injured spinal cord	84682
the glial boundary	84682
the injured spinal cord	84708
the ability of implanted glia	84745
the ability	84745
implanted glia	84760
normal host cord tissue	84791
Barakat	84816
et al. , 2005 ; Pearse et al. , 2004a	84824
et al.	84824
2005 ; Pearse et al.	84832
2005	84832
Pearse et al.	84838
Pearse	84838
et al.	84845
2004a	84853
the presence of various ECM components	84867
the presence	84867
various ECM components	84883
Faissner , 1997 ; Kapfhammer and Schwab , 1992	84907
Faissner	84907
1997 ; Kapfhammer and Schwab	84917
1997	84917
Kapfhammer and Schwab	84923
1992	84946
chondroitin sulfate proteoglycans	84961
CSPGs	84996
tenascins	85007
soluble chemorepellant molecules	85018
Barallobre	85052
et al. , 2005	85063
et al.	85063
2005	85071
even physical interactions with the astrocytic - meningeal fibroblast	85080
even physical interactions	85080
the astrocytic - meningeal fibroblast	85112
Fawcett	85158
1997	85167
A study by Plant et al. -LRB- 2003 -RRB-	85174
A study	85174
Plant et al. -LRB- 2003 -RRB-	85185
Plant et al.	85185
Plant	85185
et al.	85191
2003	85199
transplantation	85227
OEG into a moderate contusion injury at either 0 or 7 days postinjury	85246
OEG	85246
a moderate contusion injury at either 0 or 7 days postinjury	85255
a moderate contusion injury	85255
either 0 or 7 days postinjury	85286
0	85293
7 days postinjury	85298
grafts	85328
both time points , that were largely encased by reactive astrocytes	85339
both time points	85339
reactive astrocytes	85386
these implanted OEG	85410
little migration	85440
surrounding host cord tissue	85462
paradigms	85499
the use	85514
p75 immunoreactivity to identify the implant	85525
p75 immunoreactivity	85525
the	85558
endogenous SCs	85604
the ability to characterize the migratory ability of OEG	85644
the migratory ability of OEG	85672
the migratory ability	85672
OEG	85697
the lesion environment	85716
a role	85748
the ability of implanted glia	85767
the ability	85767
implanted glia	85782
the host cord	85822
Significant differences	85837
the levels of inhibitory ECM present within different injury paradigms	85880
the levels	85880
inhibitory ECM present within different injury paradigms	85894
inhibitory ECM	85894
different injury paradigms	85924
example	85956
levels of CSPGs	85965
levels	85965
CSPGs	85975
host cord tissue	86020
spinal cord hemisection	86043
contusion -LRB- Grumet M. , personal communication , 2006 -RRB- , and OEG	86081
contusion	86081
Grumet M.	86092
personal communication	86103
2006	86127
OEG	86138
an extensive migratory capacity	86172
models	86207
spinal cord hemisection -LRB- Deng et al. , 2006 ; Li et al. , 2003a -RRB-	86217
spinal cord hemisection	86217
Deng	86242
et al. , 2006 ; Li et al. , 2003a	86247
et al.	86247
2006 ; Li et al.	86255
2006	86255
Li et al.	86261
Li	86261
et al.	86264
2003a	86272
contusion	86287
Barakat	86298
et al.	86306
2005 ; Collazos - Castro et al. , 2005 ; Pearse et al. , 2004a ; Plant et al.	86314
2005 ; Collazos	86314
2005	86314
Collazos	86320
Castro et al. , 2005	86330
Castro	86330
et al. , 2005	86337
et al.	86337
2005	86345
Pearse et al. , 2004a	86351
Pearse	86351
et al. , 2004a	86358
et al.	86358
2004a	86366
Plant et al.	86373
Plant	86373
et al.	86379
2003	86387
All transplants of GFPþ glia that had formed a substantive graft	86394
All transplants	86394
GFPþ glia that had formed a substantive graft	86413
GFPþ glia	86413
a substantive graft	86439
axon growth as seen by dense labeling of neurofilament positive axons	86486
axon growth	86486
seen by dense labeling of neurofilament positive axons	86501
dense labeling of neurofilament	86509
dense labeling	86509
neurofilament	86527
them	86563
Only grafts of OEG when transplanted into the injury epicenter	86569
Only grafts	86569
OEG when transplanted into the injury epicenter	86584
OEG	86584
the injury epicenter	86611
significant axon growth	86650
the poor survival of the grafts and their inability	86692
the poor survival	86692
the grafts and their inability	86713
the grafts	86713
their inability	86728
the formation of large central cysts	86755
the formation	86755
large central cysts	86772
SC grafts	86796
neurofilament positive axons	86807
the rostral-caudal axis of the spinal cord in parallel	86861
the rostral-caudal axis	86861
the spinal cord in parallel	86888
the spinal cord	86888
parallel	86907
SC processes	86921
axons	86944
SC grafts -LRB- Bunge and Pearse , 2003 -RRB-	86987
SC grafts	86987
Bunge and Pearse	86998
2003	87016
a contused spinal cord	87041
Takami et al. , 2002b ; Pearse et al. , 2004a , b	87065
Takami et al.	87065
Takami	87065
et al.	87072
2002b ; Pearse et al.	87080
2002b	87080
Pearse et al.	87087
Pearse	87087
et al.	87094
2004a , b	87102
2004a	87102
b	87108
this report	87112
axon growth	87148
a SC graft	87165
a contusion injury	87182
the use	87209
nonpromiscuous labels	87220
grafted cell identification -LRB- see also Hill et al. , 2006 -RRB-	87246
grafted cell identification	87246
Hill	87284
et al. , 2006	87289
et al.	87289
2006	87297
contrast	87307
OEG transplanted rostral and caudal to the injury epicenter	87317
OEG transplanted rostral	87317
caudal to the injury epicenter	87346
caudal	87346
the injury epicenter	87356
neurofilament	87387
positive axon growth	87401
the rostral-caudal axis of the spinal cord in alignment	87448
the rostral-caudal axis	87448
the spinal cord in alignment	87475
the spinal cord	87475
alignment	87494
the cells	87509
These effects on axon alignment	87520
These effects	87520
axon alignment	87537
the cell type	87596
the environment into which the cells were deposited	87636
the environment	87636
the cells	87663
Combination SC and OEG grafts	87689
more cell	87729
appearance	87748
patterns of axon growth similar to the SC	87770
patterns	87770
axon growth similar to the SC	87782
axon growth	87782
the SC	87805
The implantation of OEG into normal tissue	87825
The implantation	87825
OEG into normal tissue	87845
OEG	87845
normal tissue	87854
the forced alignment of the OEG in a pattern parallel	87880
the forced alignment	87880
the OEG in a pattern parallel	87904
the OEG	87904
a pattern parallel	87915
the direction of the injection	87937
the direction	87937
the injection	87954
the injection of SCs into the fragmented tissue of the injury epicenter	87974
the injection	87974
SCs into the fragmented tissue of the injury epicenter	87991
SCs	87991
the fragmented tissue of the injury epicenter	88000
the fragmented tissue	88000
the injury epicenter	88025
the cells	88063
more	88082
These results	88095
important implications	88126
the design of surgical cell implantation strategies for the spinal cord	88153
the design	88153
surgical cell implantation strategies for the spinal cord	88167
surgical cell implantation strategies	88167
the spinal cord	88209
axonal growth	88246
a rostral-caudal fashion towards appropriate targets	88263
a rostral-caudal fashion	88263
appropriate targets	88296
Examination	88317
specific	88332
axon populations using either immunochemistry	88366
axon populations	88366
immunochemistry	88396
glial grafts	88441
increased numbers	88474
short - and long-tract sensory axons	88495
supraspinal axons from either the brainstem or sensorimotor cortex	88540
supraspinal axons	88540
either the brainstem or sensorimotor cortex	88563
the brainstem	88570
sensorimotor cortex	88587
Similar axon growth responses	88608
fibroblast implants	88657
It	88692
SC grafts	88729
local proprioceptive and sensory axons	88772
nearby spinal cord segments	88828
Pearse et al. , 2004a ; Takami et al. , 2002b ; Xu et al.	88857
Pearse	88857
et al. , 2004a ; Takami et al. , 2002b ; Xu et al.	88864
et al. , 2004a	88864
et al.	88864
2004a	88872
Takami et al. , 2002b	88879
Takami	88879
et al. , 2002b	88886
et al.	88886
2002b	88894
Xu et al.	88901
Xu	88901
et al.	88904
1995 , 1997	88912
1995	88912
1997	88918
The poor growth support	88925
long-tract axon populations in animals in which OEG graft survival was high	88952
long-tract axon populations	88952
animals in which OEG graft survival was high	88983
animals	88983
OEG graft survival	89000
they	89035
rostral and caudal	89055
the injury epicenter	89077
earlier reports of the potent ability of OEG	89114
earlier reports	89114
the potent ability of OEG	89133
the potent ability	89133
OEG	89155
long distance ascending	89170
long distance	89170
supraspinal axon regeneration	89198
Li	89229
et al. , 1997 , 1998 , 2003b ; Ram on-Cueto et al. , 1998 , 2000	89232
et al. , 1997	89232
et al.	89232
1997	89240
1998 , 2003b ; Ram on-Cueto et al.	89246
1998 , 2003b	89246
1998	89246
2003b	89252
Ram on-Cueto et al.	89259
Ram on-Cueto	89259
et al.	89272
1998 , 2000	89280
1998	89280
2000	89286
These disparate results	89293
differences	89331
the SCI models	89346
the cell culture procedures	89371
the passage of cells at time of use	89405
the passage	89405
cells at time of use	89420
cells	89420
time of use	89429
time	89429
use	89437
their exposure to mitogens	89442
their exposure	89442
mitogens	89460
the application of cell cryoprotection	89473
the application	89473
cell cryoprotection	89492
the location of the	89517
the location	89517
the	89533
site	89545
the injury	89562
Closer injections	89574
the cells to the injury epicenter	89595
the cells	89595
the injury epicenter	89608
transection injuries -LRB- Ram on - Cueto et al. , 1998 -RRB-	89656
transection injuries	89656
Ram on - Cueto et al. , 1998	89678
Ram	89678
Cueto et al. , 1998	89686
Cueto et al.	89686
Cueto	89686
et al.	89692
1998	89700
the OEG to be more conducive for long-tract axon growth	89724
long-tract axon growth	89757
The injection of OEG at 4 mm rostral and caudal to the injury epicenter	89781
The injection	89781
OEG at 4 mm rostral and caudal to the injury epicenter	89798
OEG at 4 mm rostral	89798
OEG	89798
4 mm rostral	89805
caudal to the injury epicenter	89822
caudal	89822
the injury epicenter	89832
the cells very close to the ends of the cone shaped extension	89885
cells very close to the ends of the cone	89889
cells	89889
the ends of the cone	89909
the ends	89909
the cone	89921
the contusion injury	89950
Hill	89995
et al. , 2001 ; Pearse et al. , 2004a	90000
et al.	90000
2001 ; Pearse et al.	90008
2001	90008
Pearse et al.	90014
Pearse	90014
et al.	90021
2004a	90029
closer injections	90041
the deposition of OEG	90081
the deposition	90081
OEG	90099
the injury milieu	90119
their survival	90150
contrast	90169
the poor ability	90181
EGFP glial implants	90201
significant growth of long-tract	90232
significant growth	90232
long-tract	90254
axons	90289
regions	90296
the	90328
within the lesion	90344
a mixture of largely p75þ endogenous SCs and immune cells , such as macrophages	90374
a mixture	90374
largely p75þ endogenous SCs and immune cells , such as macrophages	90387
largely p75þ endogenous SCs	90387
immune cells	90419
macrophages	90441
substantial growth/sparing of these axons	90464
substantial growth/sparing	90464
these axons	90494
the rostral or caudal EGFP	90509
the rostral	90509
caudal EGFP	90524
interface	90544
This differential growth response	90569
particularly in the EGFP-SC animals	90604
the EGFP-SC	90620
both the implant and adjacent regions in the lesion	90647
both the implant	90647
both the	90647
adjacent regions in the lesion	90668
adjacent regions	90668
the lesion	90688
SCs	90725
the presence of cell types	90753
the presence	90753
cell types	90769
the nongrafted lesion milieu	90787
appreciable numbers within the EGFP	90842
appreciable numbers	90842
the EGFP	90869
macrophages or NG2þ precursor cells	90895
macrophages	90895
NG2þ precursor cells	90910
NG2	90941
a CSPG	90948
the injured spinal cord	90987
an inhibitor of axon growth -LRB- Jones et al. , 2002 -RRB-	91032
an inhibitor	91032
axon growth -LRB- Jones et al. , 2002 -RRB-	91048
axon growth	91048
Jones	91061
et al. , 2002	91067
et al.	91067
2002	91075
a recent study	91082
chronic SCI	91111
axons	91132
regions of SCs	91157
regions	91157
SCs	91168
the lesion site	91179
both inhibitory NG2 and permissive L1 and NCAM substrates	91210
both inhibitory NG2	91210
permissive L1 and NCAM substrates	91234
Lu	91269
et al. , 2007	91272
et al.	91272
2007	91280
The presence of macrophages or microglia within this region	91287
The presence	91287
macrophages or microglia within this region	91303
macrophages or microglia	91303
this region	91335
growth	91377
their removal	91412
inhibitory myelin debris -LRB- Vallieres et al. , 2006 -RRB-	91429
inhibitory myelin debris	91429
Vallieres	91455
et al. , 2006	91465
et al.	91465
2006	91473
their secretion of a variety of growth factors	91482
their secretion	91482
a variety of growth factors	91501
a variety	91501
growth factors	91514
the survival and axon growth	91569
a variety of CNS and PNS neuron populations -LRB- Davies , 1994	91601
a variety	91601
CNS and PNS neuron populations	91614
Davies	91646
1994	91654
Eide et al.	91660
Eide	91660
et al.	91665
1993	91673
Elkabes et al.	91679
Elkabes	91679
et al.	91687
1996	91695
Nakajima	91701
et al. , 1998 ; Suzuki et al. , 2001 -RRB-	91710
et al.	91710
1998 ; Suzuki et al. , 2001 -RRB-	91718
1998	91718
Suzuki et al. , 2001 -RRB-	91724
Suzuki	91724
et al.	91731
2001	91739
Further investigation	91746
the mechanism	91773
the different growth responses within these regions	91803
the different growth responses	91803
these regions	91841
future methods	91869
cell implants	91897
their efficacy	91922
the endogenous cellular response	91949
the injured host cord milieu	91989
improved self-repair	92038
Numerous myelinated axons	92060
EGFPSC grafts	92102
no myelination	92127
areas containing EGFP-OEG	92154
areas	92154
EGFP-OEG	92171
The axons that were myelinated	92181
The axons	92181
sensory or spinal cord	92234
proprioceptive axons as very few supraspinal axons	92257
proprioceptive axons	92257
very few supraspinal axons	92281
the grafts	92319
The observed reduction	92331
p75 immunoreactivity	92357
EGFP-SCs	92381
implantation	92407
a phenomenon	92421
their conversion	92458
a myelinating phenotype -LRB- Morgan et al. , 1994 -RRB-	92478
a myelinating phenotype	92478
Morgan	92503
et al. , 1994	92510
et al.	92510
1994	92518
further	92525
the suggestion	92542
the implanted EGFP-SCs	92562
myelinate ingrowing axons	92598
The inability of SCs to migrate from their original site of deposition	92625
The inability	92625
SCs to migrate from their original site of deposition	92642
their original site of deposition	92662
their original site	92662
deposition	92685
their potential	92716
remyelination strategies	92736
demyelinated axons	92771
SCI -LRB- Guest et al. , 2005 ; Totoiu and Kierstead , 2005 -RRB-	92796
SCI	92796
Guest	92801
et al. , 2005 ; Totoiu and Kierstead , 2005	92807
et al.	92807
2005 ; Totoiu and Kierstead	92815
2005	92815
Totoiu and Kierstead	92821
2005	92843
The lack of substantial myelination in OEG	92850
The lack	92850
substantial myelination in OEG	92862
substantial myelination	92862
OEG	92889
animals	92901
SCI	92915
demyelination lesions	92992
the spinal cord -LRB- Imaizumi et al. , 1998 ; Kato et al. , 2000 -RRB-	93017
the spinal cord	93017
Imaizumi	93034
et al. , 1998 ; Kato et al. , 2000	93043
et al.	93043
1998 ; Kato et al.	93051
1998	93051
Kato et al.	93057
Kato	93057
et al.	93062
2000	93070
previous findings	93095
Boyd	93116
et al. -LRB- 2004 -RRB-	93121
et al.	93121
2004	93129
Embryonic OEG	93136
b-galactosidase	93164
7 days	93200
a clip compression injury	93213
myelinate axons	93250
immuno-electron microscopy	93285
3 weeks	93315
The myelin found near grafted , labeled OEG	93345
The myelin	93345
OEG	93384
endogenous SCs	93422
Differences in OEG myelination among these studies	93438
Differences	93438
OEG myelination among these studies	93453
OEG myelination	93453
these studies	93475
the disparate spinal cord environments	93501
the OEG	93551
incongruities in the types and amount of specific ECM proteins	93579
incongruities	93579
the types and amount of specific ECM proteins	93596
the types and amount	93596
specific ECM proteins	93620
numbers of specific cell populations	93649
numbers	93649
specific cell populations	93660
neurons , precursor cells , and immune cells	93687
neurons	93687
precursor cells	93696
immune cells	93717
OEG myelination	93744
Differences	93761
the distinct methods	93795
the OEG cultures -LRB- as described above -RRB-	93836
the OEG cultures	93836
The grafting of either SCs or OEG	93875
The grafting	93875
either SCs or OEG	93891
SCs	93898
OEG	93905
substantial improvements	93925
hind limb function	93953
a modest , though significant , improvement in open-field locomotion	93976
a modest , though significant , improvement	93976
open-field locomotion	94021
the combination grafting of both cell types	94061
the combination grafting	94061
both cell types	94089
the injury site	94110
An absence of major improvements in behavioral outcomes	94127
An absence	94127
major improvements in behavioral outcomes	94141
major improvements	94141
behavioral outcomes	94163
likely results	94183
an inability of both cell types	94203
an inability	94203
both cell types	94219
supraspinal axon growth in the current study and points	94246
supraspinal axon growth	94246
the current study and points	94273
the current study	94273
points	94295
the need for additional pharmacological or molecular strategies	94305
the need	94305
additional pharmacological or molecular strategies	94318
the efficacy of glial grafts	94380
the efficacy	94380
glial grafts	94396
axon growth and functional restitution	94413
axon growth	94413
functional restitution	94429
Bamber	94453
et al. , 2001	94460
et al.	94460
2001	94468
Fouad et al. , 2005	94474
Fouad	94474
et al. , 2005	94480
et al.	94480
2005	94488
Pearse et al. , 2004b	94494
Pearse	94494
et al. , 2004b	94501
et al.	94501
2004b	94509
Ruitenberg et al. , 2002	94516
Ruitenberg	94516
et al. , 2002	94527
et al.	94527
2002	94535
Tuszynski et al. , 1998	94541
Tuszynski	94541
et al. , 1998	94551
et al.	94551
1998	94559
The improved behavior in the combination group	94566
The improved behavior	94566
the combination group	94591
the significant increase in OEG survival	94633
the significant increase	94633
OEG survival	94661
co-implantation of SCs	94686
co-implantation	94686
SCs	94705
the subsequent growth	94713
axonal tracts not examined in the current study	94738
axonal tracts	94738
the current study	94768
the vestibulospinal or reticulospinal systems	94795
An absence of behavioral improvements in the other combination group	94842
An absence	94842
behavioral improvements in the other combination group	94856
behavioral improvements	94856
the other combination group	94883
the damage	94925
injections of OEG	94948
injections	94948
OEG	94962
either side of the injury site and possible extension of the lesion	94969
either side of the injury site	94969
either side	94969
the injury site	94984
possible extension of the lesion	95004
possible extension	95004
the lesion	95026
The microimplantation	95038
OEG to enhance their survival and thus efficacy in a contusive injury model	95063
OEG to enhance their survival and thus efficacy	95063
their survival	95078
a contusive injury model	95114
less invasive surgical techniques	95164
those previously adapted for stem cell delivery -LRB- Bakshi et al. , 2006 -RRB-	95207
those	95207
stem cell delivery -LRB- Bakshi et al. , 2006 -RRB-	95236
stem cell delivery	95236
Bakshi	95256
et al. , 2006	95263
et al.	95263
2006	95271
The present study	95278
a number	95307
cell transplantation strategies	95362
SCI	95400
-LRB- i -RRB- the need for additional strategies to enhance graft survival	95405
the need	95409
additional strategies to enhance graft survival	95422
graft survival	95455
greater understanding	95474
the mechanisms	95499
transplanted cell death	95517
the injured CNS	95548
ii	95566
identification	95570
signals or phenomena	95588
endogenous SC migration	95620
the injured spinal cord	95649
it	95678
cell transplantation	95696
this ingress	95729
the ability of grafted cells to support supraspinal axon regeneration	95760
the ability	95760
grafted cells to support supraspinal axon regeneration	95775
supraspinal axon regeneration	95800
identification	95841
the optimal density	95859
location	95880
deposition and method	95892
specific cell types	95926
adequate survival and proper orientation within the spinal cord	95956
adequate survival and proper orientation	95956
the spinal cord	96004
support of rostral-caudal directed axon growth across the injury site	96024
support	96024
rostral-caudal directed axon growth across the injury site	96035
rostral-caudal	96035
axon growth	96059
the injury site	96078
Further investigation	96095
glial transplantation using specific and reliable cell markers	96120
glial transplantation	96120
specific and reliable cell markers	96148
these questions	96197
the future	96232
